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Summary 
Haemophilia A (HA) is caused by widespread mutations in the factor VIII gene. Although genetic 
alterations responsible for HA can now be identified in a vast majority of patients, molecular 
diagnostic remains challenging in some patients. This thesis addresses important issues in the 
diagnostic and molecular mechanisms of some frequent or rare genetic alterations associated with 
HA. It demonstrates the value of computational and molecular approaches for predicting the 
causality of unreported missense mutations. It also shows that the overrepresentation of specific 
missense mutations in mild HA can be explained by a founder effect rather than by an independent 
occurrence. Also, it highlights how complex genetic rearrangements such as tandem inversion 
duplication within intron 1 and exons 1-22 duplications involving intron 22 homologous repeats 
(int22h) can be detected and their occurrence best explained. Finally, it demonstrates for the first 
time the existence of wild-type human genotype harbouring five int22h copies identified in the rare 
intron22 inversion type 3 of the factor VIII gene. 
Keywords: 
Hemophilia A, F8 mutation analysis, duplication breakpoints, intron 22 inversion, Copy Number 
Variation, genotyping, CGH array, MLPA, int22h homologous repeats 
  
 
 
  
 
 
Résumé 
L'hémophilie A (HA) est due à des mutations du gène F8 codant pour le facteur VIII de la coagulation. 
Bien que les mutations génétiques responsables de l'HA puissent désormais être identifiées pour la 
majorité des patients, le diagnostic moléculaire reste problématique chez certains sujets atteints. 
Cette thèse aborde les techniques d’identification et d’interprétation de plusieurs défauts génétiques 
concernant quelques nucléotides ou incluant de larges remaniements. Elle propose des stratégies 
bio-informatiques et moléculaires pour évaluer la causalité de mutations ponctuelles nouvellement 
décrites. Elle montre également que la surreprésentation des quelques mutations faux-sens peut 
être expliquée par un effet fondateur, plutôt que par un événement de novo récurrent. Ensuite, elle 
suggère des hypothèses pour expliquer les mécanismes moléculaires de certains réarrangements 
génétiques complexes tels qu’une duplication en miroir pour la duplication de l’exon 1 et une 
participation de deux séquences homologues int22h pour la duplication des exons 1 à 22. 
Finalement, elle montre pour la première fois qu’il existe des génotypes humains normaux contenant 
cinq copies de séquences homologues int22h qui sont techniquement visibles dans un type rare de 
l’inversion de l’intron 22. 
Mots-clés 
Hémophilie A, analyse moléculaire, gène F8, inversion de l’intron 22, copies homologues int22h, 
duplication, puce d'hybridation génomique comparative, génotypage, variabilité du nombre de 
copies, MLPA. 
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Introduction 
Blood is essential for life. This precious body liquid is composed of cells and plasmatic 
components, which allows for numerous functions so essential to life ranging from transport of 
oxygen, carbon dioxide, nutrients, vitamins, metabolites, waste products, hormones and components 
of the cellular as well as humoral immune system to homeostatic functions. Moreover, one of its 
elementary tasks is to prevent its own loss, namely by the mechanism of hemostasis – the cessation 
of blood leakage from damaged vessels. The hemostatic challenge requires a delicate balance 
between hemostasis and thrombosis. A “perfect clot” not only seals the injured vessel at the site of 
damage to stop bleeding, but also must ensure that it is sufficiently labile to be degraded at the end 
of this process. The deficit of one element of this delicate balance leads to the pathologic process of 
abnormal bleeding or, on the contrary, to the formation of persistent clot.  
The main actor of this thesis is one of the coagulation factors, the FVIII involved in clot production in 
the process of hemostasis. In case of missing, inconsistent or reduced FVIII protein, caused by 
mutations in the F8, clinical symptoms of hemophilia A (HA) appear. The presented work includes 
molecular analysis in HA patients beyond routine diagnosis to identify mechanisms behind simple 
variants or gross genomic rearrangements. Therefore, the first section of the introduction entitled 
“general introduction” will discuss the history of hemophilia, the basics of blood coagulation, the 
main bleeding disorders and provide overview of the clinical diagnosis and management of 
hemophilia. In the second section, general mechanisms and consequences of genetic variations are 
developed and applied to hemophilia A. 
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Part one: General introduction 
1. History of hemophilia 
Incidences of excessive or abnormal bleeding were first recorded hundreds of years ago. The Talmud, 
a collection of Jewish rabbinical writings on laws and traditions, from the 2nd century AD, stated that 
baby boys did not have to be circumcised if two of their brothers had previously died from the 
procedure [1]. The Arab physician considered as the greatest medieval surgeon, Abu al Qasim (936–
1013), who lived in Al-Andalus, described families whose male relatives died from uncontrolled 
bleeding after only minor traumas [2]. In 1803, Dr. John Conrad Otto (1774-1844), an American 
physician, was the first to publish an article recognizing that a hemorrhagic bleeding disorder 
primarily affected men, passed down by healthy females and ran in certain families. In 1813, John 
Hay published an article in The New England Journal of Medicine where he discussed how the 
affected male could pass the disorder to the unaffected daughters. [3]. The term "hemophilia" is 
derived from the term "hemorrhaphilia" postulated in 1828 by Friedrich Hopff, a student at the 
University of Zurich, and his professor Dr. Schonlein [4]. In 1937, Patek and Taylor, two doctors from 
Harvard, discovered anti-hemophilic globulin [5]. In 1947, Pavlosky from Buenos Aires found 
hemophilia A and hemophilia B to be separate diseases by doing a lab test. This test was done by 
transferring the blood of one hemophiliac to another hemophiliac. The fact that this corrected the 
clotting problem showed that there was more than one form of hemophilia. 
The hemophilia blood disorder became known as the royal disease because it affected the royal 
families of England, Germany, Russia and Spain in the 19th and 20th centuries. Queen Victoria passed 
the mutation responsible for hemophilia to her son Leopold, through some of her daughters who in 
turn transmitted it on to several of their children [Fig.1]. It was only in 2009 that Rogaev et al 
identified the mutation responsible for hemophilia B in Czarina Alexandra’s DNA revealing an A>G 
intronic mutation located 3 bp upstream of exon 4 (intron-exon boundary IVS3-3A>G) of the F9 gene 
coding for the coagulation factor IX [6]. 
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FIGURE 1: QUEEN VICTORIA, GRANDMOTHER OF EUROPE 
Queen Victoria of England (1837-1901) was a hemophilia carrier. Her eighth child, Leopold, 
three of her grandchildren and seven of her great-grandchildren were affected by the disease. 
Due to princely alliances, the disease spread through most European royal families notably in 
Germany, Spain, and Russia. 
2. Basics of blood coagulation 
Hemostasis is the protective physiological response to injury that results in exposure of blood to the 
subendothelial layers of the vessel wall. Hemostasis is a regulated process involving several 
coagulation factors and cofactors present in blood plasma: five proteases (Factor VII (FVII), Factor IX 
(FIX), Factor X (FX), protein C and prothrombin) interacting with five cofactors (tissue factor (TF; 
CD142), thrombomodulin, protein S, Factor V (FV) and FVIII). The coagulation factors are designated 
by Roman numerals ranging from I to XIII with a lower case “a” indicating the active form. The role of 
each coagulation factor is best illustrated by the classical coagulation cascade (Fig. 2), which consists 
of two distinct pathways; the contact pathway (also known as the intrinsic pathway), and the tissue 
factor pathway (also known as the extrinsic pathway). Both pathways are highly interconnected by 
cross-reactions and feedback mechanisms. These pathways are assayed clinically using the activated 
partial thromboplastin time (aPTT) and the prothrombin time (PT), respectively. Factor XII (FXII) and 
Factor VIIa (FVIIa) initiate the intrinsic and extrinsic pathways, respectively. After injury of a blood 
vessel, the coagulation cascade is initiated by the contact of blood with TF, a non-enzymatic 
lipoprotein present in the membrane of cells surrounding the vascular bed. Once in contact with 
blood, the TF-dependent activation of coagulation, i.e. the extrinsic pathway, is initiated. When a 
vessel is injured, membrane bound TF is exposed.  
As a consequence the circulating FVII is activated, and binds to TF and results in the formation of a 
FVIIa-TF complex. Binding of FVIIa to TF accelerates this activation about 30.000-fold. Circulating FIX 
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and FX are converted by the FVIIa-TF complex to active serine proteases FIXa and FXa, which in turn 
activate TF-bound FVII via a feedback mechanism (Fig. 2). FIXa and FXa then assemble with their 
nonenzymatic protein cofactors FVIIIa and FVa. The FVIIIa-FIXa complex termed tenase or intrinsic 
Xase generates even more FXa, whereas the FVa-FXa complex (prothrombinase) converts 
prothrombin (FII) to active thrombin (FIIa), which works in a positive feedback loop itself. Thrombin 
can activate FV and FVIII, which activates FXI. FXI itself activates in turn FIX and allows activation of 
more thrombin. This will lead to releases of FVIII from being bound to von Willebrand Factor (vWF). 
Subsequently, after sufficient amount of thrombin is present in the circulation, fibrinogen is activated 
and becomes fibrin. In the presence of activated factor 13 (FXIIIa), fibrin is polymerized and a fibrin 
clot is formed at the site of injury. 
The functional activity of FVIII is measured in vitro by determination of the clotting time of the blood 
plasma sample with depleted endogenous FVIII and added FVIII in the solution under study. 
 
FIGURE 2: Simplified scheme of the procoagulation “cascade” of proteolytic reactions initiated by 
damage of blood vessel walls and culminating in the creation of a fibrin mesh. 
Black arrows represent the conversion or activation of coagulation factors; dotted thin lines show 
additional enzymatic functions. Coagulation factors are abbreviated by “F” and their Roman number. 
FVIIIa works as a cofactor for FIX in the active tenase complex to activate FX. Ca2+ - calcium ions, 
HMWK – high molecular weight kininogen. PL – phospholipid membrane, VWF – von Willebrand 
factor; See text for details on factors and mechanisms. (figure published by Mühle C. [7). 
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3. Principal bleeding disorders 
Bleeding disorders are a group of disease that results in the inability of the blood to form a clot 
properly. They are characterized by extended bleeding after injury, surgery, trauma or menstruation. 
Improper clotting can be caused by defects in blood components, such as platelets and/or clotting 
factors. If any of them are defective or deficient, blood clotting is affected and a mild, moderate or 
severe bleeding disorder can result. Some bleeding disorders can be inherited or acquired. Others 
can occur from such conditions as cirrhosis of the liver, HIV, leukemia and vitamin K deficiency. They 
also can result from certain medications that thin the blood, including aspirin, heparin and warfarin. 
The most common hereditary coagulation abnormality described in humans, with an incidence of 
roughly 1 %, is von Willebrand disease (VWD), arising from a qualitative or quantitative deficiency of 
von Willebrand factor (VWF), which is required for platelet adhesion as well as stabilization of FVIII. It 
is thus a defect of primary hemostasis associated with a secondary defect in coagulation factor VIII 
and, therefore, is sometimes classified under hemophilia [8]. Hemophilia is the most common form 
of congenital deficiencies in a blood coagulation factor. It is subdivided into hemophilia A 
(OMIM#306700) caused by the lack or defective function of FVIII and the less frequent hemophilia B 
(OMIM#306900), due to a deficiency in FIX. The incidence of hemophilia A and B is approximately 1 
in 5.000 and 1 in 30.000 male live births, respectively, and no ethnic or geographic predisposition has 
been defined. The F8 and F9 genes are located on the X chromosome giving them the status of X-
linked disease, which stands in contrast to the other coagulation factor genes that are predominantly 
inherited as autosomal recessive traits. Hemophilia passed on through females who carry the 
defective genes. Half of the sons of a carrier are affected with HA and half of the daughters are 
carriers again. In contrast, all daughters of a hemophilic man are carriers, whereas all sons are 
healthy with respect to hemophilia. The female carriers usually do not experience problems or only 
with very mild symptoms of the disease. However, symptomatic females have been documented, 
and the proposed mechanisms include unbalanced X chromosome inactivation, or the presence of a 
true homozygous offspring due to consanguinity or to compound heterozygosity from an affected 
father and a carrier mother [9-11]. Female individuals diagnosed with Turner syndrome may suffer 
from HA similarly to hemizygous males [12]. Approximately 60% of hemophilia A cases have a family 
history, the remainder is sporadic due to de novo mutations. In 90% of these families, the mutation 
has arisen in the parents or grandparents [13]. It has been reported that mutations causing 
hemophilia A originate 3.6 times more frequently in male germ cells than female germ cells. 
However, this sex ratio of mutation frequencies differs for each type of mutation. The mutation rate 
for point mutations is 5-10-fold higher and inversions more than 10-fold higher in male germ cells, 
while deletions are more than 5-fold higher in female germ cells [14]. Therefore, a mother of a 
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sporadic case of hemophilia has a high risk of being a carrier of the disorder. Although the prevalence 
does not vary much between populations, it could be underestimated in developing countries due to 
poor diagnosis [15]. 
Low levels of factor XI (also known as Rosenthal syndrome), caused by mutations in the gene for FXI 
and parahemophilia or Owren hemophilia due to a deficiency of FV are rare. 
4. Clinical features, diagnosis and management of hemophilia 
Clinical Features 
The most common bleeding sites are joints (80% of bleeding), muscles, and the gastrointestinal 
mucosa. Ankles are the most commonly affected joints in children, whereas knees and elbows are 
more often involved in adults. Quadriceps and iliopsoas bleeding are the most common sites of 
muscle hematomas. Abdominal wall bleeding and gastrointestinal mucosal bleeding can occur. 
Depending on the amount of clotting factor in the blood, three classes of HA severities have been 
defined compared to the normal range of 50-150% [Fig. 3]: severely affected individuals have <1 
IU/dL (less than 1% of normal); moderate >1 - <5 IU/dL (1%-5% of normal); and mild >5 - <40 IU/dL 
(>5% - <40% of normal) (16)]. These classes represent 40%, 10% and 50% of patients with HA. People 
with severe hemophilia usually bleed frequently into their muscles or joints particularly the knee, 
ankle, hip and elbow associated with pain. They may bleed one to two times per week. Bleeding is 
often spontaneous, which means it happens for no obvious reason. People with moderate 
hemophilia bleed less frequently, about once a month. They are often recognized by prolonged 
bleeding after surgery, bad injury, or dental extraction. A person with moderate hemophilia will 
rarely experience spontaneous bleeding. People with mild hemophilia usually bleed only as a result 
of surgery or major injury. They do not bleed often and, in fact, may never have a bleeding problem. 
Female carriers with heterozygous mutation may exhibit various FVIII plasma levels and bleeding 
symptoms [17] that have been partly attributed to different X chromosome inactivation levels 
described by Lyon in 1962 [9]. 
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FIGURE 3: CLASSIFICATION OF HEMOPHILIA BASED ON THE ACTIVITY LEVELS OF CLOTTING FACTOR VIII. Three 
classes of HA severities have been defined compared to the normal range of 50-150%. 
Diagnosis 
Screening Tests 
 Activated Partial Thromboplastin Time (APTT) test or “one-stage” assay 
This test measures how long it takes for blood to clot. It measures the clotting ability of factors VIII 
(F8), IX (F9), XI (F11), and XII (F12). If any of these clotting factors are too low, it takes longer than 
normal for the blood to clot. In cases of a long APTT, an equal mixture of normal and test plasma 
should be tested (i.e., a mixture of 1 part test and 1 part normal plasma, called a 50:50 mix). If the 
APTT corrects by more than 50% of the difference between the clotting times of the normal and test 
plasma, a factor deficiency is indicated. Poor correction suggests an inhibitor, possibly to one of the 
clotting factors in the system or of the non-specific type, such as lupus anticoagulant. 
The one-stage factor FVIII assay is relatively simple to perform and accurate. It does have limitations 
including susceptibility to interference from preactivation of factor VIII or anti-phospholipid 
antibodies as well as misleading results when assaying recombinant factor VIII. In addition some F8 
mutations can lead to discrepant 1-stage/2-stage [chromogenic] FVIII assay results [18]. 
 Two-Stage & Chromogenic Factor Assays 
Two main alternatives to the one stage assay, the 2-stage APTT based assay and the chromogenic 
assay exist. Both are based around an initial step to produce factor Xa in a quantity proportional to 
the amount of factor VIII present and a second step to assay the amount of factor Xa and so deduce 
the amount of factor VIII present. The 2-stage assay is rarely performed today but remains an 
important test. Results by the chromogenic and 2-stage factor VIII assays are usually equivalent. For 
most patients the FVIII calculated by either the chromogenic, 2-stage or 1 stage APTT based assay will 
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be also comparable. However, some genetic mutations of the F8 gene produce discrepant results 
between 1-stage and 2-stage / chromogenic assays, particularly those which impede interaction of 
the A1 and A2 domains [18]. 
The chromogenic assay is now the reference method for potency determination of FVIII concentrates 
as recommended by: European Pharmacopoeia and the ISTH Subcommittee for FVIII and FIX [19].  
 FVIII cross-reacting material 
Factor VIII protein in plasma can be measured by polyclonal antigen ELISA assays. Depending on the 
mutation that influences FVIII level and activity, hemophiliacs can be classified into three broad 
categories with major influence on their risk of developing FVIII antibodies (see section 6) [20-21]: 
(1) Cross-reacting material (CRM)-negative patients lacking immunologically detectable FVIII antigen 
levels (in about 50 %) 
(2)  CRM-positive patients with considerable but presumably dysfunctional FVIII protein levels 
(about 5 %) caused by missense or other small mutations  
(3)  An intermediate group of CRM-reduced patients (about 45 %) possibly as a consequence of 
inefficient secretion or faster clearance of FVIII 
The majority of mutations are CRM-negative and probable affect the folding and stability of the 
protein for example in case of mRNA degradation due to nonsense-mediated decay [22]. Others 
mechanisms associated with CRM-reduced are described: the p.Phe672del mutation prevents the 
formation of the tightly packed structure of FVIII, resulting in aberrant folding and a block to 
transport through the secretory pathway [23], and the p.Arg2326Gln mutant FVIII protein showed 
reduced secretion with increased intracellular degradation [24]. 
Mutations associated with CRM-positive, such as p.Ile585Thr and p.Ser577Phe, have been described 
inducing defective interaction with factor IXa [23]. 
Management 
Replacement coagulation  
Choices for replacing factor include recombinant versus plasma-derived factor VIII. Plasma-derived 
concentrates vary in purity and must undergo viral inactivation procedures. First-generation 
recombinant products have demonstrated efficacy in clinical trials; however, they continue to carry a 
theoretic risk of viral transmission because of the added human albumin necessary for factor 
stabilization. Second-generation recombinant products do not require albumin stabilization. Factor IX 
replacement has traditionally been with prothrombin complex concentrates (PCCs) that contain 
factors II, VII, and X, as well as IX, and were associated with thrombotic risk. Newer plasma-derived 
factor IX concentrates are effective, and they undergo viral inactivation. Recombinant factor IX 
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concentrates such as Benefix are also effective and have no added albumin, hence eliminating a 
theoretic risk of viral infection. 
Bleeding episodes in mild HA patients may be successfully treated or prevented either by 
desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) to temporarily boost plasma levels of 
VWF and FVIII in good responder patients with mild severity or with FVIII concentrates. However, the 
response to desmopressin in mild HA patients was reported to be strongly influenced by the 
mutation type that affect the protein stability and thrombin activation cleavage site or interfere with 
protein secretion and the von Willebrand factor’s (vWF) protective effect against early F8 
degradation [25, 26].  
5. FVIII gene expression features 
Post-translational modifications of the FVIII precursor protein in cytoplasm 
Expression of the FVIII gene is tissue-specific and is mostly observed in liver cells. The highest level of 
the mRNA and FVIII protein have been detected in liver sinusoidal cells; significant amounts of FVIII 
are also present in hepatocytes and in Kupffer cells [27, 28]. The FVIII precursor protein is subject to a 
series of post-translational events [Fig. 4]. In the lumen of the endoplasmic reticulum (ER) where the 
FVIII polypeptide can remain for 15 min to several days, processing of the 19-amino-acid-long signal 
peptide, N-glycosylation, and disulfide bond formation occur first. Then the FVIII polypeptide is 
transferred from ER to the Golgi apparatus via the ER-Golgi intermediate compartment (ERGIC). FVIII 
and FV are recruited to this compartment by binding to the transmembrane protein (cargo receptor) 
ER GIC-53, also known as LMAN1 (lectin, mannose-binding, 1) and ensures mannose-selective, 
calcium-dependent binding and transport of glycoproteins from the ER to the Golgi apparatus [29]. 
The mutations resulting in the loss of LMAN1 function or disturbing the interaction between LMAN1 
and the component of the transport complex MCFD2 (multiple coagulation factor deficiency protein 
2) cause inherited coagulopathy, a combined deficiency of factor V and factor VIII. The FVIII level in 
the plasma of patients with mutant LMAN1 decreases to 5–30% of its normal level [30]. In the Golgi 
apparatus, high-mannose N-glycans of the FVIII molecule are modified; O-glycosylation and sulfation 
of tyrosine residues occur in the trans-Golgi. The final stage of FVIII processing in the trans-Golgi 
prior to secretion in the plasma involves proteolysis of the single-chain precursor at residues R1313 
and R1648, giving rise to a light and a heavy chain [31].  
Factor VIII in the bloodstream 
The coagulation factor VIII secreted in the plasma comprises a carboxy-terminally derived 79 kDa 
light chain with the domain structure A3-C1-C2, and an amino-terminally derived heavy chain ranging 
in size from 90 to 200 kDa composed of the A1 and A2 domains and a B-domain of variable length. A 
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metal iondependent interaction links both chains via their A1 and A3 subunits. This factor VIII 
circulates at a relatively low concentration of about 0.2 μg/ml, corresponding to 0.7 nM. The 
glycoprotein is complexed non-covalently to the huge multimeric von Willebrand factor (VWF) which 
acts as a carrier protein to protect FVIII from degradation [32]. In normal adult patients, the 
elimination half-life of substituted FVIII is in the range of 8–32 h. 
During activation, the circulating FVIII is further cleaved by thrombin (FIIa) or FXa at distinct sites. 
Breakdowns are introduced at positions R372, R740, and R1689 [33] and result in removal of the B 
domain, in cleavage of the heavy chain into the A1 and A2 domains that remain noncovalently 
bound, and in elimination of the short acidic region a3 preceding the A3 domain. 
 
 
FIGURE 4: CYTOPLASMIC TRAFFIC OF THE FVIII POLYPEPTIDE BEFORE ITS SECRETION.  
Before secretion of Factor VIII in the bloodstream, the precursor protein is subjected to a series of 
post-translational events in the lumen of the endoplasmic reticulum and the Golgi apparatus. The 
transfer from ER to Golgi is assured by the ER -Golgi intermediate compartment (ER GIC) recruiting 
the COPII (coat protein II) vesicles. The coagulation factor VIII circulating in the plasma comprise a 
carboxy-terminally derived 79 kDa light chain with the domain structure A3-C1-C2 and an amino-
terminally derived heavy chain ranging in size from 90 to 200 kDa composed of the A1 and A2 
domains and a B-domain. A metal iondependent interaction links both chains via their A1 and A3 
subunits 
 
Low levels FVIII 
Low levels of factor VIII may not only originate from mutations affecting F8 or its promoter but also 
from defective proteins involved in processing or secretion of FVIII. Because of its homology to FVIII, 
the coagulation factor V may be simultaneously affected, as seen in patients with a combined 
deficiency of FV and FVIII due to mutations in genes encoding cargo receptors for trafficking FV and 
 
 
13 
 
FVIII from the endoplasmic reticulum to the Golgi apparatus for subsequent secretion (MCFD2 or 
LMAN1) [34-36]. Another hemophilia phenotype has been identified in a patient with a mutation in 
VWF affecting its binding to FVIII (also called von Willebrand disease type 2N) and thereby reducing 
the half-life of FVIII from the normal 12 hours to one hour [37]. 
Low FVIII expression is principally caused by inefficient expression of the mRNA [38] a significant 
proportion of protein misfolding with subsequent intracellular degradation, and inefficient transport 
of the primary translation product from the endoplasmic reticulum (ER) to the Golgi [24, 39]. 
6. Complication of hemophilia 
Development of an immune response to supplemented FVIII remains the most serious and 
challenging complication in the treatment of patients with severe HA (approximately 30% of the 
patients). FVIII inhibitors are immunoglobulin IgG (IgG1 and IgG4) antibodies that neutralize FVIII 
procoagulant activity in plasma. Inhibitors can be quantified in the Bethesda assay by their ability to 
neutralize FVIII activity of normal plasma [40] and are usually classified according to their levels in 
plasma as a “high-titer” inhibitors, those with the highest activity >5 Bethesda Units (BU)/ml or a low-
titer inhibitor type. In hemophilia A approximately 60-70% of inhibitors are high titer inhibitors, and 
the remainders are low titer. Some patients develop transient inhibitors (usually low titer inhibitors 
that never exceed a titer of 5 BU/ml and disappear spontaneously with time) [16].  
Various predisposing factors may increase the risk to develop FVIII inhibitory antibodies that usually 
appear within 50 exposure days [41]. These depend mainly on the type of mutation [42]. Indeed, 
splice site and missense mutations are associated with a relatively low risk, whereas around 21% of 
patients with the recurrent intron 22 inversion develop FVIII-inhibitory antibodies. Inhibitor 
prevalence is highest in HA patients with large deletions until 88% in patients with deletions 
encoding multiple domains. Other genetics factors include severity of the FVIII deficiency, family 
history of inhibitors, patient ethnicity as well as mutations and polymorphisms in immune response 
genes [43-47]. In mild/moderate hemophilia A, a few missense mutations potentially contributing to 
a higher risk of inhibitor development have also been described [48]. 
7. Modifier genes in hemophilia A 
The phenotype of hereditary disorder depends on a number of variables:  
 Gene sequence factors: type of mutation and associated of polymorphisms  
 Epigenetic factors that can influence gene regulation and expression by the way of 
enhancers, silencers, alternative promoters, imprinting and methylation 
 RNA factors, such as alternative splicing or antisense regulation 
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 Protein metabolism factors involved in the balance between the formation and the 
degradation of the protein. Interindividual differences in genes involved in protein stability 
(proteolytic enzymes or chaperones) could account for phenotypic variation of patients with 
the same mutation. For example, the missense p.Arg2169His has been reported 103 in the 
HAMSTeRS database [http://www.eahad-db.org/version 1.3], with FVIII:C activity varying 
from <1% to 40% of normal plasma values. This large variability in these multiple reports 
suggests that additional factors besides the defined mutation in the F8 gene influence 
circulating FVIII protein levels as discussed in the previously section [34-36]. 
 Environmental factors that influence cell context 
It is therefore apparent that the gene mutation alone does not always determine the final outcome. 
In HA, severely affected patients usually show a significant number of spontaneous or traumatic 
bleeding episodes and require on average more than 60 000–80 000 units of replacement factor per 
year. However, there are patients with similar levels of factor activity whose bleeding episodes are 
very sporadic and factor utilization is much lower. Several studies suggested that the coinheritance of 
the FV Leiden mutation [49, 50], the variant G20210A (PT20210A) in the prothrombin gene [51.52] 
could influence the phenotype of severe HA patients sharing an identical FVIII:C mutation. Given that 
the mechanisms of coagulation and fibrinolysis are very complex and involve a large number of 
genes, multiple genetic variants influence the final phenotype of an individual. 
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Abstract 
DNA structure alterations are the ultimate source of genetic variations. Without them, evolution 
would be impossible. While they are essential for DNA diversity, defects in DNA synthesis can lead to 
numerous genetic diseases. Due to increasingly innovative technologies, our knowledge of the 
human genome and genetic diseases has grown considerably over the last few years, allowing us to 
detect another class of variants affecting the chromosomal structure. DNA sequence can be altered 
in multiple ways: DNA sequence changes by substitution, deletion, or duplication of some 
nucleotides; chromosomal structure alterations by deletion, duplication, translocation, and inversion, 
ranging in size from kilobases to megabases; changes in the cell's genome size. If the alteration is 
located within a gene and sufficiently deleterious, it can cause genetic disorders. 
Due to the F8 gene’s high rate of new small mutations and its location at the tip of X chromosome, 
containing high repetitive sequences, a wide variety of genetic variants have been described as the 
cause of hemophilia A (HA). In addition to the intron 22 inversion, HA can also result from point 
mutations, other inversions, complex rearrangements, such as duplications or deletions, and 
transposon insertions causing phenotypes of variable severity characterized by complete or partial 
deficiency of circulating FVIII.  
This review aims to present the origins, mechanisms, and consequences of F8 alterations. A sound 
understanding of the multiple genetic mechanisms responsible for HA is essential to determine the 
appropriate strategy for molecular diagnosis and detect each type of genetic variant.  
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Introduction  
In the last 25 years of the twentieth century, our knowledge about human genetic variations was 
primarily limited to restriction, identifying single nucleotide and microsatellite/minisatellite variants 
by means of traditional polymer chain reaction- (PCR) based DNA sequencing. In recent years, the 
rapid development and expanded use of microarray technologies, such as array comparative 
genomic hybridization (aCGH) and next-generation sequencing (NGS), have led to the discovery of 
submicroscopic structural variations that are not identified by classical sequencing and not visible 
using traditional light microscopes. The size of these rearrangements, termed copy-number 
variations (CNVs), is estimated to range from kilobases (kb) to megabases (mb). These 
rearrangements can involve deletions, duplications or insertions of DNA sections, and account for a 
significant amount of the individual variability within species. It is estimated that over 13% of the 
human genome is affected by numerous CNVs. These appear to be the main source of genetic 
diversity, competing with the single nucleotide variants (SNVs) [1]. On account of this, it is clear that 
the sequence of a gene can be altered in a number of ways: small-scale mutations, such as those 
affecting a gene in one or a small number of nucleotides, including point mutations (missense, 
nonsense, splicing, and small deletions/duplications); large-scale mutations that alter the 
chromosomal structure, causing large duplications/deletions, translocations, inversions, and 
insertions. Thus, if the variant is sufficiently deleterious to affect the gene structure and the protein 
synthesis associated with it, this causes genetic disease [2-4]. 
This study sought to review the different variants reported in the F8 gene, which encodes the 
coagulation Factor VIII, and their underlying mechanisms. Hemophilia A (HA) is an X-linked congenital 
bleeding disorder, caused by a lack or dysfunction of coagulation Factor VIII, and is classified as 
severe (<1%), moderate (1–5%), or mild (5–40%), according to the FVIII plasma activity. The genetic 
alterations responsible for hemophilia can be classified into three categories. The first consists of 
alterations that change the sequence of the gene’s components, or gene variants, including the 
promoter, exons, and introns. The large size of the F8 gene results in a high rate of new small 
mutations (2.5x10-5 to 4.2x10-5, versus the median mutation rate estimated at approximately 1x10-
6/gene/cell division). The F8 location at the tip of X chromosome (Xq28), which contains high 
repetitive sequences in close proximity to each other, renders this gene region prone to 
rearrangement of the second category, classified as chromosome variants, thus accounting for the 
wide variety of large genetic alterations observed in HA patients [5-7]. The third source of DNA 
damage corresponds to the insertion of mobile elements, termed “transposons”, which has also 
been described among HA patients. 
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Genomic organization of F8 at locus Xq28 
First cloned in 1984, the Factor VIII gene (F8) was mapped to the distal end of the long arm of the X 
chromosome (Xq28) on the minus strand. This gene spans 186kb (hg19: chrX:154064064-154250998 
UCSC genome browser, see http://genome.ucsc.edu/) of genomic DNA. The gene is divided into 26 
exons and transcribed into an mRNA of 9029bp, with a coding sequence of 7053 nucleotides, 
encoding a mature protein of 2332 amino acid residues that are arranged within six domains, 
organized as follows: A1-a1-A2-a2-B-a3-A3-C1-C2. Compared to all other exons, and with the 
exception of exon 26 that mostly codes for the 3’ untranslated region, exon 14 is very long, 
measuring 3106bp, and encodes most of the B domain (Figure 1). The F8 gene contains the 
particularly large intron 22, measuring 32.8kb, which exhibits several particularities. These include 
the presence of a bidirectional promoter that initiates the transcription of expressed genes (F8A and 
F8B) and whose function is not yet well understood. The intronless F8A (OMIM 305423) spans 2kb 
and is transcribed in the opposite direction to F8. It encodes a 40-kDa Huntingtin-associated protein 
[8], thought to be involved in the aberrant nuclear localization of the huntingtin protein observed in 
Huntington’s disease. F8B (OMIM 305424) is transcribed in the same direction using a private exon 
within intron 22 that is spliced to exons 23 through 26, with the F8 reading frame creating a final 
overlapping transcript spanning 2.5kb. The function of the F8B transcript and its potential translated 
product remain unknown [9]. This arrangement is further complicated by the association between 
these three sequences (F8A, the first exon of F8B, and their common promoter) within a 9.5kb 
fragment labelled int22h-1 that is duplicated at two positions towards the Xq-telomere (int22h-2 and 
int22h-3), situated more telomerically at approximately 488 and 566kb [10]. Int22h-2 and int22h-3 
demonstrate 99.93% overall similarity, while the homology between Int22h-1 and int22h-3 is of 
99.24% and that of the other int22h-2 repeats 99.18%. Interestingly, the statistics and distribution of 
the sequence differences between the homologous copies strongly support theories that the copy in 
the F8 gene was introduced by a duplication more than 25 million years ago [11]. Similar to the 
int22h sequence, a different repeat has been identified within the F8 intron 1, labelled int1h-1 and 
located approximately 15.26kb downstream of exon 1. An inverted homologous copy of this was 
found approximately 125kb upstream of F8 (labelled int1h-2). Bagnall et al. postulated that int1h, like 
int22h, duplicated more than 25 million years ago [11]. 
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FIGURE 1: GENOMIC ORGANIZATION OF THE F8 GENE AT THE F8 LOCUS (XQ28) 
Graph not to scale 
A: The F8 gene is mapped to the distal end of the long arm of the X chromosome at locus Xq28 
(pointed by a red arrow) 
B: The F8 locus consists of the F8 gene and homologous sequences positioned in intron 1 (int1h-1) 
and intron 22 (int22h-1), along with additional extragenic sequences positioned at 125kb (int1h-2) 
and 488 and 566kb (int22h-2 or 3) upstream of F8 exon 1 
C: The large intron 22 contains a 9.5kb sequence, named int22h-1, composed by two genes (F8A), the 
first exon of F8B, and their common promoter 
D and E: 26 exons of the F8 gene encode the coagulation Factor VIII (FVIII) protein with the domain 
structure A1-A2-B-A3-C1-C2 
Human DNA variants: origins, mechanisms, and consequences  
Genetic variations can be divided into different categories according to size and type of genomic 
variation. These include small-scale sequence variations, affecting a small number of nucleotides; 
large-scale structural chromosomal aberrations, affecting >1kb; numerical chromosomal aberrations, 
more commonly found in the evolution of plants than animals and not developed in this review; 
changes in the cell's genome size by insertion of transposable genetic elements, called transposons. 
The origins, mechanisms, and consequences of these aberrations are all summarized in Table 1. The 
specific consequences for HA, percentages encountered among all HA patients (all confused 
severity), and molecular technologies for their detection are summarized in Table 2. 
1. Genome variants causing the alteration of a small  number of nucleotides 
Genome variants, such as base-pair substitutions, insertions/duplications, and deletions, can 
originate from two basic intrinsic mechanisms: errors introduced during the normal process of DNA 
replication, termed replication errors, or alterations caused by cell metabolism, called spontaneous 
lesions [12]. The latter is the consequence of natural processes in cells, distinguishable from 
mutations that are induced by the interaction of DNA with external physical or chemical agents called 
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mutagens and not addressed in this review. These DNA damages are typically repaired by the DNA 
mismatch repair (MMR) system in order to maintain genomic stability. 
 Sequence variation Structural (chromosomal) variation Genome size variation 
Origin 
DNA polymerase 
Spontaneous lesion 
Double break strand Transposable element 
Mechanisms 
Replication errors DNA 
lesions:  
depurination, 
deamination, 
frameshift mutations 
Non-allelic homologous 
recombination (NAHR) 
Non-homologous DNA end joining 
(NHEJ) 
Microhomology-mediated end 
joining (MMEJ) 
“Copy and paste” 
“mechanism 
Consequence 
and applications 
in HA 
Substitutions  
Frameshift alterations 
Deletion, duplication, inversion, 
insertion, translocation 
DNA insertion 
 
TABLE 1: ORIGINS, MECHANISMS, AND CONSEQUENCES OF HUMAN DNA VARIANTS 
Sequence variation can be generated by different processes, such as replication errors, or occur 
spontaneously. If they are not corrected by repair enzymes (mismatch DNA repair system), base-
substitution and frameshift mutations are generated.  
Structural variation is the variation in structure of a chromosome. Submicroscopic structural 
variations include copy-number variation (CNV), such as insertions, deletions, and duplications of 
approximately 1 kilobases-3 megabases segments. This variation also induces microscopic structural 
variation that can be detected using optical microscopes, such as aneuploidies, marker chromosome, 
and gross rearrangements (not developed in this review). 
Genome size variation increases the amount of DNA in the cell genome. One source of this variation 
are retrotransposons (LINEs and SINEs), which make cDNA copies of an RNA transcript that are then 
integrated into a new genomic location when active. 
 
a. Replication errors: Although DNA replicates with immensely high fidelity, during the 
process of assembling millions of nucleotides, a DNA polymerase can make mistakes. An incorrect 
nucleotide is introduced only once every 10 million base pairs. However, corrections are performed by 
a series of DNA repair enzymes that first recognize which strand in the newly synthesized fragment 
contains error and then replace it with the correct complementary base. The overall number of 
mutations caused by replication errors has been estimated to be remarkably low (10-10/base pair/cell 
division). As the human genome contains approximately 6x109 nucleotides divided into two DNA 
molecules, replication errors introduce less than one new base-pair mutation per cell division. 
b. Spontaneous lesions: It has been estimated that between 10,000 and 1000,000 
nucleotides are damaged per cell per day by spontaneous chemical processes, such as 
depurination/depyrimidination and deamination.  
Depurination/depyrimidination consists of the interruption of the glycosidic bond between the base 
and deoxyribose. When this occurs, it leads to the formation of an apurinic site and provokes an 
alteration in the DNA structure. Studies estimate that as many as 5,000-10,000 purines are lost in this 
way each day in a typical human cell [13]. Apurinic sites in double-stranded DNA are efficiently 
repaired by portions of the base excision repair (BER) pathway. However, in the absence of 
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information from the complementary strand, BER can add an incorrect base at the apurinic site, 
resulting in a substitution mutation.  
The deamination of the cytosine consists of the removal of the amine group by hydrolysis reaction. 
This is a common process and results in the replacement of cytosine by uracil. Deamination can also 
occur with guanine and adenine, leading to the production of xanthine and hypoxanthine, 
respectively. The deamination of the cytosine can be easily repaired by the uracil-DNA glycosylase, 
which recognizes the uracil residues in the DNA, as well as by the BER mechanism. 
However, the deamination of 5-methylcytosine, which generates thymine and ammonia, poses a 
particular problem since it is not recognized by the uracil-DNA glycosylase enzyme, as thymine is a 
normal base of DNA, and thus is not repaired. The major form of DNA modification in the human 
genome involves the methylation of cytosine residues, especially when 5-methylcytosine 
immediately precedes a guanine, such as in the dinucleotide 5’-CG-3’. The spontaneous deamination 
of 5-methylcytosine in the CG doublet gives rise to C>T or G>A substitutions, depending on the 
strand of DNA in which the 5-methylcytosine is located. This type of mutation thus represents over 
30% of all single nucleotide substitutions in the human genome and they occur at a rate that is 25 
times greater than that of any other single nucleotide mutation [14]. This is why the CG dinucleotide 
represents a “true hotspot” for mutation in the human genome.  
 
Classical HA is caused by widespread deleterious mutations in the F8 gene. The mutations that create 
significant disruption in F8 lead to severe disease, whereas those that alter apparently “minor” 
regions of the Factor VIII protein result in mild to moderate disease. HA also presents with genetic 
heterogeneity, with over 2015 variants described in the HAMSTeRS database [http://www.eahad-
db.org/version 1.3]. These 2015 variants correspond to 5472 individual case reports and include 
substitutions as well as small and large duplications/deletions. The vast majority of these variations 
are substitutions producing missense, nonsense in the coding sequence, and splice defects of the 
mRNA when located in the exon/intron junction. Recently, substitutions in the promoter and deep 
intron have also been reported as associated with mild HA [15-17]. 
 
The F8 gene is composed of 70 cytosine-phosphate-guanine (CpG) sites that are not mutated in the 
same proportion [18, 19]. However, nearly 35% of all F8 substitution mutation reports (point and 
polymorphism mutations providing missense, nonsense, and silent effects) occur at one of these CG 
dinucleotides. The Lannoy et al. study suggested that if the same recurrent substitution shared by 
unrelated HA patients is located somewhere in the F8 gene, the founder effect is the more probable 
mechanism than for those positioned precisely in the 5’-CG-3’ dinucleotide [19]. A number of reports 
have, in fact, described F8 mutations that are present in high frequencies in specific populations: 
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c.6104T>C (p.Val2035Alanine), c.1538-18G>A, c.788-14T>G, and c.3780C>G (p.Asp1260Glu) [20-23]. 
These substitutions were not located in the 5’-CG-3’ dinucleotide and have, in all cases, been 
reported in subjects exhibiting the mild HA phenotype and who share a common ancestor. Through 
haplotyping patients sharing the same mutation in a group of HA-positive Swedish families, 22% 
were revealed to have a common ancestor [24]. This study also revealed that some mutations could 
date back to the Middle Ages. When investigating the location of these Swedish mutations in 
patients who apparently share a common ancestor, they were all found to be located outside of a 5’-
CG-3’ dinucleotide site (c.67, c.121, c.1195, c.1244, c.1595, c.2211, c.3146, c.5093, c.6371, c.6658, 
c.6680, and c.6932) except for those located at c.1834 and c.5806. 
Spontaneous frameshift mutations: Streisinger et al. observed that frameshift mutations in 
bacteriophages tended to occur in areas with "runs" of repeats of one nucleotide. He proposed that 
these frameshifts were the result of "slipped mispairing" or strand slippage between the template 
DNA strand and the newly synthesized strand during DNA replication [25]. Subsequent studies on 
genes taken from other organisms, including humans, have since demonstrated that runs of repeated 
nucleotides are indeed hotspots for frameshift mutations [26, 27]. 
Another mutation hotspot has thus been identified in the F8 gene, associated with frameshift 
deletion or duplication. It has, in fact, been shown that 25% of all F8 small deletions/duplications 
affect one of the two adenine stretches composed of eight or nine adenine nucleotides within exon 
14 (at codons 1210-1213 and 1458-1460) [18]. The remaining 75% of small 
deletions/duplications/insertions are the result of poor DNA breaks repairs by the non-homologous 
DNA end joining (NHEJ) and microhomology-mediated end joining (MMEJ) pathways described 
below. 
2. Chromosomal variant, providing inversions, and CNVs 
In human cells, both normal metabolic activities and environmental factors, such as UV light and 
radiation, can cause DNA damage like double-strand breaks (DSBs), resulting in as many as a million 
individual molecular lesions per cell per day [28]. There are three principal mechanisms that enable 
DSB repair, thereby ensuring genome stability is maintained: homologous recombination (HR) 
between homologous sequences, the non-homologous DNA end joining (NHEJ) and microhomology-
mediated end joining (MMEJ) pathways. 
 The homologous recombination mechanism. HR is critical both for repairing DNA lesions in 
mitosis and for chromosomal pairing and exchange during meiosis. It is also the most accurate 
mechanism as it requires extensive DNA sequence identity and uses an intact copy of the DNA from 
the sister chromatid or homologue chromosome to repair the break.  
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 The non-homologous or microhomology recombination mechanisms. In addition to the HR 
pathways, there are other mechanisms that serve to repair DSBs which use little or no homology 
sequences and are termed non-homologous recombination mechanisms. NHEJ is referred to as "non-
homologous" due to the break ends being directly ligated without the need for a homologous 
template. This contrasts with HR pathways, which require a homologous sequence to guide the 
repair. The Microhomology-mediated end joining (MMEJ) mechanism should be distinguished from 
NHEJ by its use of 5–25 base-pair microhomologous sequences in order to align the broken strands 
prior to joining them. Other DNA replication-based mechanisms, such as fork stalling and template 
switching (FoSTeS) or microhomology-mediated break-induced replication (MMBIR), have been 
proposed to repair DSBs [29-32]. 
When homology is not used to ensure that the DBSs are rejoined in the correct positions, the process 
can cause damage in the chromosome and induce CNVs. The detection of chromosomal changes 
requires specialized technologies, such as aCGH, multiplex ligation dependent probe amplification 
(MLPA), and NGS. Taking advantage of these new bio-molecular technologies, recent studies have 
demonstrated that the human genome is also composed of high-order sequences that predispose it 
to genome instability and CNV formation [1]. These genomic architectural features are primarily 
highly homologous sequences located throughout the human genome, named low-copy repeats 
(LCRs) or segmental duplications (SDs). Typically, they measure 10-300kb in length and exhibit a 
>97% sequence identity, yet are not alleles. Though rare in most mammals, LCRs comprise a large 
portion of the human genome, estimated at up to 5%, due to a significant expansion that occurred 
during primate evolution over the past 25-40 million years.  
Due to their high degree of sequence identity, these non-allelic copies (LCRs) provide a substrate for 
genomic rearrangement via non-allelic homologous recombination (NAHR) when misalignment 
occurs during meiosis or mitosis. In this way, if a crossover forms when high homologous sequences 
are positioned in non-allelic positions and in direct orientation, the result is duplication and deletion 
of sequences between the repeats. These can subsequently segregate from each other at the next 
cell division, thus changing the copy number in both daughter cells. Crossing over during 
intrachromosomal recombination between inverted repeats leads to the inversion of the sequence 
located between them. The NAHR mechanism, occurring between repeats on different 
chromosomes, can lead to chromosomal translocation. In summary, this NAHR mechanism is one of 
the principal processes for recurrent rearrangements [33]. The Xq28 locus is considered a 
rearrangement hotspot for NAHR and is associated with several disease phenotypes, such as 
hemophilia A, incontinentia pigmenti, Emery-Dreifuss muscular dystrophy, and the MECP2 X-linked 
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mental retardation syndrome [34-37]. In HA, the int22h/int1h repeats, as detailed above, fulfill the 
criteria defined for LCRs.  
 
Chromosomal alterations in F8 have been observed and documented for a long time. The F8 intron 
22 inversion was, in fact, one of the first examples of chromosomal rearrangement reported in 
genetic diseases. Deletions of one or more exons, easily identified in male patients due to the 
presence of only one X chromosome, have been widely documented in HA and account for 
approximately 5% of cases [18]. Recently, with the implementation of the MLPA and aCGH 
techniques, we have been able to identify large F8 duplications and better understand the 
mechanisms for their occurrence [38, 39]. 
 Inversion in F8: When intrachromosomal HR occurs between inverted homologous 
sequences, this results in inversion, classically described in severe HA. The most common genetic 
defect in HA patients is the F8 intron 22 inversion, which is responsible for up to 45% of severe cases. 
This specific inversion has been reported independently by two different groups [34, 40], each of 
whom observed that half of the severe HA patients exhibited F8 mRNA defects that prevented 
message amplification across the boundary between exon 22 and 23. These studies explained 
inversion intron 22 (Inv22) rearrangements to be the result of intrachromosomal recombination 
between homologous sequences (int22h) located in intron 22 (int22h-1) and two others (int22h-2 
and int22h-3) positioned more telomerically outside the F8 gene. This event lead to an inversion of a 
portion of the F8 gene (exons 1 to 22), preventing the production of intact Factor VIII protein. The 
mechanism for intron 22 inversions involves flipping the end of the X chromosome to position two 
inverted int22h repeats face to face, enabling NAHR events to occur during male gametogenesis [41]. 
These events result in inversion and separate F8 exons 1-22 from the exons 23-26 that completely 
disrupt FVIII. Similar to the inversion of intron 22, another inversion has also been identified resulting 
from homologous recombination between int1h-1 repeats within F8 intron 1 and its extragenic 
inverted homologous copies (int1h-2). This inversion causes the splitting of F8 into two reading 
frames in opposite directions, producing a short F8 mRNA segment consisting solely of F8 exon 1. 
This mutation affects 2 to 5% of patients with severe HA [42, 43]. More recently, a third inversion 
was described in a severe HA case that was caused by the homologous recombination of inverted 
repeats within F8 intron 1 [44]. This complex rearrangement occurs between a repeat in F8 intron 1 
(Int1R-1, different from int1h) and an inverted identical repeat (Int1R-2d) in intron 2 of a duplicated 
copy of IKBKG. 
 Deletions/duplications in F8: When intrachromosomal HR occurs between direct int22h 
homologous sequences, the result is duplications/deletions of 0.5/0.6Mb of the sequence [45, 46]. 
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Other alterations of the F8 structure, such as large deletions or duplications, are relatively 
uncommon in F8, compared to the small genic variants, and account for approximately 5 and 0.07%, 
respectively [18, 39]. Exon deletion in F8 in male hemophiliacs can be detected through repeated 
failures to amplify the gene using PCR, a process that is not possible in females due to their second 
normal X chromosome. Over 206 large deletions have been reported in the Hemophilia A Mutation 
database. These deletions range from just a few hundreds of bases up to sequences of over 210kb, 
thus constituting deletion of the entire gene. The molecular characterization of these deletion 
breakpoints in the F8 gene indicated that NHEJ and microhomology-mediated replication-dependent 
recombinations (MMEJ, FoSTeS or MMBIR) represent the probable causative mechanisms in these 
deletions [47]. For large F8 duplications, the breakpoints of 10 large F8 duplications were 
characterized in the study of Zimmermann et al. [39]. In nine duplications, at least one of the two 
breakpoints was mapped within LINEs (long interspersed elements) or SINEs (short interspersed 
elements). Molecular mechanisms, such as NHEJ, MMEJ, MMBIR, or FoSTeS, may mediate the 
formation of these duplications through sequence motifs, microhomologies, and larger stretches of 
homology, such as Alu repeat sequences. 
3. Genome size variation 
"Transposon-induced mutations" are the last category of mutations. Transposable elements (TEs), 
also known as “jumping genes” or “transposons”, were first discovered by Barbara McClintock, a 
U.S.A. geneticist and Nobel laureate, in 1950. These represent DNA sequences that can move or jump 
position within the genome. As a result of this movement, these insertions provide a source of 
genetic variation and, in rare cases, cause mutations that lead to disease. TEs are categorized into 
two major classes based on their distinct mechanisms of transposition. Only the retrotransposons 
remain actively mobile in the human genome. These are represented by the LINEs, which represent 
the most abundant autonomous retrotransposons in humans, accounting for approximately over one 
million copies and representing 19% of human DNA, as well as the SINEs, or Alu sequences. These 
retrotransposons have the ability to duplicate and insert themselves into a new location in the 
genome by means of a "copy and paste" mechanism. These LINEs and SINEs still have a significant 
impact on the human genome and their jumping can lead to sporadic cases of disease, such as 
hemophilia B, muscular dystrophy, and neurofibromatosis Type 1 if they insert themselves into the 
functional gene [48-50].  
In hemophilia A, rearrangements like the insertion of LINE sequences of several kb (3.8 and 2.3kb, 
respectively) into F8 exon 14 have been described in a few unrelated sporadic cases of HA [51].  
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Polymorphism versus causal mutation 
One of the major genetic challenges is to distinguish causal change from polymorphism. Due to the 
high rate of new small mutations that occur in the F8 gene, unreported substitutions are frequently 
identified during molecular analysis screening. Special care should thus be taken when novel 
substitutions are identified before concluding that they are responsible for HA disease. Guidelines 
have been published to help predict what consequences these new F8 variants will have on protein 
function [52]. 
Numerous identified human CNVs represent benign polymorphic variants. Interpreting the clinical 
relevance of copy number variation is thus a complex exercise and requires both cytogenetic and 
molecular genetic expertise, as well as the involvement of an experienced geneticist [53]. Due to its 
location at the tip of the X chromosome, which contains high repetitive sequences, the F8 locus has 
been widely reported to harbor CNVs, with the vast majority being deleterious. However, the 
duplication of 0.5/06kb sections involving F8 gene exons 1-22 is probably not associated with HA or 
intellectual disability [45]. 
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TABLE 2: MECHANISMS AND CONSEQUENCES OF DNA VARIANTS IN HA, PERCENTAGE ENCOUNTERED AMONG ALL HA 
PATIENTS (ALL CONFUSED SEVERITY) AND MOLECULAR TECHNOLOGIES FOR THEIR DETECTION  
 
Categories 
Mechanisms 
Consequences 
in HA 
% in HA all 
severities* 
Molecular 
detectionβ 
Sequence 
variant (small 
number of 
nucleotides) 
 Replication errors 
 Depurination 
 
1. Deamination 
 
2. Slipped strand mispairing and NHEJ/MMEJ (detailed below) 
 
 
 
 
 
 
 
 
Substitutions 
 
 
 
 
 
 
Deletion 
 
Duplication 
 
Insertion 
 
Insertion/del 
  
 
 
Missense:36.5 
Nonsense:8.3 
Splicing: 5.5 
Polymorphism:
2.3 
 
 
 
 
 
15.2 
 
3.2 
 
1.3 
 
1.4 
 
For all 
variants of 
this 
category: 
Pre-
sceening:  
DGGE 
CSGE 
DHPLC 
HRM 
 
Sequencing 
 
Structural 
chromosomal 
variant (1kb to 
3mb) 
 NAHR: junction with extended homologies  
a) between inverted repeats 
 
b) between direct repeats 
 
 NEJH/MMEJ: junction with/without extended 
(micro)homologies 
 
 
Inversion int 22 
 
Inversion int 1 
 
Del: lethal in 
males[54] 
Dupl: probably 
polymorphic 
 
 
 
Deletion 
Duplication 
 
 
22.5 
 
2 
Very rare 
Very rare 
 
 
 
 
 
2.5 
0.3 
 
SB, LR-PCR, 
IS-PCR 
 
PCR 
Other 
variants: 
aCGH, 
MLPA 
 
Genome size 
variant 
 “copy and paste" mechanism for insertion of new 
transposons 
 
Insertion DNA 
sequence 
Very rare Sequencing 
*: These unique F8 variants were provided from HAMSTeRS database [http://www.eahad-db.org/version 1.3], with the 
exception of the intron 22/1 inversion, not listed (extraction 2015) 
β: DGGE: denaturing gradient gel electrophoresis; CSGE: conformational sensitive gel electrophoresis; DHPLC: denaturing 
high performance liquid chromatography (dHPLC); HRM: high-resolution melting analysis; SB: southern blotting; LR-PCR: 
long range-polymerase chain reaction; IS-PCR: inversion-polymerase chain reaction; PCR: polymerase chain reaction; aCGH: 
array comparative genomic hybridization; MLPA: multiplex ligation-dependent probe amplification; DNA: deoxyribonucleic 
acid; HA: hemophilia A; NHEJ: non-homologous DNA end joining; MMEJ: microhomology-mediated end joining  
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Conclusion  
Our knowledge of the human genome has grown considerably over the last 10 years, advanced by 
the identification of CNVs. It has now become clear that the human genome mutates, recombines, 
deletes, and duplicates to ensure its survival and evolution, adapting to on-going environmental 
changes. However, if a DNA variant affects the structure of a gene, protein synthesis can be changed 
to such a degree that it no longer functions properly and leads to disease. 
 
Due to the high rate of new small mutations in the F8 gene, as well as its location at the tip of the X 
chromosome, alterations in F8 are frequent and are caused by the three molecular mechanisms 
associated with genetic diversity. Our understanding of these causal mutations and their mechanisms 
is essential to determine the optimal strategy of molecular diagnostics for HA cases, given that each 
type of genetic change requires a different technique for detection.  
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Aim of the study and experimental strategy  
Results developed throughout this work were presented in two parts. 
The first part mainly studies the F8 gene by establishing a registry of variations from 148 families 
with molecular biology technologies (Southern blot, sequencing, MLPA, RT-PCR, genotyping). At the 
end of the thesis, a total of more than 200 patients, apparently unrelated, have been analyzed. As 
expected, the nature and the percentage of the identified mutations correspond to those published 
in the literature. However, several specific variations that have never been reported previously 
require a delicate interpretation to conclude on their deleterious effect or not. For this, other 
approaches reported in the first chapter were undertaken as the study of cDNA, bioinformatics or 
family cosegregation. Another finding of this study is the recurrence (up to more than 10 times) of 
four missense mutations in families with mild hemophilia A. With allelic segregation analyzes, we 
have suggested in chapter 2 that an identical mutation shared in several unrelated families is 
probably associated with a founder mutation if this mutation does not affect a CpG sequence. 
The second part of this thesis will focus on the study of three different chromosomal duplications 
located in the F8 gene and at its Xq28 locus. The first, identified in two patients with HA and a third 
patient presenting intellectual disability and dysmorphic features, involves duplication of 0.5 or 0.6 
Megabases (Mb) including F8 exons 1 to 22. Molecular analysis of this rearrangement with Southern 
blot, long-range PCR and aCGH, detailed in chapter 3, have been shown to involve repetitive highly 
homologous sequences, called "int22h", positioned in direct position in the formation of this type of 
duplication by a NAHR mechanism These sequences are present in three copies in the general 
population, one being located in F8 intron 22, the two extragenic others positioned side by side more 
telomerically. The genotype-phenotype correlation of these three patients lead to the conclusion 
that these specific rearrangements are probably not responsible for HA and should be carefully 
considered in genetic counseling, while continuing to investigate the causal mutation of hemophilia. 
However, controversy about the causality of the int22h1/int22h2-mediated Xq28 duplication in 
intellectual disability persists in the scientific literature. In chapter 4, we are interested in the third 
type of inversion of intron 22. Rarely encountered, this inversion is a variation of types 1 and 2 easily 
recognized by abnormal profile when it is revealed by Southern blot. The three types of inversion 
cause a severe phenotype of HA since the 3’ extremity of the F8 gene (exons 23-26) is separated 
from the rest of the gene (exons 1-22) during a intrachromosomal illegitimate recombination 
between two "int22h" repeats. With aCGH technology, an approximate 180kb duplication delimited 
on either side of the two extragenic copies "int22h" was found in DNA of three unrelated HA patients 
(one with type 3A, the two others with type 3B). This duplication in size and location was also 
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reported in the "DECIPHER" database that classifies this rearrangement as "likely benign". This 
allowed us to hypothesize that there are probably in the general population polymorphic genotypes 
with five int22h copies generated by 180kb duplication. This rearrangement is not responsible of the 
intron 22 inversion but it is technically visible by the method of Southern blot in HA patients with the 
third type of inversion. Finally, the third rearrangement of 210kb, explained in the fifth chapter, 
involves duplication of F8 exon 1. This duplication, never reported, was found in mild HA patients of 
three apparently unrelated families. After showing normal sequence of the mRNA and quantitative 
deficiency of FVIII activity, we postulated that the rearrangement responsible for this duplication 
could have arisen due to a tandem inversed duplication producing novel 233kb F8 intron 1 instead of 
normally 22kb present in the gene. This new intron could provide small amounts of intact F8 mRNA 
transcripts which explain the mild severity of patients of these families. The family segregation 
analyses also suggested that the ~210kb duplication involving F8 exon 1 was likely a single, one-time 
event that was then disseminated via a founder effect. 
  
 
 
43 
 
  
 
 
44 
 
  
 
 
45 
 
 
 
 
 
 
 
 
 
RESULTS 
  
 
 
46 
 
  
 
 
47 
 
SECTION 1 
F8 alterations in a cohort of patients with 
hemophilia A 
  
 
 
48 
 
  
 
 
49 
 
Chapter 1 
 
Computational and molecular approaches for predicting unreported causal 
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Summary 
Introduction 
Haemophilia A (HA) is caused by widespread mutations in the factor VIII gene. The high spontaneous 
mutation rate of this gene means that roughly 40% of HA mutations are private. This study aimed to 
describe the approaches used to confirm private disease-causing mutations in a cohort of Belgian HA 
patients. 
Methods 
We studied 148 unrelated HA families for the presence of intron 22 and intron 1 inversion by 
Southern blotting and polymerase chain reaction (PCR). Multiplex ligation-dependent probe 
amplification (MLPA) assay was used to detect large genomic rearrangements. Detection of point 
mutations was performed by DNA sequencing. Predicting the causal impact of new non-synonymous 
changes was studied by two general strategies: 1) molecular approaches such as family 
cosegregation, evaluation of the implicated codon based on phylogenic separated species, and 
absence of the mutation in the general Belgian population; 2) bioinformatics approaches to analyse 
the potential functional consequences of missense mutations. 
Results 
Among the 148 HA patients, in addition to common intron 22 and intron 1 inversions as well as large 
deletions or duplications, 67 different point mutations were identified, of which 42 had been 
reported in the HAMSTeRS database, and 25 were novel including 10 null variants for which RNA 
analyses confirmed the causal effect of 4 mutations located in a splice site consensus and 15 
missense mutations whose causality was demonstrated by molecular approaches and bio-
informatics. 
Conclusions 
This article reports several strategies to evaluate the deleterious consequences of unreported F8 
substitutions in a large cohort of HA patients. 
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Introduction 
Haemophilia A (HA) (OMIM 306700), an X-linked hereditary disease, is one of the most common 
coagulation disorders with a worldwide incidence of approximately one in 5,000 male newborns. 
Factor VIII gene (F8) maps to the distal end of the long arm of the X-chromosome (Xq28), and spans 
186kb of genomic DNA that is divided into 26 exons (approximately 9kb cDNA) containing 2332 
amino acids residues that are arranged within six domains organized as A1-a1-A2-a2-B-a3-A3-C1-C2. 
More than 1,000 mutations within the FVIII coding region and splice site junctions including more 
than 580 missense mutations have been identified and reported in the major HA mutation database 
[1]. The type of mutation in F8 predicts HA severity. Mutations that produce a significant disruption 
in factor VIII lead to severe disease, whereas mutations that alter apparently “minor” regions of the 
factor VIII protein result in mild to moderate disease. Typically, the most common genetic defect in 
HA patients is the F8 intron 22 inversion, which is responsible for up to 45% of severe cases [2]. An 
additional inversion of intron 1 of F8 affecting 2 to 5% of patients with severe HA has been described 
[3]. The large size of F8 predisposes to deletions and duplications, which respectively account for 
approximately 5% and 1% [4, 5] of characterised mutations in patients with severe HA. Single base 
pair changes spread all over exons of F8.  In severe types, they account for 15% of missense 
mutations and approximately 25% of other variation types that result in non-sense, splice junction 
mutations, and small deletions or duplications, while they comprise almost 100% of moderate and 
minor forms. 
In spite of multiple techniques, no mutation is detected in 1 to 2% of HA patients, suggesting that 
other still-unknown regulatory regions are responsible for the disease [6, 7]. 
The main objective of this study was to describe the current approaches used to confirm disease-
causing mutations in 25 small private mutations that produce mild to severe phenotype changes in 
Belgian HA patients. To date, these mutations have not been reported in HA databases.  
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Patients and methods 
Patients 
Diagnosis of HA was carried out on the basis of the following laboratory analysis: FVIII activity using 
the one-stage coagulative method (FVIII:C) and chromogenic substrate assays. 
Haemophilia severity was defined by FVIII:C levels in plasma, according to which individuals with 
severe HA had <0.01 IU/l (<1% of normal), moderate HA 0.01-0.05 IU/l (1 to 5% of normal), and mild 
HA 0.05-0.40 IU/l (5 to 40% of normal) [8]. 
In our cohort of 148 Belgian HA subjects mainly followed within the Haemostasis and Thrombosis 
Unit of the Cliniques Universitaires Saint Luc, Brussels, Belgium, 74 (50%) had severe, nine (6%) 
moderate, and 55 (37%) mild phenotype. Ten (7%) of the patients were females presenting with mild 
disease or normal factor VIII level, who were referred for analysis due to their father's haemophilia 
history (n=6) or their presentation of de novo FVIII (or first case in the family) deficiency and bleeding 
symptoms (n=4). As they were the first family cases, they acted as case indices. 
DNA collection 
A blood sample (5-10ml) was collected in EDTA from 148 unrelated Belgian patients with HA, 
followed by a genomic DNA purification from peripheral leucocytes using the salting-out procedure. 
Detection of intron 1 and intron 22 inversions 
Intron 22 inversion was detected by southern blotting. In short, 7µg of genomic DNA from patients 
was digested with BclI, and thereafter DNA fragments were electrophoresed in a 0.8% agarose gel for 
20 hours at 35V and then transferred to nylon membranes. The membranes were probed with the 
0.9kb EcoRI/SstI fragment from plasmid p482.6 (American Type Culture Collection [ATCC] catalogue 
n°.57203). 
The PCR amplification of the F8 intron 1 region and the intron 1 h repeats were performed on 100ng 
of genomic DNA in a 25µl reaction volume containing 1x PCR Faststart buffer, 1U of Faststart Taq 
polymerase (Hoffmann-La Roche, Basel, Switzerland), 0.2mM of each dNTP, and 10pmol of 9F, 9CR, 
and int1h-2F primers, as previously described by Bagnall [3]. After the initial denaturing step at 95°C 
for 5 min, 30 cycles of PCR were carried out at 94°C for 30 sec, 65°C for 30 sec, and 72°C for 2 min. 
Finally, 5µl of PCR product were electrophoresed for 1 hour in an 8% polyacrylamide gel. 
MLPA  
In order to detect large genomic rearrangements in F8, a specifically designed SALSA MLPA P178 FVIII 
kit (<MRC-Holland, Amsterdam, The Netherlands) was used for screening [9]. The P178 probe mix 
contains probes for each of the 26 exons of F8 as well as 11 control probes for sequences located in 
other genes. More than one probe was present for exons 1, 7, 12, 14, and 26. This probe mix did not 
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contain a probe for exon 22B, which was only present in an alternative transcript. Procedures had 
been described previously [10] and applied according to the manufacturer’s protocol. Amplification 
products were identified on an ABI 3130xl capillary sequencer (Applied Biosystem, Foster City, CA, 
USA) using Genescan-ROX-500 as a size standard, and were interpreted using GeneMarker software 
v1.5 (SoftGenetics LLC, State College, PA, USA) that normalises data in relation to control peaks from 
other genes. Peak ratios of <0.70 were considered to be deletions and ratios >1.40 to be duplications. 
DNA samples from healthy individuals were used as negative controls. 
Detection of point mutations by DNA sequencing 
All known functional regions, including the 26 exons with their immediate 5’ and 3’ flanking splice 
junctions, the approximately 1.2 kb of contiguous promoter sequence corresponding to nucleotide -
1214 to +441 of the F8 reference sequence NM_000132 http://www.ncbi.nlm.nih.gov), and the 
309bp of flanking 3’-genomic DNA of F8 gene, were amplified by the polymerase chain reaction (PCR) 
and sequenced as previously described [11, 12]. Primers for screening exons 17-20 and 24-27 of von 
Willebrand factor (vWF) gene were created using Primer 3 software v.0.3.0 (SourceForge, Inc., 
Massachusets, USA). Forward and reverse sequences and amplification conditions were available on 
request. All primers were synthesized using Sigma Proligo or Eurogentec. Amplified DNA fragments 
were purified and subjected to direct cycle sequence analysis using the Taq dye-deoxy terminator 
method and an ABI PRISM 3130xl Genetic Analyzer sequencer (Applied Biosystem, Foster City, CA, 
USA) according to the manufacturer’s instructions. All the nucleotide changes identified were 
confirmed by repeating the PCR and sequencing reactions. 
Sequence variation nomenclature used to generate the factor VIII genotype (the nucleotide number 
was assigned according to the F8 cDNA sequence from A of the initiator ATG site as +1 (NM_000132)) 
and protein changes are reported according to international recommendations for the description of 
sequence variants on the Human Genome Variation Society (HGVS; http://www.HGVS.org; update 
June 2010). Variants are also reported in italics and in parentheses according to the numbering of 
HAMSTeRS (http://europium.csc.mrc.ac.uk/) since this numbering is used in most haemophilia A 
reports. All identified genomic variations were screened against HAMSTeRS and Alamut®-Mutation 
Interpretation Software (http://www.interactive-biosoftware.com/) which displays information from 
the Human Gene Mutation Database, available to HGMD® Professional subscribers.  
RNA Analysis 
Total cytoplasmic RNA was isolated from peripheral leucocytes using Tri reagent (Invitrogen Life 
Science, California, USA) according to the manufacturer’s protocol based on standard procedures. 
Primers and conditions had been previously reported [13, 14]. 
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Analysis of missense mutations 
Causal missense mutations were determined according to the following criteria: (a) the mutation 
cosegregated in other affected or carrier individuals from the same family; (b) it was not detected in 
200 X-chromosomes from the general Belgian population; (c) no other nucleotide variation was 
found in the F8 coding region or in exon-intron boundaries; (d) the mutated nucleotide was not 
reported in non-affected individuals in the available population SNP databases, NCBI 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) and the International HapMap Project 
(http://www.hapmap.org/); (e) the mutated nucleotide was situated in highly conserved regions of 
F8; (f) the mutated residue was conserved or conservatively replaced in F8 from eleven phylogenetic 
separated species (human, chimpanzee, macaque, rat, mouse, dog, cat, cow, chicken, xenopus, and 
tetraodon) and were located in a highly conserved regions of F8; (g) the prediction of variations in 
RNA splicing was analysed using the Splice Site Prediction program 
(http://fruitly.org/seq_tools/splice.html); (h) finally, three commonly used algorithms to predict the 
impact of missence mutations on protein structure and function were employed: 
PolyPhen-2 (Polymorphism Phenotyping, 
http://genetics.bwh.harvard.edu/pph2/,SupplementarySoftware), SIFT (Sorting Intolerant From 
Tolerant, http://sift.jcvi.org/www/SIFT_aligned_seqs_submit.html), Align GVGD 
(http://agvgd.iarc.fr/agvgd_input.php). 
PolyPhen-2 [15] is an automatic tool for prediction of possible impact of an amino acid substitution 
on the structure and function of a human protein. This prediction is based on a number of features 
comprising Sequence-based features, the Position-Specific Independent Counts (PSIC) profile scores 
for two amino acid, the mapping of the substitution site to known protein 3D structures. PolyPhen-2 
predicts variants as “benign”, “possibly damaging”, or “probably damaging” accompanied by a 
prediction confidence score ranging between 1 (probably damaging) to 0 (benign).  
SIFT [16] predicts the functional importance of amino acid substitutions and their potential 
pathogenicity based on the alignment of orthologous or paralogous protein sequences. SIFT scores 
were classified as intolerant (0.00-0.05), potentially intolerant (0.051-0.10), borderline tolerant 
(0.101-0.20), or tolerant (0.201-1.00) according to a classification previously proposed. The higher 
the tolerance index, the less functional impact a particular amino acid substitution was likely to have, 
and vice versa. 
Align GVGD [17] is a web-based program that combines the biophysical characteristics of amino acids 
and protein multiple sequence alignments to predict where missense substitutions in genes of 
interest fall in a spectrum from enriched delterious to enriched neutral. GVGD calculates the 
Grantham Variation (GV), which measures the degree of biochemical variation among amino acids 
found at a given position in the multiple sequence alignment of the gene and the Grantham 
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Deviation (GD), which reflects the ‘biochemical distance’ of the mutant amino acid from the 
observed amino acid at a particular position (given by GV).If (GV = 0) and (GD > 0): the position of 
interest is invariant (100% conservation) so any mutation at the position is predicted as deleterious. 
The classifier provides ordered grades ranging from the most likely pathogenic to least likely 
pathogenic. 
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Results  
Overall population of haemophilia patients 
In this study, F8 mutations were identified in 139 of 148 unrelated patients with a history of HA, 
representing a mutation detection rate of 94%.  
Intron 22 and intron 1 inversion screening  
All patients with severe HA as well as female index cases were initially tested for the presence of F8 
intron 22 and intron 1 inversions (n=84). Intron 22 was found in 44% (37/84) of patients: 34 affected 
male patients and three female index cases. All intron 22 inversions were type 1 with exception of 
two cases: the first corresponding to a type 2 inversion and the second to type 3B as outlined in an 
international consortium study [2]. Intron 1 inversion was observed in one severe case (1.2%). 
Large deletion and unrelated duplication by MLPA assay 
Following standard 1 and 22 inversion screening in patients with a severe phenotype and in females 
referred for F8 analysis, MLPA assay was applied as routine molecular screening. Six different large 
rearrangements were detected. In three families, only one exon was found to be deleted: exon 2 in 
female patient HA86, and exon 5 and 15 in patients HA78 and HA65, respectively. Two other female 
index cases showed larger deletions: heterozygous deletion of exons 1-12 in patient HA73 and 
heterozygous deletion of exon 26 extending to the 3’UTR region in patient HA51 (cases HA 86 and 51 
had already been reported [11]). A large duplication of exons 1-22 was detected in a sixth patient 
with a severe phenotype. 
When sequencing F8 in moderate and mild HA patients failed to show any causal mutation, MLPA 
analysis was performed allowing for the identification of two novel large duplications: exons 1-22 
combined with a triplication of exons 2-14 in a moderate case and only exon 1 in a mild case. 
As recommended [18], all deletions and duplications affecting only one exon were confirmed by 
examining mRNA or using quantitative PCR in order to exclude nucleotide mismatch at the probe 
binding site. 
Small mutations by DNA sequencing  
Nucleotide sequencing was carried out in the remaining HA patients corresponding to 98 affected 
males and four possible carriers (n=102), allowing for the identification of the causal variant in 93 
unrelated families. Of the 67 different point mutations detected in our study, 42 previously reported 
in the HAMSTeRS database were considered to cause HA (Table 1). Thirty severe HA patients 
exhibited 20 mutations that were predicted to result in premature termination of the protein: two 
nonsense, three splicing, and 15 frameshift mutations, as well as 12 missense mutations. All mild and 
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moderate cases with the exception of two families with large duplications were associated with 
missense mutations comprising 36 different mutations. In HA117 family, the impact of the mutation 
on the FVIII basal level was unknown as no affected male could be assessed. Eleven different 
missense mutations were found to be present between two and seven times in 37 apparently 
unrelated Belgian families with HA.  
 
Novel mutations causing haemophilia A  
Twenty-five novel small mutations were neither deposited in the HAMSTeRS database nor reported 
in recent publications. They were identified as relating to 10 null mutations: one nonsense, five 
frameshift, and four splice site mutations (Table 2). The remaining 15 mutations were determined to 
pertain to missense type to which the aforementioned criteria applied. A detailed description of 
these mutations is provided in Table 3. None of these mutations was associated with development of 
inhibitor to FVIII in affected subjects enrolled in our study. 
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Discussion  
Our study investigated the first series of HA patients analysed for F8 genomic mutations in Belgium. 
The causative mutation within F8 was identified in 94% of families. Despite repeated sequencing of 
all coding exons and their splice site junctions, the approximately 1.2kb promoter and 0.3kb 3’UTR 
region, no mutation was detected in two severe (one sporadic, one with family history) and seven 
mild HA patients with a FVIII level ranging between 15 and 38% (5 sporadic, 2 with family history). 
The von Willebrand disease type 2N mutation was excluded in all these patients by analysing exons 
17-20 and 24-27 of the vWF gene where mutations have been associated with vWF/F8 binding 
defects [19-22]. As expected, the analysis of RNA when available (one severe and two mild HA 
patients) did not show rearrangements that excluded mutations located deep in the introns and 
either affected normal splicing or led to mechanisms causing some unknown rearrangements of F8 as 
the cause of HA.  
Inversions 
As expected, 44% of severe HA was associated with intron 22 inversion. Recent data revealed that 
int22h-2 was oriented in the same direction as int22h-1, while int22h-3 was in the opposite direction 
to both [23], which allowed for intrachromosomal homologous recombination between int22h-1 and 
int22h-3 (F8 “distal” inversion or type 1 inversion). In addition, data showed [24, 25] that int22h-2 
and int22h-3 formed an imperfect palindrome separated by a 65kb loop containing the BclI sites that 
characterise int22h-2 and int22h-3. Homologous recombination between int22h-1 and int22h-2 (F8 
“proximal” inversion or type 2 inversion) required prior recombination between int22h-2 and int22h-
3 by means of a polymorphic inversion that created alleles, where the int22h-2 repeat was the most 
telomeric and was in inverse orientation to int22h-1. The frequency of this polymorphic allele may 
explain the rarity of the int22h-2 inversion, which is five times rarer than that of type 1 [2]. In our 
study, all severe HA patients documented as having inversions exhibited a type 1 inversion except for 
one case with a type 2 inversion. In one family with severe HA, a Southern blot pattern of the intron 
22 inversion differing from type 1 and 2 inversions was associated with form 3B, as previously 
suggested [2]. This kind of inversion was explained by the presence of at least two copies of the 
tandem palindromic int22h-2 and int22h-3, where the copy int22h-2 was the most telomeric and had 
the opposite orientation to int22h-1. 
Large duplications 
Large duplications have been reported in many diseases resulting from Non-Allelic Homologous 
Recombination (NAHR) between low-copy repeats oriented in the same position. By consequence, a 
 
 
59 
 
simple unequal crossing-over mechanism was expected to produce deletions and duplications by a 
reciprocal recombination mechanism [26,27]. 
Theoretically, intrachromosomal homologous recombination between F8 int22h-1 and extragenic 
int22h homologs involving two normal copies may cause highly deleterious 0.5Mb deletions and loss 
of the 5’ portion of F8, including exons 1-22, as suggested in the article of Pegoraro [28]. This 
recombination may also result in duplication of the 5’ portion of F8 without inversion [29]. In our 
study, we described two HA families with two duplications of the 5’ portion of F8 containing exons 1-
22 by MLPA assay. The first duplication in combination with a triplication of exons 2-14 was present 
in one family with moderate HA affecting a 26-year-old male with factor VIII:C levels of 2% and his 
obligate carrier mother, while the second duplication was identified in another family with severe 
HA. Small mutation in the functional copy of F8 was excluded by means of repeated sequencing, 
which suggested the deleterious effect of these types of duplication or triplication. These 
descriptions that have not yet been reported but only theoretically suggested [29] provide evidence 
that duplications exist in the 5’ region of F8 and confer different phenotypes. 
In this study, we also identified a familial duplication of exon 1 in males with mild HA. NAHR 
mechanism of this rearrangement seemed unlikely due to the opposite orientation of the int1h 
copies situated in the intron 1 of F8 and mapped to a 70-100kb region telomeric to F8 [3, 30]. Since 
deletions of exon 1 were described in the HA database HAMSTeRS as resulting in a severe 
phenotype, we propose that duplication in the opposite orientation of one of the inth1h copies 
allows for non-allelic homologous recombination mechanism that results in deletion and duplication 
of exon 1. However, other mechanisms that create large duplication or deletion have also been 
reported as corresponding to unequal crossing-over between repetitive elements (SINES or LINES) 
and to microhomologies genomic features, which would explain the duplication of exon 1 in this 
particular family [31, 32].  
Large deletions 
We previously highlighted the efficacy of using MLPA techniques in female patients presenting factor 
VIII deficiency in the absence of a family history of haemophilia or von Willebrand disease. We 
confirm in this report the value of this easy-to-use and fast method for detecting and determining 
the size of large deletion and duplication in a single reaction in both patients and carriers. Our study 
suggests that MLPA should be applied prior to any screening for point mutations in F8 in cases of 
severe phenotypes or following a negative mutation result in mild and moderate HA patients. 
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Missense mutations already reported 
Missense mutations are the most prevalent mutation type responsible for all severities of HA, 
whereby the severity depends on the location of the mutation. Our study confirms the well-known 
correlation between genotype and phenotype. As expected, most patients with a severe phenotype 
carry a molecular defect predicting a null allele, while missense mutations were found in nearly all 
patients with a non-severe phenotype. 
Missense mutations were located throughout F8 with the exception of exons 2, 3, 5, 10, and 17. In 
agreement with the HAMSTeRS mutation database, our Belgian series detected very few missense 
mutations in exon 14 that represents about half of the coding region and of which codons 741 to 
1648 encodes for the F8 B domain, a region lacking pro-coagulant activity that is spliced out from the 
mature protein. These missense mutations, p.Val727Phe and p.Arg1708Cys, identified in the F8 exon 
14 are located in A2 and a3 domains respectively. 
Unpublished small mutations 
Based on the patient data investigated in this paper, a total of 25 novel genetic alterations in F8, i.e., 
10 null and 15 missense mutations were not included in the HAMSTeRS database nor identified in 
recent reports [33-36].  
  SEVERITY 
TYPE OF 
MUTATION 
GEMONIC PROTEINIC EXON 
HA117* (female) Unknown§ missense c.6195G>C p.Trp2065Cys (p.Trp2046Cys) 21 
HA149 mild missense c.71A>G p.Tyr24Cys (p.Tyr5Cys) 1 
HA133 mild missense c.683A>G p.His228Arg (p.His209Arg) 6 
HA109*,±  mild missense c.733C>T p.Arg245Trp (p.Arg226Trp) 6 
HA92 mild missense c.751C>G p.His251Asp (p.His232Asp) 6 
HA53* mild missense c.775A>G p.Arg259Gly (p.Arg240Gly) 6 
HA28 mild missense c.1172G>A p.Arg391His (p.Arg372His) 8 
HA5, HA47, HA97 mild/ moderate missense c.1293G>T p.Leu431Phe (p.Leu412Phe) 9 
HA2± mild missense c.1648C>T p.Arg550Cys (p.Arg531Cys) 11 
HA50, HA124 (female) mild missense c.1649G>A p.Arg550His (p.Arg531His) 11 
HA48± mild missense c.1834C>T p.Arg612Cys (p.Arg593Cys) 12 
HA88* mild missense c.1982T>A p.Ile661Asn (p.Ile642Asn) 13 
HA37 mild missense c.1988C>T p.Ala663Val (p.Ala644Val) 13 
HA1*,± mild missense c.2099C>T p.Ser700Leu (p.Ser681Leu) 13 
HA9* mild missense c.5186G>A p.Gly1729Glu (p.Gly1710Glu) 14 
HA15, HA74 mild missense c.5305G>A p.Gly1769Arg (p.Gly1750Arg) 15 
HA40 mild missense c.5926C>G p.His1976Asp (p.His1957Asp) 18 
HA52 (female), HA128 mild missense c.5954G>A p.Arg1985Gln (p.Arg1966Gln) 18 
HA83 mild missense c.5981T>A p.Leu1994Pro (p.Leu1975Pro) 18 
HA103* mild missense c.6067G>A p.Glu2023Lys (p.Glu2004Lys) 19 
HA150* mild missense c.6082G>T. p.Gly2028Trp (p.Gly2009Trp) 19 
HA39,HA46, HA81, 
HA108, HA126, HA127, 
HA55 
mild missense c.6089G>A p.Ser2030Asn (p.Ser2011Asn) 19 
HA19 mild missense c.6371A>G p.Tyr2124Cys (p.Tyr2105Cys) 22 
HA113* mild missense c.6439G>A p.Gly2147Ser (p.Gly2128Ser) 23 
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HA38 mild missense c.6443A>G p.Asn2148Ser (p.Asn2129Ser) 23 
HA114± mild missense c.6505C>T p.Arg2169Cys (p.Arg2150Cys) 23 
HA71 mild missense c.6506G>A p.Arg2169His (p.Arg2150His) 23 
HA10, HA18, HA104, 
HA105, HA141, HA150, 
HA17 (female) ± 
mild missense c.6532C>T p.Arg2178Cys (p.Arg2159Cys) 23 
HA84, HA115, HA137, 
HA11 
mild missense c.6533C>A p.Arg2178His (p.Arg2159His) 23 
HA134± mild missense  c.6544C>T p.Arg2182Cys (p.Arg2163Cys) 23 
HA42* mild missense c.6823T>C p.Tyr2275His (p.Tyr2256His) 25 
HA136, HA13, HA142, 
HA56 
mild /moderate missense c.6932C>A p.Pro2311His (p.Pro2292His) 26 
HA90* moderate missense c.73T>C et c.75C>G p.Tyr25Gln (p.Tyr6Gln) 1 
HA91 moderate missense c.992T>G p.Ile331Ser (p.Ile312Ser) 7 
HA68 moderate missense c.2059C>T p.Leu687Phe (p.Leu668Phe) 13 
HA14, HA72± moderate missense c.5398C>T p.Arg1800Cys (p.Arg1781Cys) 16 
HA64 moderate missense c.6350T>G p.Ile2117Ser (p.Ile2098Ser) 22 
HA3 severe missense c.463T>A p.Tyr155Asn (p.Tyr136Asn) 4 
HA41* severe missense c.471G>C p.Trp157Cys (p.Trp138Cys) 4 
HA98 severe missense c.757G>T p.Val253Phe (p.Val234Phe) 6 
HA102* severe missense c.830T>G p.Ile277Ser (p.Ile258Ser) 7 
HA58* severe splicing c.1271+1G>T pAsp337GlyfsX40 (pAsp318GlyfsX40) 8 
HA143± severe missense c.1171C>T p.Arg391Cys (p.Arg372Cys) 8 
HA16 severe missense c.1814A>G p.Tyr605Cys (p.Tyr586Cys) 12 
HA94* severe deletion c.2006_2007delCT p.Ser669CysfsX14 (p.Ser650CysfsX14) 13 
HA138* severe deletion c.2347_2348delAA p.Asn783fsX (p.Asn764fsX) 14 
HA32 severe missense c.2179G>T p.Val727Phe (p.Val708Phe) 14 
HA26 severe duplication c.2945dupA p.Asn982Lysfs*9 (p.Asn963Lysfs*9) 14 
HA6* severe nonsense c.3155T>A p.Leu1052* (p.Leu1033*) 14 
HA80 severe duplication c.3637dupA p.Ile1213Asnfs*28(p.Ile1194Asnfs*28) 14 
HA25, HA62, HA82 severe deletion c.3637delA p.Ile1213Phefs*5 (p.Ile1194PhefsX5) 14 
HA24* severe deletion c.3784delG p.Ala1262Hisfs*11 (p.Ala1243Hisfs*11) 14 
HA12 severe deletion c.4379delA p.Asn1460Ilefs*4 (p.Asn1441Ilefs*4) 14 
HA129, HA140 severe duplication c.4379_4380dupA p.Asn1460Lysfs*5 (p.Asn1441Lysfs*5) 14 
HA95* severe deletion c.4981delG p.Val1661Serfs*1 (p.Val1642Serfs*1) 14 
HA135± severe missense c.5122C>T p.Arg1708Cys (p.Arg1689Cys) 14 
HA112* severe deletion c.5380_5381delTT p.Phe1794Glufs*12 (p.Phe1775Glufs*12) 16 
HA27 severe deletion c.5956delA p.Lys1987Lysfs*42 (p.Lys1968LysfsX42) 18 
HA44* severe deletion c.5999-8_6006del16 p.Gly2000Gludel39 (p.Gly1981Gludel39) 19 
HA29± severe missense c.6046C>T p.Arg2016Trp (p.Arg1997Trp) 19 
HA45* severe splicing c.6188+1G>A 
p.Lys2039_Gly2063delinsAsp 
(p.Lys2020_Gly2044delinsAsp) 
20 
HA35* severe missense c.6241T>C p.Trp2081Arg (p.Trp2062Arg) 21 
HA21* severe splicing  c.6274-8A>G 
p.Val2092_Met2143del 
(p.Val2073_Met2124del) 
22 
HA63± severe nonsense c.6496C>T p.Arg2166Ter (p.Arg2147Ter) 23 
HA31 severe missense c.6683G>A p.Arg2228Gln (p.Arg2209Gln) 24 
HA107 severe deletion c.6699delG p.Arg2234Glyfs*9(p.Arg2215Glyfs*9) 24 
HA70* severe missense c.6797G>T p.Gly2266Val (p.Gly2247Val) 25 
TABLE 1: SIXTY-SEVEN DIFFERENT POINT MUTATIONS DETECTED BY DNA SEQUENCING 
Mutations are reported in two different nomenclature forms: as suggested by HGVS and as reported 
in HAMSTeRS in italic and in parentheses. 
*Mutations not reported by the HAMSTeRS or by the Alamut®-Mutation Interpretation Software. 
± Mutations localised in a CpG dinucleotide. 
§ Only female carriers tested 
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Family 
Family history 
(sporadic/familial) 
Genomic level Protein level RNA level Exon 
HA58 Sporadic c.1271+1G>T p.Asp337Glyfs*40 r.1134_1271del 8 
HA94 Sporadic c.2006_2007delCT p.Ser669Cysfx*14 / 13 
HA138 Familial c.2347_2348delAA p.Asn783fs* / 14 
HA6 Sporadic c.3155T>A p.Leu1052* / 14 
HA24 Familial c.3784delG p.Ala1262Hisfs*11 / 14 
HA95 Sporadic c.4981delG p.Val1661Serfs*1 / 14 
HA112 Sporadic c.5380_5381delTT p.Phe1794Glnfs*12 / 16 
HA44 Familial c.5999-8_6006del16 p.Gly2000Gludel39 r.5999_6115del 19 
HA45 Sporadic c.6188+1G>A p.Lys2039_Gly2063delinsAsp r.6116_6187del 20 
HA21 Sporadic c.6274-8A>G p.Val2092_Met2143del r.6274_6429del 22 
 
TABLE 2: TEN NOVEL MUTATIONS IN FACTOR VIII GENE LEADING TO PREMATURE PROTEIN TERMINATION IN 
SEVERE HAEMOPHILIA A 
The column corresponding to RNA level shows results of the study of RNA sample from patients with 
novel splicing mutations to confirm the deleterious effect on splicing. RNA study for the six others 
null mutations was not performed as indicated by a /. 
 
Null mutations 
As expected, all ten null mutations were associated with a severe phenotype. Six of these were 
nonsense and small duplication or deletion mutations, which would result in a frameshift and 
premature introduction of a stop codon. The four others were novel splicing mutations located in the 
splice donor sites of exon 8 for the first and exon 20 for the second, and in the splice acceptors of 
exon 19 and 22 for the remaining two. The study of RNA samples showed an exon skipping for the 
mutations c.6188+1G>A (exon 20) and c.6274-8A>G (exon 22), while for the mutation c.1271+1G>T, 
alteration of the splice acceptor site resulted in an incomplete exon skipping, which generated a 
cryptic out-of-frame splice site activation of exon 8. RNA analysis of the fourth mutation 
corresponding to a deletion of 16pb in the splice acceptor of exon 19, c.5999-8_6006del16, 
confirmed its deleterious effect on splicing. 
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TABLE 3: DESCRIPTION AND EVALUATION OF CAUSALITY OF FIFTEEN NOVEL MISSENSE MUTATIONS IN FACTOR VIII 
GENE IN SEVERE AND MODERATE/MILD HAEMOPHILIA A 
a) Family history of Haemophilia, FVIII activity levels, description of mutations and clinical severity 
  Family history FVIII:C 
Mutation 
Clinical 
severity Nucleotide Protein Exon Domain 
HA90  Sporadic 3% c.73T>C and c.75C>G p.Tyr25Gln 1 A1 Moderate 
HA41  Familial < 1% c.471G>C p.Trp157Cys 4 A1 Severe 
HA109  Familial 46% c.733C>T p.Arg245Trp 6 A1 Mild 
HA53 Sporadic 40% c.775A>G p.Arg259Gly 6 A1 Mild 
HA102  Familial < 1% c.830T>G p.Ile277Ser 7 A1 Severe 
HA88 Familial 28% c.1982T>A p.Ile661Asn 13 A2 Mild 
HA1  Sporadic 35% c.2099C>T p.Ser700Leu 13 A2 Mild 
HA9  Familial 20% c.5186G>A p.Gly1729Glu 14 B Mild 
HA103  Familial 41% c.6067G>A p.Glu2023Lys 19  C1 Mild 
HA150  Familial 17% c.6082G>T  p.Gly2028Trp 19 C1 Mild 
HA117 Familial Unknown* c.6195G>C p.Trp2065Cys 21 C1 Unknown* 
HA35  Sporadic < 1% c.6241T>C p.Trp2081Arg 21 C1 Severe 
HA113  Familial 18% c.6439G>A p.Gly2147Ser 23 C1 Mild 
HA70  Familial < 1% c.6797G>T p.Gly2266Val 25 C2 Severe 
HA42  Familial 22% c.6823T>C p.Tyr2275His 25 C2 Mild 
 
* Only female carriers tested 
 
b) Predicted deleterious effect based on multiple alignment and algorithms studies 
  
Family 
history 
Mutation at 
protein level 
Ex 
Clinical 
severity 
Multiple Alignment* PolyPhen prediction score SIFT prediction Align-GVGD 
HA90  Familial p.Tyr25Gln 1 Moderate YYYYYYYYYYY, identical probably damaging (1) Affect function most likely  
HA41  Familial p.Trp157Cys 4 Severe 
WWWWWWWWWWW, 
identical 
probably damaging (1) Affect function most likely  
HA109  Familial p.Arg245Trp 6 Mild 
RRRPREQDHKD, 
dissimilar 
benign (0.012) Affect function most likely  
HA53 Sporadic p.Arg259Gly 6 Mild 
RRRSRRRRSSA, 
dissimilar 
probably damaging (1) Affect function most likely  
HA102  Familial p.Ile277Ser 7 Severe IIIMIIIIIII, identical possibly damaging (0.93) Affect function most likely  
HA88 Familial p.Ile661Asn 13 Mild IIIVVVVVVVA, dissimilar possibly damaging (0.82) Affect function most likely  
HA1  Sporadic p.Ser700Leu 13 Mild SSSSSSSSSKE, similar probably damaging (0.99) Affect function most likely  
HA9  Familial p.Gly1729Glu 14 Mild 
GGGGGGGGGDG, 
identical 
probably damaging (0.99) Affect function most likely  
HA103  Familial p.Glu2023Lys 19 Mild EEEEEEEEEEE, identical possibly damaging (0.86) Affect function most likely  
HA150  Familial p.Gly2028Trp 19 Mild 
 GGGGGGGGGEG, 
identical 
probably damaging (1) Affect function most likely  
HA117 Familial p.Trp2065Cys 21 Unknown 
WWWWWWWWWCW, 
identical 
probably damaging (0.99) Affect function most likely  
HA35  Sporadic p.Trp2081Arg 21 Severe 
WWWWWWWWWFW, 
identical 
probably damaging (1) Affect function most likely  
HA113  Familial p.Gly2147Ser 23 Mild 
GGGGGGGGAGG, 
identical 
probably damaging (1) Affect function most likely  
HA70  Familial p.Gly2266Val 25 Severe 
GGGGGGGGGGG, 
identical 
probably damaging (1) Affect function most likely  
HA42  Familial p.Tyr2275His 25 Mild 
YYYFFYYYYFFM, 
dissimilar 
probably damaging (0.99) Affect function most likely  
 
*Multiple alignments: Each novel missense mutation was compared with sequences from 11 species 
described above in order to examine the conservation of amino acids. . All substitutions in severe, 
moderate/mild and indefinite clinical severity were classified as “identical” if the amino acid was 
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conserved in all 11 phylogenic separated species Human, Homo sapiens; Primates: 1) chimpanzee, 
Pan troglodytes; 2) macaque, Macaca; Rodent: 1) rat, Rattus norvegicus; 2) mouse, Mus musculus; 
Laurasiatheria: 1) dog, Canis faliliaris; 2) cat, Felis catus; 3) cow, Bos taurus; Bird, chicken, Gallus 
gallus domesticus; Amphibians, xenopus, Xenopus laevis; and Fish, tetraodon, tetraodon nigroviridis, 
“similar” if conserved in nine of the species, or "dissimilar" if it conserved in eight or less species. 
 
Missense mutations 
Two-thirds of the 15 novel missense mutations affect residues within domains A1 or C1, with five 
changes occurring in each domain. The pathological consequences of these mutations need to be 
examined. Although the structure-function relationships of some missense mutations are known or 
can be deduced, e.g. alteration of vWF binding site, thrombin cleavage, or interaction with co-factor 
FIXa and FX, the structural consequences of most mutations are still undefined. Therefore, 
characterising the F8 causal mutations is crucial not only to better understand the structure-function 
relationship of the FVIII molecule, but also to give reliable genetic counselling to patients and their 
families. 
One of the most difficult tasks in genetics consists of distinguishing a deleterious mutation from 
polymorphism that has no consequence on the protein. Thus, a number of methods based on genetic 
analyses are employed: 1) genotype-phenotype correlation; 2) segregation of the mutation in 
affected patients from a same family; 3) localisation of mutations in highly conserved regions of the 
gene and in several animal species with a divergent evolution; 4) absence of mutations' description in 
non-affected individuals and in the available population SNP database in order to exclude known 
polymorphisms; 5) finally, change in the polarity or load of amino-acid substitutions that makes it 
possible to deduce the causal character of such substitutions. The potential functional consequences 
of missense mutations must also be examined by bioinformatics approaches, as multiple 
computational methods have been developed to estimate the deleterious effects of amino acid 
substitutions (Fig. 1). However, it is clear that the pathogenic nature of each novel missense 
mutation should be proven by means of the recombinant expression of the mutant F8, although this 
analysis is difficult due to the large number of novel mutations in F8 and thus, its time-consuming 
nature.  
None of the 15 missense mutations described in this study were found in the 200 X-chromosomes 
from the general Belgian population or in the SNP databases. All were situated in the highly 
conserved regions of F8. The majority of these mutations are transmitted over several generations 
and cosegregate in other affected patients or carriers from the same family. Moreover, several of 
these new genetic alterations can be definitively considered as pathologic, as a substitution in the 
codon that they deteriorate was already reported in HAMSTeRS database. This is the case for the 
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missense mutations described in this study: p.Tyr25Gln, p.Trp157Cys, p.Ser700Leu, p.Gly2028Trp, 
and p.Trp2266Cys. 
Relying on in silico structural analysis, all of the new missense substitutions appeared to have a 
significant impact on the protein structure. Indeed, none of these mutations were found to induce 
theoretically alternative splicing, and all were predicted to affect protein function with the algorithm 
SIFT, Align GVGD. In addition, there was a good correlation between amino-acid conservation 
through the phylogenic separated species, predictions using the algorithm PolyPhen-2, and the 
severe and moderate aspects of HA. This correlation also applied to the minor phenotype of the 
disease with the exception of p.Arg245Trp mutation for which the algorithm PolyPhen-2 predicted a 
benign effect on the factor VIII function. 
Since amino-acid polymorphism of FVIII is rare, our 15 new missense mutations in HA patients may 
be considered as causal in general practice, especially when no other variant is detected using 
complete F8 sequencing and bioinformatics approaches support the deleterious effects of such 
mutation. 
The strategies proposed in this study to evaluate the deleterious impact of genetic variations of the 
FVIII gene have some limitations which should be emphasized. One could indeed assume that any 
approach based on amino-acid species homologies or predicted change algorithms or even molecular 
modelling would miss effects of point mutations on mRNA stability or of missence variants leading to 
decreased protein secretion, both shown to account for low circulating factor levels associated with 
severe hemophilic mutations. Indeed, few studies have been conducted to understand the reason 
why missence mutations are associated with severe phenotype in some patients. Different strategies 
could be proposed to understand the underlying mechanisms: expression by qPCR to explore the F8 
mRNA stability, sequencing of the mRNA to exclude a splicing defect and CRM (cross-reacting 
material) quantification to estimate the level of protein secretion.  
Conclusion 
This study showed the genotype-phenotype correlation in 139 out of 148 unrelated patients, among 
who 25 showed new deleterious variants corresponding to 10 null and 15 missense mutations that 
had never been reported. Among the 10 null mutations, RNA analyses confirmed the causal effect of 
mutations located in a splice site consensus. In addition, we described two general strategies 
currently available to estimate the deleterious effects of amino acid substitutions and assess the 
potential causality of 15 new missense mutations identified in F8.   
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Chapter 2 
 
Overrepresentation of missense mutations in mild hemophilia A patients 
from Belgium: founder effect or independent occurrence?  
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Summary 
Roughly 40% of observed mutations responsible for hemophilia A (HA) are novel and present in 
either a single family or a limited number of unrelated families. During routine diagnostic analysis of 
73 unrelated Belgian patients with mild HA, 4 out of 43 different mutations (p.Ser2030Asn, 
p.Arg2178Cys, p.Arg2178His, and p.Pro2311His) were detected in more than one family, 
representing 35% of total identified mutations. 
To discriminate between an independent recurrence or a founder effect, an analysis of intra- and -
extragenic single nucleotide polymorphisms (SNPs) and short tandem repeats (STRs) flanking the F8 
gene was conducted.  
SNP haplotype and microsatellite analysis revealed strong evidence that p.Ser2030Asn and 
p.Pro2311His mutations were probably associated with a founder effect. The two other mutations 
localized in an F8 cytosine-phosphate-guanine (CpG) site likely resulted from recurrent de novo 
events.  
This study suggests that missense mutations producing C-to-T or G-to-A substitutions in CpG 
dinucleotide can occur de novo with more repetition than other causal substitutions that do not 
affect the CpG site. Analysis of F8 database implied that CpG sites throughout the F8 gene are not all 
mutated with the same frequency. Causes are still unknown and remain to be identified.  
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Introduction 
Hemophilia A (HA) (OMIM 306700), an X-linked hereditary disease, is one of the most common 
coagulation disorders, caused by a spectrum of mutations in the F8 gene. With the exception of 
intron 1 and 22 inversions, present in approximately 45% of severe hemophilia A cases (Antonarakis 
et al.1995; Bagnall et al. 2002), more than 2015 unique variants spread throughout the F8 gene’s 26 
exons have been identified and recorded in the international hemophilia A mutation database 
[http://www.eahad-db.org/February 2014 update]. 
Due to the high rate of spontaneous F8 gene mutations, approximately 40% of families, with 
phenotypes of variable severity, have affected individuals being either sporadic or confined to one 
family branch (Oldenburg et al. 2004). However, several publications have described F8 mutations 
that are highly prevalent in specific populations sharing the same haplotype, indicating the existence 
of a single, common ancestor. Examples of this can be seen with the c.6104T>C or p.Val2035Alanine 
(legacy AA No.2016) mutation, identified in an isolated population in rural Newfoundland (Xie et al. 
2002), the exon 13 duplication located in northern Italy (Acquila et al. 2004), and the novel G-to-A 
mutation (c.1538-18G>A) in intron 10 of the F8 gene, which was identified as a putative cause of mild 
hemophilia A in southern Italy (Santacroce et al. 2008). All these mutations were associated with the 
mild HA phenotype.  
Within the setting of a study comprising 73 apparently unrelated French-speaking Belgian HA families 
with mild severity screened for F8 gene mutations, 4 different missense mutations were detected as 
occurring between 4 and 10 times. By way of haplotype analysis constructed with single nucleotide 
polymorphisms (SNPs) and microsatellites repeats, this study sought to assess the origins of these 
mutations. We investigated whether they represent a recurrent molecular defect, occurring 
repeatedly de novo, or whether they may have manifested as a single molecular event that was then 
disseminated throughout French-speaking Belgium via a founder effect. This study and analysis of the 
EAHAD database (EAHAD db) will attempt to demonstrate that certain F8 CpG sites ("CpG" standing 
for "—C—phosphate—G—) are more susceptible to mutations than others, and that mutations 
frequently reported outside of a CpG site are possibly the result of a founder effect. 
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Patients and Methods 
Patients  
This study involved 73 apparently unrelated subjects exhibiting mild HA with Factor VIII clotting 
activity from >5 to <40 IU/dL (>5% to <40% of normal levels) recruited for genetic testing from 
hospitals in Brussels and the French-speaking part of Belgium. The study was approved by the 
medical ethics committee of the medical faculty of the Université catholique de Louvain, Brussels 
(Belgium). Blood samples were obtained during medical care where patients were informed and gave 
their consent for DNA analysis.  
Methods 
DNA extraction and genotyping of coding sequences 
Genomic DNA was extracted from white blood cells using standard procedures, and mutation 
screening was performed as previously described (Lannoy et al. 2012). Causal mutations were 
defined in line with recommendations of the Human Genome Variation Society (HGVS; 
http://www.HGVS.org; June 2010 update) with codon 1 representing the first residue (Met) of the 
signal peptide (this is -19 in Legacy numbering). In Legacy numbering, codon +1 refers to that coding 
for the first amino-acid of the mature FVIII protein (in HGVS numbering, this is codon +20). As Legacy 
numbering is extensively used in FVIII publications, particularly before the year 2000, this numbering 
is maintained within parenthesis.  
In addition, 50 DNA samples from anonymous French-speaking Belgian males, referred for pre-
conception genetic counselling, were selected from the DNA bank and genotyped as below. This was 
in order to facilitate the interpretation of results obtained by haplotype analysis. 
SNP and microsatellite genotyping 
Flanking markers from 1.4Mb centromeric to 0.6Mb telomeric of the F8 locus were genotyped, 
including the four previously reported (Wehnert et al. 1993; Sánchez-García et al. 2005; Lalloz et al. 
1991; Freije et al. 1992) extragenic and intronic microsatellites (3’ DXS15–DXSint22–DXSint13–
DXS1108-5’) and ten SNPs, as displayed in Appendix section C tables 3C1 and 3C2. The PCR was 
conducted in a 25µL containing 1x PCR Faststart buffer, 1U of Faststart Taq polymerase (Hoffmann-La 
Roche, Basel, Switzerland), 0.2mM of each dNTP, and 10pmol of each primer. Cycling conditions 
were set to initial denaturation at 94°C for 5 minutes, followed by 30 cycles of amplification. These 
comprised 30 second denaturation at 94°C; 1 minute annealing at 55°C; 1 minute elongation at 72°C; 
and 5 minutes final extension at 72°C. A 1.5µL aliquot of STR PCR product was added to 10µL of Hi-Di 
Formamide (Applied Biosystems, Foster city, CA, USA). Amplification products were identified using 
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an ABI3130xl capillary sequencer by employing the Genescan-ROX-500 (Applied Biosystem, Foster 
City, CA, USA) size standard, and were interpreted with GeneMarker software V1.5 (SoftGenetics LLC, 
State College, PA, USA). Amplified SNP DNA fragments were purified and subjected to direct cycle 
sequence analysis using the Taq di-deoxy terminator method and an ABI PRISM 3130xl Genetic 
Analyzer sequencer, in accordance with the manufacturer’s instructions. 
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Results 
In this cohort, routine genetic analysis of the F8 gene was undertaken, and 43 different missense 
mutations were identified in a group of 73 unrelated subjects from separate families with mild HA 
[Appendix section B; Table a]. Recurrent missense causal mutations were noted 10 times for the 
p.Ser2030Asn (c.6089G>A) in exon 19, 7 times for the p.Arg2178Cys (c.6532C>T) in exon 23, 4 times 
for the p.Arg2178His (c.6533G>A) in exon 23, and 4 times for the p.Pro2311His (c.6932C>A) in exon 
26. All mutations were associated with the mild phenotype. These 4 mutations accounted for 35% of 
all mutations identified in the routine genetic F8 analysis of mild phenotype patients. Other recurrent 
missense mutations were also observed (p.Leu431Phe and p.Gly1769Arg). However, these families 
were not included in this study due to a lack of DNA. 
In the first part of this study, haplotypes at the F8 locus were generated with extra- and intragenic 
SNPs from Belgian male control individuals among whom 6 different haplotypes were identified, as 
displayed in Table 1a. The most common haplotype (haplotype 4) manifested at 58% prevalence, 
while 3 others (haplotypes 2, 5, and 6) were found at ≤10% prevalence in the normal population. It 
was of particular interest to note that 2 haplotypes in the Belgian control population were not 
present in the general CEU population, which consists of Utah residents with ancestry from northern 
and western Europe. In contrast, one haplotype in the general CEU population was not present in our 
Belgian male controls (Table 1b). In order to increase the discriminative value of the Belgian SNP 
haplotype, we conducted further analyses of the microsatellite data at the F8 locus. A total of 35 
different haplotypes were identified in the 50 controls (Table 1c). 
TABLE 1: HAPLOTYPE RESULTS  
1a) Identification of six different SNP haplotypes in 50 Belgian male controls 
 
 
haplotype 1 = 
haplotype X5
#
 
haplotype 2 = 
haplotype X2
#
 
haplotype 3* 
haplotype 4 = 
haplotype X4
#
 
haplotype 5* 
haplotype 6= 
haplotype X3
#
 
rs6643620 G G A A A G 
rs5945250 T T G G G G 
rs1050705 G G A A A A 
rs4898352 T T A A A A 
rs6643714 C C T T C C 
rs1800291 C G C C C C 
rs5987079 A A G G G G 
rs6649625 C C C T C C 
rs2313058 T T C C C C 
rs5945279 T T C C C C 
Percentage  10% 6% 14% 58% 4% 8% 
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*Haplotypes 3 and 5 are present in the Belgian and not in the general CEU population, and haplotype 
X1 from the CEU is absent in Belgian male controls (details of SNP haplotypes from the CEU 
population are shown in table 2b) 
# corresponds to the haplotype identified in the general CEU population  
 
1b) Identification of five different SNP haplotypes from the CEU population (Utah residents with 
ancestry from northern and western Europe). 
These values were extracted from http://www.ncbi.nlm.nih.gov/projects/SNP/snp_gf.cgi (consulted 
on 12 December 1999) from 44 male individuals 
 Haplotype 
X1 
Haplotype 
X2 
Haplotype 
X3 
Haplotype 
X4 
Haplotype 
X5 
rs6643620 A G G A G 
rs5945250 G T G G T 
rs1050705 G G A A G 
rs4898352 T T A A T 
rs6643714 C C C T C 
rs1800291 G G C C C 
rs5987079 A A G G A 
rs6649625 C C C T C 
rs2313058 T T C C T 
rs5945279 C T C C T 
Percentage 4.50% 9% 9% 63.75 13.75 
 
1c) Identification of 35 different STR haplotypes in 50 Belgian male controls 
 
DXS15 164 158 154 144 160 156 158 162 154 158 158 160 160 160 164 162 162 156 154 162 158 158 152 162 162 154 162 154 162 154 154 164 158 154 160 
STR22 80 80 82 82 80 82 82 82 80 82 82 80 80 82 82 84 80 82 82 82 82 80 82 82 82 82 82 80 80 82 82 82 80 82 82 
STR13 145 149 145 145 147 143 143 145 145 143 145 145 145 143 143 143 145 143 143 143 143 145 143 143 143 143 145 145 145 143 143 145 145 143 143 
DXS1108 161 161 171 173 161 171 175 173 161 161 171 171 161 173 173 173 171 175 173 173 173 161 173 171 175 173 161 171 161 161 175 173 171 171 161 
Number 1 2 1 1 1 1 1 1 1 2 2 1 1 5 2 1 1 1 1 2 1 1 1 2 2 5 1 1 1 1 1 1 1 1 1 
Percentage 2% 4% 2% 2% 2% 2% 2% 2% 2% 4% 4% 2% 1% 10% 4% 2% 2% 2% 2% 4% 2% 2% 2% 4% 4% 10% 2% 2% 2% 2% 2% 2% 2% 2% 2% 
 
For the p.Ser2030Asn mutation in F8 exon 19, all 10 unrelated patients exhibited the same SNP 
haplotype, corresponding to the most commonly found (haplotype 4) in the Belgian control 
population (Tables 1 and 2). Analysis of short tandem repeat (STR) microsatellites identified the same 
microsatellite haplotype in eight patients, while the two other haplotypes differed in only one (family 
HA55 for DXS15 marker) or two alleles (family HA39 for DXS15 and STR13 markers). The HA39 STR 
haplotype was absent in the Belgian male controls while the HA55 microsatellites allele was present 
in 2% of the same control population.  
For the p.Pro2311His causal mutation in F8 exon 26, haplotyping by way of SNP markers revealed 
that the 4 unrelated index cases shared the same haplotype (Table 2). Yet while this SNP haplotype 
was absent in the Belgian control population, it was present in 4.50% of cases in the CEU population, 
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as reported in the international HapMap project (Haplotype Map of the human genome: 
http://www.ncbi.nlm.nih.gov/projects/SNP/snp_gf.cgi, consulted on 12 December 2009). These 
results were confirmed by STR haplotype, except for the 139bp/STR allele in family HA56.  
TABLE 2: SNP AND STR HAPLOTYPE RESULTS FOR FAMILIES SHARING IDENTICAL MUTATIONS  
The color of SNP Haplotypes is identical as described in the controls. Due to the impossibility of 
associating microsatellite alleles with an SNP haplotype, they will be colorless 
 
Mutation p.Ser2030Asn in F8 exon 19 identified in ten families 
Markers Position allele in pb for microsatelite and SNP allele 
DXS15 extragenic 158 152 158 152 158 158 158 158 158 158 
rs6643620 extragenic A A A A A A A A A A 
rs5945250  extragenic G G G G G G G G G G 
rs1050705 3’-UTR A A A A A A A A A A 
STR22 intron 22 82 82 82 82 82 82 82 82 82 82 
rs4898352 intron 18 A A A A A A A A A A 
rs6643714 intron 14 T T T T T T T T T T 
rs1800291 exon 14 C C C C C C C C C C 
STR13 intron 13 143 141 143 143 143 143 143 143 143 143 
rs5987079 intron 2 G G G G G G G G G G 
rs6649625 intron 2 T T T T T T T T T T 
rs2313058  extragenic C C C C C C C C C C 
rs5945279 extragenic C C C C C C C C C C 
DXS1108 extragenic 175 175 175 175 175 175 175 175 175 175 
Family n° HA126 HA39 HA46 HA55 HA127 HA81 HA108 HA152 HA153 HA157 
 
p.Pro2311His mutation in F8 exon 26 identified in four families 
The SNP haplotype of these families is not present in the Belgian control population 
Markers Position allele in pb for microsatelite 
and SNP allele 
DXS15 extragenic 162 162 162 162 
rs6643620 extragenic A A A A 
rs5945250  extragenic G G G G 
rs1050705 3’-UTR G G G G 
STR22 intron 22 78 78 78 78 
rs4898352 intron 18 T T T T 
rs6643714 intron 14 C C C C 
STR13 intron 13 141 141 139** 141 
rs1800291 exon 14 G G G G 
rs5987079 intron 2 A A A A 
rs6649625 intron 2 C C C C 
rs2313058  extragenic T T T T 
rs5945279 extragenic C C C C 
DXS1108 extragenic 173 173 173 173 
Family n° HA13 HA136 HA56 HA142 
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For the two other exon 23 mutations at the same codon, namely p.Arg2178Cys and p.Arg2178His, 
genotyping of unrelated patients by means of SNP and STR markers clearly revealed 3 different 
haplotypes in each mutation type. However, several families exhibited an identical genotype, with 
the sole exception of the 143bp/STR13 allele in family HA10, the 160bp/DXS15 allele in family HA17, 
and the 164bp/DXS15 allele in family HA137 (Table 2).  
p.Arg2178Cys mutation in F8 exon 23 identified in seven families 
Markers Position allele in pb for microsatellite and SNP allele 
DXS15 extragenic 160 160 160 158 162 162 160 
rs6643620 extragenic A A A A G G G 
rs5945250  extragenic G G G G G G G 
rs1050705 3’-UTR A A A A A A A 
DXSint22 intron 22 82 82 82 82 80 80 80 
rs4898352 intron 18 A A A A A A A 
rs6643714 intron 14 T T T T C C C 
rs1800291 exon 14 C C C C C C C 
DXSint13 intron 13 143 141 141 143 145 145 145 
rs5987079 intron 2 G G G G G G G 
rs6649625 intron 2 C C C T C C C 
rs2313058  extragenic C C C C C C C 
rs5945279 extragenic C C C C C C C 
DXS1108 extragenic 175 175 175 173 171 171 171 
Family n° HA10 HA104 HA105 HA18 HA141 HA154 HA17 
 
p Arg2178His mutation in F8 exon 23 identified in four families 
Markers Position allele in pb for microsatelite 
and SNP allele 
DXS15 extragenic 164 162 162 158 
rs6643620 extragenic A A G A 
rs5945250  extragenic G G G G 
rs1050705 3’-UTR A A A A 
DXSint22 intron 22 82 82 80 82 
rs4898352 intron 18 A A A A 
rs6643714 intron 14 T T C T 
rs1800291 exon 14 C C C C 
DXSint13 intron 13 143 143 145 145 
rs5987079 intron 2 G G G G 
rs6649625 intron 2 T T C C 
rs2313058  extragenic C C C C 
rs5945279 extragenic C C C C 
DXS1108 extragenic 173 173 171 173 
Family n° HA137 HA84 HA115 HA11 
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To integrate these findings in a larger study, we exploited substitution mutation reports (point and 
polymorphism mutations providing missense, nonsense and silent effects) available in the EAHAD db 
(“Advanced Search” section/February 2014 release). A wide spectrum of 3,894 mutations, which 
were identified in the coding sequence, was reported to affect the entirety of the F8 gene. This 
number represents the total of separate reports in unrelated individuals, unless otherwise stated.  
Among these missense mutations, 35 codons containing a CpG dinucleotide in a total of 16 exons 
were mutated. This represented only 1.5% of the F8 protein sequence (2322 aa). When we calculated 
the total point mutations (n=1376; Table 3), which affected these CpG dinucleotides, an 
overrepresentation was observed equal to more than 35% of all 3,894 mutations reported in the F8 
gene. Nevertheless, the number of mutations reported in these 35 codons varied greatly, with a 
range of one (codons 362, 437, 446, 1500, 1671, 2016, or 2109) to 137 descriptions (codon 612). 
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TABLE 3: NUMBER OF 1.375 SUBSTITUTIONS MUTATIONS IN 33 CpG SITES OF THE F8 CODING SEQUENCE WERE 
REPORTED AND EXTRACTED FROM “ADVANCED SEARCH” IN THE EAHAD DB. 
Exon number Position in codon * Aminoacid Missence mutation Number of reports Severity 
1 15 (-5) arginine CGA>TGA 14 severe 
7 
301 (282) arginine 
CGC>TGC 14 severe/moderate/mild 
CGC>CAC 28 severe/moderate/mild 
308 (289) serine TCG>TTG 28 mild/severe 
8 
355 (336) arginine CGA>TGA 27 severe 
362 (343) alanine GCG>GCA 1 polymorphism 
391 (372)
 β
 arginine 
CGC>TGC 15 severe/moderate/mild 
CGC>CAC 25 severe/moderate/mild 
9 
437 (418) arginine CGG>TGG 1 mild 
446 (427) arginine 
CGA>TGA 22 severe/moderate 
CGA>CAA 1 severe 
458 (439) arginine CGT>TGG 2 mild 
10 503 (484) arginine CGT<CAT 2 polymorphism 
11 
546 (527)
 β
 arginine CGG>TGG 45 mild/moderate 
550 (531)
β
 arginine 
CGC>TGC 58 mild/moderate 
CGC>CAC 44 mild 
12 
602 (583) arginine CGA>TGA 20 severe/moderate 
612 (593)
 β
 arginine CGC>TGC 137 severe/moderate/mild 
14 
717 (698) arginine 
CGC>CAG 5 mild 
CGC>TGC 43 mild/moderate 
814 (795) arginine CGA>TGA 32 severe 
1500 (1481) arginine CCG>CCA 1 polymorphism 
1671 (1652) arginine CGT>CAT 1 severe 
1708 (1689)
 β
 arginine 
CGC>TGC 31 severe/moderate/mild 
CGC>CAG 19 mild 
1715 (1696) arginine 
CGA>CAA 3 severe/mild 
CGA>TGA 13 severe 
15 1768 (1749) arginine 
CGT>TGT 2 mild 
CGT>CAT 6 mild 
16 1800 (1781)
 β
 arginine 
CGT>TGT 13 severe/moderate/mild 
CGT>CAT 32 severe/moderate/mild 
18 
1960 (1941) arginine 
CGA>CAA 23 severe/moderate/mild 
CGA>TGA 20 severe 
1985 (1966)
 β
 arginine 
CGA>CAA 69 severe/mild 
CGA>TGA 31 severe 
19 2016 (1997)
 β
 arginine 
CGG>TGG 61 severe/moderate/mild 
CGG>CAG 1 mild 
22 
2109 (2090) arginine CGT>TGT 1 mild 
2135 (2116) arginine CGA>TGA 27 severe 
23 
2166 (2147) arginine CGA>TGA 34 severe 
2169 (2150)
 β
 arginine 
CGT>TGT 5 mild 
CGT>CAT 103 severe/moderate/mild 
2178 (2159) arginine 
CGC>TGC 69 severe/moderate/mild 
CGC>CAC 11 mild 
2182 (2163)
 β
 arginine 
CGC>TGC 16 severe/moderate 
CGC>CAC 36 severe/moderate/mild 
24 2228 (2209)
 β
 arginine 
CGA>CAA 37 severe/moderate/mild 
CGA>TGA 41 severe 
26 
2319 (2300) proline CCG>CTG 30 severe/mild 
2323 (2304) arginine 
CGC>TGC 20 severe/moderate 
CGC>CAC 3 mild 
2326 (2307) arginine 
CGA>CAA 30 severe/moderate/mild 
CGA>TGA 23 severe/moderate 
16 exons 35 different codons     1,376 reports   
 
* Variants reported as HGVS nomenclature. Legacy numbering is noted within parenthesis.  
β
 reported in Lannoy et al. publication (2012). 
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Discussion 
In order to determine whether the 35% recurrent four mutations found in our cohort of unrelated 
mild HA patients represented a hotspot or founder mutation, we analyzed the mutation positions in 
the F8 gene and constructed haplotypes with intragenic and extragenic SNP and STR markers in 
unrelated mild HA subjects sharing the same causal mutation. The p.Ser2030Asn (AGC>AAC) and 
p.Pro2311His (CCT>CAT) in F8 exons 19 and 26, respectively, that were not located in a CpG 
dinucleotide were identified 10 and 4 times in patients with FVIII:C levels ranging between 20 and 
30%. One patient of family HA13 developed an inhibitor following surgery. Microsatellites and SNP 
data indicated that the common haplotype identified in the patients was probably a founder rather 
than common recurrent mutation. The presence of other STR haplotypes in the HA55 and HA39 
(exon 19) and HA56 (exon 26) was not significant. Hereditary transmission of STR markers is unstable 
due to the distance between the marker DXS15 and the F8 gene (high probability of crossing-over) 
and the STR13 microsatellite mutation rate in germ line (Ellegren, 2004). 
The two other mutations, namely p.Arg2178Cys (CGC>TGC) and p.Arg2178His (CGC>CAC), involved a 
CpG dinucleotide. These mutations were associated with the mild HA phenotype with FVIII:C levels 
ranging from 9 to 43%, and no inhibitor development. Haplotyping revealed 3 different haplotypes 
for each mutation, indicating probably three de novo events and a potential shared ancestor among 
those with the same mutation and genotyping. 
The methylation process of mammalian DNA occurs within the cytosine residues inside CpG 
dinucleotide ("CpG" standing for "—C—phosphate—G—), attaining percentages between 70 and 
80%. CpGs are unevenly distributed in the genome, and are implicated in the process of mutagenesis 
(Cooper et al. 1988). Indeed, the hypermutability of the CpG dinucleotide has been explained by the 
spontaneously deamination of cytosine to uracil by a process known as hydraulic deamination. When 
this occurs, guanine which was originally linked to the molecule of cytosine is found opposite the 
uracil (uracil is normally complementary to adenine). Thereafter, when the cell begins a new round of 
DNA replication, the position on uracil becomes occupied by an adenine rather than guanine would 
have been there in normal times, so modifying the code gene expressed by this DNA sequence. The 
deamination of cytosine results transitional mutations (i.e., C>T) at CpGs. Given the symmetry of 
these CpG motifs, the methylcytosine on the opposite strand may also be affected, leading to G>A 
changes. The theory that cytosine–guanine (CpG) dinucleotide potentially constitutes a hotspot for 
pathological mutations in the human genome was first advanced nearly 25 years ago, based on the 
ﬁnding that two different CGA >TGA (Arg to Term) nonsense mutations had recurred quite 
independently at different locations in the factor VIII (F8) gene, thus causing hemophilia A 
 
 
81 
 
(Youssoufian et al. 1988). Other studies have subsequently drawn the same conclusions (Knobloch et 
al 1993; Mancini et al 1997).  
In hemophilia A, a wide spectrum of 3,894 substitutions identified have been reported as affecting 
the entirety of the F8 gene, according to the EAHAD db (point and polymorphism mutations 
providing missense, nonsense and silent effects from the “Advanced Search” section). Of all these 
variants, 1.376 reports were located in CpG dinucleotide. These types of genetic alterations do not, 
however, appear to be homogeneously distributed. This is illustrated by the fact that on all 70 CpG 
sites (Oldenburg et al 2004) considered as hotspots of highly frequent mutations in the F8 gene 
coding sequence, only 35 codons containing a CpG dinucleotide over 16 exons were mutated. To 
date, the mechanisms of selective methylation of particular CpG codons in particular regions of the 
F8 gene, and of the disproportion of some recurrent mutations from others, remain unclear, and 
warrant further investigation. We have also yet to establish why some of these mutations are 
associated with such widely ranging levels of severity, from severe to mild phenotypes, rendering 
genetic counseling difficult. Our Belgian mutations in CpG sites, as detailed in Lannoy’s publication 
(2012) and in this study, are also in line with the majority reported in the EAHAD db, with the 
exception of p.Arg245Trp (legacy AA No.226), p.Arg259Gly (legacy AA No.240)., and p.Arg298Thr 
(legacy AA No.279). 
The two mutations described in our study, namely p.Arg2178Cys (CGC>TGC) and p.Arg2178His 
(CGC>CAC), have also been integrated into the complete EAHAD db listing of all individual mutation 
submissions, consisting of 69 reports with 32 different references and in 11 separate entries with 9 
different references, respectively. These findings were probably in accordance with the 
hypermutability of this CpG site. However, further haplotype analysis needs to be examined as 
bisulfite sequencing to determine the pattern of F8 CpG sites methylation. 
With the exception of mutations in CpG sites being reported at a high prevalence, others are also 
consistently observed with no clear explanation. This is the case for, among others, the following 
missense mutations: p.Val181Met (legacy AA No.162) in exon 4, pTyr365Cys (legacy AA No.346) in 
exon 8, p.Val2035Ala (legacy AA No.2016) in exon 19, and p.Trp2248Cys (legacy AA No.2229) in exon 
25, representing 52, 47, 35, and 42 reports in the EAHAD db, respectively. In our study, the 
p.Ser2030Asn mutation has been identified 10 times in French-speaking Belgian families, who were 
allegedly unrelated. Furthermore, this mutation has been reported 33 times in the full listing of all 
individual mutation submissions of EAHAD db, with 9 different references, including one possible 
founder effect. Given that most families sharing the p.Ser2030Asn mutation described in EAHAD db 
originated from England, it would be interesting to study their genetic identity in comparison with 
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our data in the interests of identifying any similar haplotype, drawing up an estimate of when the 
mutation first appeared, and to enable mapping of human migration pathways. 
The p.Pro2311His mutation in F8 exon 26 was also reported 4 times in EAHAD db with four different 
references. It was of particular interest to note that the SNP haplotype described in these 4 patients 
was not encountered in the Belgian controls, yet was clearly present in the CEU population.  
Conclusion 
Haplotype analysis enabled us to determine either if a specific mutation within the F8 gene was 
associated with a shared genetic background, thus indicating that it was inherited from a common 
ancestor, or if the shared mutation seemed to have occurred independently multiple times. Firstly, 
this study suggested that a founder effect of mutations not located in hotspots was a stronger 
likelihood if these mutations were shared by several apparently unrelated families. Secondly, our 
findings implied that if the substitution affected one CpG site, it was more likely that the mutation 
manifested de novo than other causal substitutions affecting the F8 gene. However, the 
disproportionate number of missense mutation reports in some CpG dinucleotides is as yet 
unexplained, and their implication in the widely ranging HA severity remains to be determined. 
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SECTION 2 
Chromosomal alterations at the F8 locus 
producing larges duplication: 
mechanisms and implications in the 
diagnosis of hemophilia A 
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Chapter 3 
 
Intron 22 homologous regions are implicated in exons 1-22 duplications of the 
factor 8 gene 
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Abstract 
The intron 22 inversion found in up to 50% of severe hemophilia A patients results from a 
recombination between three intron 22 homologous copies (int22h). This study evaluated the 
implication of these copies in the formation of extended duplications comprising exons 1 to 22 of the 
factor 8 (F8) gene and their association with hemophilia and mental retardation. Two hemophilic 
patients with moderate and severe phenotypes and a third non-hemophilic patient with 
developmental delay were studied. All exhibited a duplication of F8 gene exons 1-22 identified by 
MLPA along with abnormal patterns on Southern blotting and unexpected long-range PCR 
amplification. Breakpoint analysis using array-comparative genomic hybridization was performed to 
delimit the extent of these rearrangements. These duplications were bounded on one side by the F8 
intragenic int22h-1 repeat and on the other side by extragenic int22h-2 or int22h-3 copies. However, 
the simultaneous identification of a second duplication containing F8 gene exons 2-14 for the 
moderate patient and the classical intron 22 inversion for the severe patient are considered in this 
study as the genetic causal defects of hemophilia. This study shows that the well-known int22h 
copies are involved in extended duplications comprising F8 gene exons 1-22. These specific 
duplications are probably not responsible for hemophilia and intellectual disability, but should be 
carefully considered in genetic counseling, while continuing to investigate the causal mutation of 
hemophilia. 
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Introduction 
The X-linked coagulation disorder hemophilia A (HA) is caused by mutations in the factor 8 (F8) gene, 
which encodes coagulation factor VIII (FVIII) and is located at Xq28, the telomeric end of the long arm 
of the X chromosome. The most recurrent mutations associated with severe HA are intron 1 and 22 
inversions in the F8 gene. During male gametogenesis, both inversions are mediated by 
intrachromosomal homologous recombination between the highly homologous copies located in 
intron 1 or 22 and other extragenic copies positioned more telomerically outside the gene [1-4]. 
Point mutations, deletions, and insertions were detected in all 26 exons of the F8 gene in HA 
patients, causing phenotypes of variable severity characterized by complete or partial deficiency of 
circulating FVIII. Large deletions in the F8 gene involving one or more exons account for about 5% of 
all severe HA cases [5-6 (HADB(aka HAMSTeRS) the Hemophilia A Database, http://hadb.org.uk/)]. 
The identification of a large duplication comprising one or more F8 gene exons was recently made 
possible following the introduction of multiplex ligation-dependent probe amplification (MLPA) 
technology, with an estimated occurrence of 1% [7-8]. Large duplications are associated with 
different severity of hemophilia A depending on the localization, length of exons involved, and on 
whether the duplications generate an in-frame or out-frame protein [9-10].  
In a large HA cohort from Belgium undergoing diagnostic analysis [11], two male patients with 
moderate and severe phenotypes were found with an abnormal band pattern of intron 22 inversion 
on Southern blotting (SB) and large duplications involving F8 gene exons 1 to 22  using MLPA. These 
cases were further analyzed using high-resolution custom array-comparative genomic hybridization. 
As supported by a third non-hemophilic patient with intellectual disability but the same duplication 
of F8 gene exons 1 to 22 by MLPA, a comprehensive mechanistic model was proposed to explain 
these complex rearrangements.  
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Materails and Methods 
Case histories 
Case 1: This 25-year-old male was diagnosed with HA at four months of age. FVIII concentrations 
measured by one-stage and chromogenic assays were between 2 and 4%, and thus considered as 
moderate HA. The patient had a history of recurrent knee, elbow, and ankle hemarthroses since 
infancy, without inhibitor development during replacement therapy. HA was observed in at least 
three generations. DNA samples from his obligate carrier mother and cousins of his maternal obligate 
carrier were tested. 
Case 2: This 18-year-old patient was the only son of non-consanguineous parents without a family 
history of coagulation disorders. Severe HA was diagnosed at the age of 1 year on account of large 
hematomas. The patient had a history of recurrent knee, elbow, and ankle hemarthroses since 
infancy. No inhibitor development occurred during replacement therapy. His mother was diagnosed 
as a carrier female. 
Case 3: This 21/2-year-old patient was prematurely born at 342/7 weeks of gestation. At birth, Pierre 
Robin sequence with micrognathia, cleft palate, glossoptosis, and upper airway obstruction was 
diagnosed. The patient was developmentally delayed: at 11 months he sat upright and at 21/2 years 
started walking, saying just a few words. Facial features comprised a high forehead, long face, upper 
eyelid fullness, and convergent strabismus. The nasal bridge was broad, and anteversion of the 
nostrils was observed together with a long philtrum, open mouth, thin upper lip, and 
microrethrognatia. Large ears, fetal fingertip pads, rocker bottom feet, and pes valgus were noted. 
Array CGH revealed a large duplication at Xq28 located in the intron 22 homologous region (int22h) 
between int22h-1 and int22h-2 repeats. The patient had no coagulation disorder, with normal FVIII 
activity. 
FVIII activity and FVIII inhibitor screening 
FVIII activity levels (FVIII:C) were determined by standard one-stage coagulation and chromogenic 
assays. FVIII inhibitor screening and titration were performed according to Bethesda/Nijmegen 
modification assays.  
DNA collection 
A blood sample (5-10ml) was collected in an EDTA tube, and genomic DNA purification from 
peripheral leucocytes was performed using salting-out procedures [12]. 
Detection of intron 1 and 22 inversions 
The intron 22 inversion was detected using both SB [11] and a modified long-range polymerase chain 
reaction (LR-PCR) adapted from Bagnall et al. [13]. Details of this method are available upon request. 
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To interpret the abnormal band patterns obtained using SB, a combination of primers was analyzed 
in separate reactions: H1-F and H1-R for detecting int22h-1; H2-F and H2-3R for int22h-2; H3-F and 
H2-3R for the int22h-3 repeat; H1-F and H2-3R in addition to H3-F and H1-R for detecting 
rearrangements between int22h copies. 
The method for the detection of intron 1 inversion was performed as previously described [4]. 
MLPA 
MLPA was performed as previously described [11]. 
Array CGH, hybridization procedures, and analysis 
High-resolution custom array CGH (Agilent 8x15K) targeting duplications was designed using e-arrays 
(Agilent, Santa Clara, CA, USA). A backbone set of 2,247 probes was selected on chromosome X, 
while 10,384 probes were chosen in a targeted region between position 153,346,981 Mb and the q-
telomeric end of chromosome X (hg19 [GRCh37] assembly). Array CGH was performed according to 
the manufacturer’s instructions using 350ng of genomic DNA in a random priming labeling reaction 
(Bioprime Total Genomic Labelling Module, Invitrogen, Paisley, UK). Expected log ratio values for 
duplication in males and females were 1 and 0.58, respectively. Aberration calls were performed 
using ADM2, with a threshold of 6.0 in Genomic Work Bench. Incorporation of non-unique probes in 
the analysis may slightly modify the aberration breakpoints. These alternative breakpoints are 
represented as light gray boxes in Figure 2. 
Quantitative PCR to validate duplication breakpoints 
Amplifications distal to repeat int22h-3 were not easily assessed using microarray analysis given the 
highly repetitive nature of the genomic interval between int22h-3 and the TMLHE gene. To confirm 
the array results, a quantitative PCR (qPCR) system was developed. It was impossible to design a 
single-site amplification site. The selected primers (forward: TGTGCCAAAGTCCAGAAATAGT; reverse: 
CCAACAGAGAAAGTAGCAGGAA) amplified two loci, namely chrX: 154575182-154575278 (proximal to 
repeat a2) and chrX: 154724935-154725031 (distal to repeat a3). Consequently, in a male, if the 
duplication encompassed a single site, a genome equivalent to 0.75 was expected (3 copies vs. 4 in 
normal females); if both sites were duplicated, a genome equivalent to 1 was expected. In a female 
carrier with duplication at one or two sites, a genome equivalent to1.25 or 1.5, respectively, was 
expected (versusnormal female DNA). Normalization and qPCR data analysis were conducted 
according to Hoebeeck et al. [14] using two reference genes. An additional gene on chromosome X 
(MECP2) was used as negative control. 
Multiplex PCR assays 
Multiplex amplicon quantification (MAQ) is a robust, rapid, and easy-to-perform method for 
analyzing specific copy-number variations (CNVs). The method, performed according to the 
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manufacturer’s protocol, consists of fluorescently labeled multiplex PCR with amplicons in the CNVs 
(target amplicons) and amplicons with a stable copy number. Two series of five primer pairs 
extending from position 154,147,798 to 154,344,960 on chromosome X for the first series, and from 
154,441,804 to 154,664,293 on chromosome X for the second were designed to target F8 locus (See 
appendix, section C, table C4). The first amplicon was located in F8 gene intron 14, and the last 
between int22h-2 and int22h-3 repeats.  
MAQ analysis was performed according to the manufacturer’s protocol. Details of this method are 
available upon request. Raw data generated by fragment analysis on a capillary sequencer was 
analyzed using MAQ-S [Multiplicom [http://www.multiplicom.com]], a specially designed software 
program, to calculate and visualize the normalized peak area or dosage quotient, which reflected the 
copy number of each target amplicon.  
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Results 
For the three patients with chromosomal rearrangements affecting gene F8, data including gene 
dosage analysis obtained by SB and LR-PCR (Fig. 1), MLPA (data not shown), targeted array CGH, and 
MAQ (Fig. 2) is described below case-by-case. The extent of the duplication was confirmed using 
qPCR. Due to the highly repetitive genomic sequence around the int22h-2 and int22h-3 repeats, 
alternative quantification methods were required to validate the extent of the rearranged regions 
that were not clearly defined using array CGH (Fig. 2). 
FIGURE 1: RESULTS OF SOUTHERN BLOTTING AND LONG-RANGE POLYMERASE CHAIN REACTION 
i) Schematic representation of int22h copies at the Xq28 locus according to Bagnall et al. [1] (figure 
not to scale) 
 
The large arrows indicate the position of the int22h copies. The arrowhead represents the 
orientation of the DNA sequence. Gray boxes correspond to exons 1-22 and 23-26 of the F8 gene. 
The location of primer binding sites and expected long-range polymerase chain reaction (PCR) 
product size are drawn above, while the expected BclI restriction fragments sizes obtained by 
Southern blotting are indicated below 
 
ii) Results of Southern blotting
 
M: male; F: female; A: hemophilia A affected patient; C: carrier hemophilia A female 
Blot 1 
Lanes 1 and 2 correspond to a normal pattern. The probe hybridized with three fragments. The 
largest 21.5kb BclI fragment contains 9.5kb segment of intron 22 (int22h-1 or a1). The int22h-3 
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repeat or a3, considered the most telomeric, is located in the 16kb BclI fragment. The int22h-2 
repeat or a2 is positioned in the 14kb BclI fragment. 
Lanes 3 and 4: classical inversion of intron 22 type 1 in a male (A) and in a female carrier (C). + 
indicates the rearranged 20 kb int22h-1/3; * is associated with the rearranged 17.5kb int22-3/1 
centromeric repeat. For further details, see Figure 3A. 
Lanes 5 and 6: Case 2 patient with his carrier mother. Fragments corresponding to int22h-2 and 
int22h-3 repeats have normal size. However, the band associated with int22h-2 copies or a2 appears 
duplicated. The fragment corresponding to 17.5kb (also duplicated) indicates the presence of the 
classical inversion of intron 22 type 1. However, the absence of the 20kb fragment suggests a more 
complex rearrangement.  
 
Blot 2 
Lane 1: Carrier mother of case 1 patient. Normal pattern with an additional 20kb fragment.  
Lane 2: Case 3 without the hemophilia A phenotype. Case 1 patient presented the same pattern as 
case 3 (data not shown). 
Lane 3 corresponds to a normal pattern. 
 
iii) Results of long-range PCR 
 
As shown in a wild-type patient (WT), PCR amplification was only obtained using combinations of 
primers: H1-F/H1-R for detecting int22h-1; H2-F/H2-3R for int22h-2; H3-F/H2-3R for int22h-3 
repeat. 
For a patient harboring the classical inversion of intron 22 type1, PCR fragments could be only 
obtained using primers H3F/H1R and H1F/H2-3R, indicating the recombination between the 
intragenic int22h-1 repeat with its extragenic int22h-3 homologues. As shown in Figure 3A, 
amplification of the int22h-2 copy with primers H2F/H2-3R is conserved. 
For case 1 (A), PCR amplification of the three int22 copies was obtained as the wild-type patient. 
However, PCR obtained with H1F/H2-3R indicates a rearrangement between int22h copies. 
For case 2 (B), amplification with primers H3F/H1R and H1F/H2-3R indicates the inversion of 
intron 22 type 1. However, PCR obtained with primers H3F/H2-3R shows a more complex 
recombination  
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Case 1 
A normal profile with an additional 20kb fragment was observed using SB. The normal amplification 
of int22h copies was obtained in LR-PCR using repeat specific primers pairs. However, amplification 
was also obtained with the combination of H1-F and H2-3R primers. A large duplication of F8 gene 
exons 1 to 22 was identified using MLPA assay, along with a second duplication of exons 2 to 14. Due 
to insufficient patient DNA, DNA samples from his obligate carrier mother, presenting the same SB 
and MLPA patterns, were used for array CGH analysis. A 0.5Mb duplication (log ratio=0.520) 
extending from intron 22 of factor F8 (position 154117967bp on genome build hg19) to repeat 
sequences int22h-2 (position 154609974bp) was revealed in the vicinity of the H2AFB2 and F8A2 
genes, which was confirmed by MAQ assay. Higher log ratios between positions 154146529-
154229174bp (0.870) suggested that this region within the duplication was present in three copies 
(i.e., “second duplication”). The breakpoints of this second 82kb duplication fell within intron 14 and 
intron 1 of F8 gene, respectively.  
Case 2 
An abnormal pattern was observed using SB, with normal fragments containing int22h-2 and int22h-
3 repeats as well as a 17.5kb band (probably duplicated), which was associated with one of the two 
rearranged fragments in an intron 22 type 1 inversion. This classic inversion was confirmed by the 
int22h-1 rearranged 11.5kb fragment via LR-PCR. A large duplication of F8 gene exons 1 to 22 was 
identified using MLPA. Array CGH analysis revealed a large duplication of 0.6MB extending from the 
int22h-1 to int22h-3 repeats, or even further distally and so nearer the TMLHE gene. The region 
between the int22h-2 and int22h-3 repeats was clearly duplicated, but the highly repetitive nature of 
the region distal to h3 did not clarify whether this duplication extended more distally, given the lack 
of a unique probe in this interval. Thus, the duplication ranged from 154118907-154722370 or 
154731487bp on chromosome X. Quantitative PCR using this male patient’s DNA with primers 
hybridizing to both sides of int22h-2 and int22h-3 repeats provided a genome equivalent of 0.83, 
versus normal female DNA. This suggested that the region close to the int22h-2 repeat was 
duplicated, while the duplication did probably not extend beyond the int22h-3 repeat in the TMLHE 
gene region: (2 copies close to int22h-2 + 1 copy close to int22h-3 vs. 4 copies in the reference 
female).  
The patient’s mother had the same MLPA and SB profiles. 
Case 3 
The patient’s SB results were the same as case 1. A large duplication of F8 gene exons 1 to 22 was 
identified using MLPA. His mother presented the same SB and MLPA patterns. Array CGH for both 
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mother and son showed a large duplication between positions 154116088 and 154606719, which 
was located between int22h-1 and int22h-2 repeats (confirmed by MAQ analysis), whereas the 
interval between int22h-2 and int22h-3 repeats was not duplicated. Quantitative PCR performed 
using patient DNA provided a genome equivalent of 0.79, in line with a duplication in the proximal 
region of int22h-2 repeat, but not distal to int22h-3. 
FIGURE 2: FINE-MAPPING AND BREAKPOINT ANALYSES USING ARRAY COMPARATIVE GENOMIC HYBRIDIZATION OR 
MULTIPLEX POLYMERASE CHAIN REACTION ASSAYS 
 
 
 
Illustration of the rearrangements of the Xq28 region using custom tracks in the UCSC browser. The 
scale is provided above. The section “probes” shows the distribution of probes on the targeted 
custom array in the selected region (6526 probes in the selected window). Each vertical line 
corresponds to a probe. Sections “qPCR” and “MAQ systems 1 and 2” illustrate the localization of the 
qPCR and PCR systems used to confirm copy number changes (see article and Table 1 for details). 
Thereafter follow the rearrangement intervals as determined from the array CGH results for patients 
1, 2, and 3 and from the 2011 publication by El Hattab et al. (patients with duplication or deletion in 
fetus and carrier females). Clearly duplicated (or deleted) intervals are depicted in dark gray, while 
regions not clearly rearranged are shown in light gray. The region with three copies (“triplication”) in 
female patient 1 is shown in black. The deletion identified by Pegoraro et al. (1997) is not provided as 
no fine mapping information is available. The section “repeats” show the int22h-1, int22h-2 and 
int22h-3 repeats in dark gray as well as intron 22 of F8 (gray rectangle). Genes and segmental 
duplications (>99% similarity) are depicted using information provided by the University of California, 
Santa Crus (University of California, Santa Crus genome browser. http://genome.ucsc.edu). 
MAQ analysis on normal DNA controls 
Multiplex PCR assays were developed to detect the same 0.5 or 0.6Mb duplication extending from 
int22h-1 to int22h-2 or 3 repeats on 420 X chromosomes (84 females and 252 males). No duplication 
between int22h-1 and extragenic int22h sequences was found. However, one 0.5Mb heterozygous 
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deletion between int22h-1 and int22h-2 repeats was identified in a normal female. This deletion 
including F8 gene exon 1 to 22 was confirmed via MLPA.  
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Discussion 
In a large cohort of 148 Belgian HA families analyzed for F8 gene mutations, we identified a 
duplication of F8 gene exons 1 to 22 in two male patients with moderate and severe HA [11]. A third 
duplication of F8 gene exons 1 to 22 in a non-hemophilic patient suffering from intellectual disability 
and Pierre Robin syndrome (case 3) was added to this study. Case 1 patient with moderate HA 
presented a second duplication of F8 gene exons 2-14, while case 2 with severe HA harbored the 
classic inversion of intron 22 type 1. Breakpoint array CGH analyses revealed that rearrangements 
were delimited by the intragenic int22h-1 repeat on one side and on the other side, by int22h-2 for 
cases 1 and 3, and int22h-3 copies for case 2. These results demonstrate that partial F8 gene 
segments may be duplicated by mechanisms involving the same DNA repeats as those involved in the 
classical intron 22 inversion. Based on these results, we propose a comprehensive modeling of the 
mechanisms involved. 
FIGURE 3: NON-ALLELIC HOMOLOGOUS RECOMBINATION EVENTS BETWEEN INT22H COPIES  
(figures not to scale) 
i) Schematic mechanism of the recurrent int22h inversion type 1 in severe hemophilia A. This mode 
of rearrangement is facilitated in male meiosis, as this mechanism involves flipping the end of the X 
chromosome, which is inhibited in female germ cells by X chromosome pairing 
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ii) Proposed mechanisms for the formation of complex duplication/deletion in cases 1 and 3 (a) 
and in case 2 (b) 
 
a) Misalignment of two normal maternal X chromatids during meiosis, which may result in a non-
allelic homologous recombination mechanism in an unequal crossing-over that provides copies 
with the duplication of 0.5 Mb between the int22h-1 and int22h-2 copies or the deletion of 0.5 
Mb. The duplication maintains a normal and functional copy of the F8 gene. Normal long-range 
polymerase chain reaction products and BclI restriction fragment sizes using Southern blotting are 
obtained for the three int22h copies. However, the duplication generates an additional fragment 
of 20kb observed on Southern blotting as well as amplification with the combination of primers, 
H1F and H2-3R. 
 
b) Misalignment between one normal chromatid and another chromatid with an inversion of intron 
22 in a carrier female during meiosis Unequal crossing-over by a non-allelic homologous 
recombination NAHR mechanism produces duplication between int22h-1 and int22h-3 copies 
instead of duplication between int22h-1 and int22h-2 in the mechanism proposed in part ii.a of 
this Figure. This rearrangement involves the presence of two incomplete sequences of exons 1 to 
22 of the F8 gene, two copies of int22h-2, one copy of the int22h-3 repeats, one copy associated 
with the rearranged fragment of 17.5kb in the int22-3/1 repeat, and one copy associated with 
another 17.5kb rearranged fragment corresponding to the newly produced int22-1/3 repeat  
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Xq28 locus is considered a region at high risk of genomic instability, with micro-rearrangements 
(deletion or duplication) described for example in adrenoleukodystrophy [15], X-linked mental 
retardation syndrome (MECP2) [16], and HA [1, 2]. Indeed, the F8 gene intron 22 contains a 9.5kb 
region known as copy int22h-1, which is outside the gene and situated approximately 0.5 and 0.6Mb 
more telomerically to the two other highly homologous copies, namely int22h-2 and int22h-3 [1,2]. 
The int22h-1 and int22h-3 copies lying in opposite directions are responsible for recurrent 
intrachromosomal rearrangements involving the F8 “distal” inversion or inversion type 1. Recently, 
int22h-1 and int22h-2 sequences were reported to display the same orientation [17], which may 
cause, theoretically, highly deleterious 0.5Mb deletions or duplications in the case of recombination 
between misaligned sister chromatids or homologous chromosomes. It has been suggested that they 
are either extremely rare or non-existent [13, 18, 19] and could cause problems in mutation testing 
in HA [20]. However, a very recent publication [21] reported novel 0.5Mb duplications between 
int22h-1 and int22h-2 copies in three unrelated males, presenting cognitive impairment, behavioral 
abnormalities, recurrent infections, and characteristic facial features. 
 
Our report describes the same rearrangement in two patients (cases 1 and 3), both presenting a large 
duplication of F8 gene exons 1 to 22 extending from int22h-1 to int22h-2 repeats. The presence of an 
extra 20kb BclI band detected using SB is likely to be the consequence of genomic rearrangement, 
which produced the altered int22h restriction fragment as confirmed by LR-PCR (Fig 3). Additionally, 
we describe a more complex not previously described rearrangement in a severe HA patient (case 2) 
presenting a large duplication estimated at 0.6Mb extending from int22h-1 to int22h-3 repeats. If the 
large duplication in the F8 locus in cases 1 and 3 could be the consequence of int22h-1 misaligning 
with a similarly oriented and more telomeric int22h repeat from the sister chromatid via a NAHR 
mechanism, we presume that numerous different duplications are possible depending on the initial 
alignments. In case 2, our results suggest a non-allelic recombination in the female carrier between a 
normal X chromosome and intron 22 inversion of the sister X chromosome, resulting in a large 
duplication between int22h-1 and int22h-3 copies as well as fragments compatible with an intron 22 
type 1 (Fig. 3). This explains why this duplication extended between repeats int22h-1 and int22h-3. 
Whether these 0.5/0.6Mb duplications mediated by int22h-1/int22h-2 or 3 rearrangement are 
associated with HA is uncertain. After excluding other causal mutations in F8 gene exons via 
bidirectional sequencing, we assume that the HA phenotype of case 1 was associated with a second 
duplication of F8 gene exons 2 to 14. Numerous publications have reported the causality of large 
intragenic duplications, especially in HA patients with different phenotypes [7, 22, 23]. Despite using 
different primer combinations, it was impossible to characterize the duplication breakpoints for this 
patient and his relative. In case 2, the recombination between the normal X chromosome and intron 
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22 inversion of the sister X chromosome produced a more complex rearrangement without 
maintaining a complete copy of the F8 gene [Fig. 3]. Again, after complete gene sequencing we 
concluded that the severe HA phenotype of case 2 was caused by classical intron 22 inversion. In the 
study by El-Hattab et al. [21], the index case of family 3 presented, along with his intellectual 
disability, a minor HA type with FVIII levels estimated at 24%. The complete sequencing of the F8 
gene revealed hemizygosity for the point mutation c.6089G>A (p.Ser2030Asn), which was associated 
with mild HA (HADB (aka HAMSTeRS) http://hadb.org.uk/). According to Figure 3b and as suggested 
by Bagnall et al. [13], a complete copy of the F8 gene is preserved after the formation of the 0.5Mb 
duplication mediated by int22h-1/int22h-2 rearrangement, thus producing normal FVIII levels. We 
propose that males or females with such an extending 0.5Mb duplicated rearrangement would not 
be at risk of HA, as they maintain a normal copy of the F8 gene unless if a causal mutation, such as 
the large duplication of exons 2-14 in case 1 or point mutation in family 3 of El-Hattab’s study, occurs 
in the normal F8 copy. 
El-Hattab suggested that the 0.5Mb duplication mediated by int22h-1/int22h-2 rearrangement was 
associated with a novel X-linked intellectual disability. However, several arguments are in 
contradiction with this conclusion. Indeed, no intellectual disability was observed in our hemophilic 
cases, nor was there any developmental delay noted in the mothers and their relatives (obligate 
carrier grand-mother, affected uncle, and his two obligate carrier cousins for the first case; carrier 
grand-mother for the third case), whereas in El-Hattab’s study, carrier mothers exhibited learning 
difficulties despite the abnormal X chromosome being preferentially inactivated. In our study, 
chromosome X-inactivation (XCI) analysis at the androgen receptor [24, 25] showed skewed XCI for 
the case 1 mother (ratio 87:13) but no skewed XCI for the case 3 mother (ratio 80:20). Case 3 
displayed dysmorphic features identical to those described in the three El-Hattab families, with 
several dissimilar features. Additionally, none of the six known genes localized in the 0.5/0.6Mb 
duplicated intervals (see Figure 2) were shown to be associated with X-linked intellectual disability. 
These genes exhibit low expression levels in the brain with the exception of the RAB39B gene for 
which two different hemizygous mutations have recently been identified in male patients presenting 
autism, spectrum disorder, epileptic seizures, and macrocephaly [26]. 
These 0.5/0.6Mb duplications mediated by int22h-1/int22h-2 or 3 rearrangement must be very rare, 
as they are not reported in the CNV database Copy-Number Variation Database (database of 
genomic variants http://projects.tcag.ca/variation/). No new duplication was found in a screen of 
420 X chromosomes via specific multiplex PCR. However, a new 0.5Mb reciprocal deletion between 
int22h-1 and int22h-2 copies was reported in a normal female. As suggested by Pegoraro et al. [27] 
and El-Hattab et al. [21], these deletions may be lethal for males in utero but have no phenotypic 
consequences in females, as they result in completely skewed XCI. As CGH is an increasingly used 
 
 
104 
 
screening method in prenatal diagnosis and patients with cognitive and behavioral abnormalities, 
this 0.5Mb deletion or the corresponding duplication is likely to be increasingly found in the future. 
Clinical interpretation of large rare rearrangements identified by arrays is an important problem in 
current genetic testing and require guidelines to assess their clinical relevance [28]. 
In the literature, we found three studies [29-31] describing patients with severe HA phenotypes 
associated with the same SB combination of fragments of 21.5, 20, 16 and 14kb as found in our cases 
1 and 3. The study of Zimmermann et al. [32] identified an aberrant 20kb band associated with a 
duplication of exons 7-22 in a patient with severe HA resulting from rearrangement with int22h 
repeats. Furthermore, two other studies [33, 34] reported the same abnormal SB profiles associated 
with severe HA (17.5, 16, and 14kb) as in case 2. Only further analyses (sequencing and MLPA) are 
likely to reveal whether these abnormal SB patterns are the real cause of HA, thus improving genetic 
counseling. 
The inversion of intron 22 occurs almost exclusively in male germ cells [35], as the mechanism for 
intron 22 involves flipping the end of the X chromosome, which is facilitated in male meiosis but 
inhibited in female germ cells by X-chromosome pairing. Thus, the 0.5/0.6Mb deletion or duplication 
mediated by int22h rearrangement could occur in maternal meiosis, as these rearrangements require 
the pairing of two homologous chromatids (Fig. 3). 
All duplications described in this article were maternally inherited. However, the parental origin of 
the arrangement could not be determined, as DNA from the ascending generation was not available. 
For case 1, it is currently impossible to determine which duplication (0.5MB or F8 exons 2 to 14) 
occurred first or to identify the parental origin.  
Conclusion 
Our data provides additional proof for the genomic instability at Xq28, showing that the int22h 
copies responsible for the well-known intr22 inversion are implicated in extended duplications (and 
deletion) involving F8 gene exons 1-22. These duplications are probably not associated with HA, as 
they coexisted with other molecular defects clearly responsible for HA. Contrary to a previous report 
and based on our study results [21], these duplications do not appear to be associated with 
intellectual disability. 
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Since the Factor VIII gene (F8) was first cloned in 1984, our ability to analyze it has vastly progressed, 
facilitated by recent innovative technologies. The heterogeneity of its genomic structure and the 
various and complex molecular mechanisms affecting it were largely documented. The extensive 
length of the F8 gene (186kb, containing 26 exons), the presence of internal repeat sequences 
(localized in F8 introns 1 and 22), and its location at the extremity of chromosome X (the Xq28 locus) 
all account for the wide variety of genetic abnormalities that may occur, causing hemophilia A (HA). 
In spite of this heterogeneity, the intron 22 inversion (Inv22) is known to be the most prevalent 
genetic abnormality among patients with severe HA [1, 2]. From what we understand of its 
mechanism, F8 Inv22 results from a recombination between three highly homologous copies 
(int22h): one located in intron 22 of the F8 gene (int22h-1) and two extragenic copies (int22h-2 and 
int22h-3) occupying more telomeric positions outside of the gene. Intrachromosomal 
rearrangements between int22h-1 and int22h-3 are responsible for the so-called F8 inv22 type 1, 
whereas F8 Inv22 type 2 is caused by the int22-h2 repeat sequence [3]. The existence of an 
infrequent and more complex third type of Inv22, referred to as 3A or 3B, has also been described 
[4]. Some authors hypothesize that 3A and 3B implicate duplicated copies of int22h-3 or int22h-2, 
respectively, although their underlying molecular mechanisms have yet to be fully elucidated [5, 6]. 
Antonarakis et al. estimated the frequency of Inv22 3A or 3B to be 0.05%, based on the pooled data 
of nearly 3,000 severe hemophiliac patients [5]. The three inversion types cause a severe HA 
phenotype due to the 3’ extremity of the F8 gene (exons 23-26) being separated from the remaining 
gene (exons 1-22) during an intrachromosomal illegitimate recombination between two "int22h" 
repeats. 
FIGURE 1: DUPLICATION AT THE XQ28 LOCUS DETECTED BY AFFYMETRIX CYTOSCAN HD ASSAY 
The figure corresponds to results obtained from HA54 proband (II.2) 
 
 
A large duplication at the Xq28 locus was detected in all patients with Inv22 type 3 delimited to 
intron 1 of the CLIC2 gene (hg19: position 154,542,523) and repeat int22h-3 (hg19: position 
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154,681,275), comprising part of the coding gene CLIC2 (ONIM #300138) and genes H2AFB2 (ONIM 
#300445) F8A2 (ONIM #305423). Symbol A corresponds to a graphical representation of the gain 
identified in the Xq28 region, B shows the log2 ratio intensity for each probe, C is the copy number 
for each probe, D identifies genes in this region, and E shows cytogenetic bands and base pair 
positions on/of chromosome X. 
Genomic DNA purification from peripheral leucocytes was performed using salting-out procedures. 
Whole-genome copy number variation (CNV) analysis was conducted using the Affymetrix CytoScan 
High-Density array and the Chromosomal Analysis Suite V1.2.2 (ChAS) software (Affymetrix, Santa 
Clara, CA, USA), according to the manufacturer’s instructions. 
In our study, we employed comparative genomic hybridization (CGH) to study the genotype of three 
severe HA patients harboring F8 Inv22 type 3 (one with type 3A, two with type 3B). This enabled us 
to identify an approximately 180kb-long duplication delimited on either side of the two extragenic 
"int22h" copies. We also reviewed individuals who had previously presented with similar 
rearrangement and discussed its probably polymorphic nature. 
Of 99 unrelated severe HA DNA patients investigated for the presence of an F8 gene Inv22 by 
Southern blot analysis, 49 unrelated severe HA patients (49%) exhibited evidence of the F8 Inv22 
mutation. The classical Inv22 type 1 was detected in 92% (n=45), while the second and third types 
were found in 2% (n=1) and 6%, respectively (n=1 for Inv22 type 3A and n=2 for the 3B) (Fig. S1). In 
order to delimitate the quantitative genomic changes at the Xq28 locus, we performed a whole-
genome copy number variation (CNV) analysis using the Affymetrix CytoScan High-Density array 
(Affymetrix, Santa Clara, CA, USA). Breakpoint analyses in all patients with Inv22 type 3 revealed the 
same duplication of approximately 180kb between intron 1 of the CLIC2 gene (hg19: position 
154,542,523-154,556,313) and int22h-3 repeat (at hg19: position 154,680,732-154,739,500) (Fig.1). A 
maximum of six genes were included within this range: part of CLIC2, H2AFB2, F8A2, H2AFB3, and 
F8A3 and part of TMLHE (Table1). The HA54 proband (II.2 at Fig. S2) was also analyzed for copy 
number alteration by an X chromosome CNV-specific custom array probes (Agilent, Santa Clara, CA, 
USA), as previously described [7]. The results produced using this array confirmed the presence of a 
duplication between intron 1 of the CLIC2 gene (at position hg19 154,543,828 bp) and int22h-3 
repeat (at position hg19 154,724,508 bp) or slightly more distal toward the TMLHE gene (position 
154,733,993 bp). Intron 1 of CLIC2 was aligned with the whole human genome to determine if there 
are sequence homologies between intron 1 of CLIC2 and the distal breakpoint. High homologies 
between intron 1 of CLIC2 and intron 3 of TMLHE with sequences in direct orientation were 
observed. These homologies do not exactly fit with the position of the breakpoint as determined by 
our targeted custom array. However the resolution in determining the breakpoint is not precise given 
the highly repetitive nature of these regions and the relative probe paucity. Furthermore quantitative 
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PCR performed using case 3 DNA shows a genome equivalent of 0.80 suggesting that the proximal 
region of TMLHE is not actually duplicated. 
In addition to the three aforementioned HA cases, a similar ~180kb duplication was also identified in 
patients reported in the ʺDatabasE of genomiC varIation and Phenotype in Humans using Ensembl 
Resourcesʺ (DECIPHER) [https://decipher.sanger.ac.uk/] and the ʺDatabase of Genomic Variantsʺ 
[http://projects.tcag.ca/variation/]. Clinical characteristics of each patient have been presented in 
Table1. 
FIGURE 2: SOUTHERN BLOT OF HA54 FAMILY 
Southern blots of BclI-digested genomic DNA were carried out via a standard procedure, as 
previously described, using the 0.9kb EcoRI/SacI fragment from plasmid p482.6 (ATCC catalog n° 
57203) for hybridization process [8]. 
 
Lane 1: corresponds to a normal pattern. The probe hybridized with three fragments. The largest 
21.5kb BclI fragment contains 9.5kb segment of intron 22 (int22h-1). The int22h-3 repeat, considered 
the most telomeric, is located in the 16kb BclI fragment. The Int22h-2 repeat is positioned in the 
14kb BclI fragment. 
Lanes 2 and 3: classical inversion of intron 22 type 1 in a male (M) and in a female carrier (C). The 
white arrow indicates the rearranged 20 kb int22h-1/3 or int22h-1/2; The gray arrow is associated 
with the rearranged 17.5kb int22-3/1 centromeric repeat. 
Lanes 4 and 5: classical inversion of intron 22 type 2 in a male (M) and in a female carrier (C). The 
black arrow is associated with the rearranged 15.5kb int22-2/1 centromeric repeat. 
Lane 6; Southern blot is compatible with a rare inversion of intron 22 type 3 (B) presented in HA54 
patient by the presence of rearranged fragments compatible with the type 2 inversion and by the 
presence of an additional normal fragment corresponding with migration of int22h-2 repeat. 
As expected, 49% of the severe HA cases exhibited intron 22 inversion. To account for the 
observed 5- to 6-fold excess of type I inversions in comparison with type II, Bagnall et al. [3, 9] have 
advanced a promising hypothesis. Int22h-2 and int22h-3 repeats are located in complex sequences, 
composed by two imperfect 9.5kb palindromes separated by a central 65kb segment and extended 
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duplicated sequence of 40kb. These large palindrome arms can recombine frequently with each 
other so as to generate an inversion of the central 65kb segment and create a polymorphism 
genotype, where the int22h-2 repeat is in the most telomeric position. In the human population, 
these two structural inversion polymorphisms are present at up to 80% (int22h-123) and 20% 
(int22h-132) incidence, respectively. 
In this study, we have identified an approximately 180kb duplication at the Xq28 locus between 
intron 1 of the CLIC2 gene and int22h-3 repeat in all patients presenting with the third type of F8 
Inv22. An analysis of the “Database of Genomic Variants” and “DECIPHER”, which catalog structural 
variations identified in healthy individuals and genomic variation data from patient analyses, 
respectively, reported three other duplications of the same size and located at the same locus. The 
imprecise breakpoint distal to the int22h-2/int22h-3 repeats is probably due to the highly repetitive 
nature and relative probe paucity of this genomic interval, rendering it difficult to access by 
microarray and other types of technology employed. 
The human genome is not a stable entity, especially when one considers the presence of the 
duplicated region containing extragenic int22h repeats, as described above. The Xq28 locus is 
considered a region at high risk of genomic instability, with a multitude of reported micro-
rearrangements (deletion or duplication) [10-13]. However, several variants are novel or extremely 
rare, rendering the clinical interpretation problematic and genotype-phenotype correlations 
uncertain. A large number of recombination events could give rise to this duplication, depending on 
the initial alignments, its position, and the mechanisms involved. It could even result from a 
transposition of the duplicated part to a genomic position outside of the affected locus. This latter 
hypothesis did not appear to fit for one family with Inv22 type 3B (HA54), as the family’s HA history 
and that of the duplication were found to segregate over at least four generations (Fig. S2). As 
discussed above, the int22h-2 and int22h-3 repeats of this complex sequence could have recombined 
with each other, generating two palindromic genotypes in the normal human population. 
Consequently, it would be logical to assume that this complex sequence could also be subject to a 
duplication mechanism, creating a genotype of five copies in the F8 locus, one in the F8 intron 22, 
and four positioned more telomerically. Further investigation should now be undertaken in order to 
identify the precise duplication breakpoints.  
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FIGURE 3: PEDIGREE OF HA54 FAMILY 
 
Males are indicated by squares, females by circles. Carriers are indicated by circles with inner dots, 
affected males by solid black squares. Symbol with a diagonal line designs the case’s death. 
Termination of pregnancy is specified with smaller solid black square. Index case (proband) is shown 
by arrow. Patients analyzed with Southern blotting are indicated by *. 
This ~180kb duplication was also identified in three other non-HA patients (Table1). We can 
therefore assume that this duplication is not associated with hemophilia A. Firstly, given that the 
severe phenotype of these three cases with Inv22 type 3 is solely due to intrachromosomal 
recombination taking place between two homologous int22h repeats. These events result in 
inversion separating F8 exons 1-22 from exons 23-26, which completely disrupt FVIII. This was 
confirmed by c-DNA analysis of F8 mRNA extracted from index case HA183, which revealed a unique 
mRNA defect that prevents message amplification across the boundary between exon 22 and 23 
(data not shown). Secondly, this duplication is believed to be unconnected with HA given that it was 
also found in patients without the severe HA phenotype (Table 1). In addition, this duplication is 
probably not responsible for other genetic disorders, and should thus be considered a polymorphism. 
Conclusions 
In conclusion, our study reports the unsuspected existence of a wild-type genotype harboring five 
int22h copies (one in F8 intron 22 and four positioned more telomerically) mediated by a 180kb 
duplication at the Xq28 locus. This genotype should be considered a polymorphism and is technically 
identified by Southern blot analysis, long range-PCR and inverse shifting-PCR in severe HA patients 
bearing intron22 type 3 inversion [3, 14]. These results provide further evidence of the major and 
complex role played by repeated sequences in the cause and development of HA. 
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TABLE 1: RELEVANT DATA OF APPROXIMATIVELY 180KB DUPLICATION DELIMITED BETWEEN INTRON 1 OF THE CLIC2 GENE AND REPEAT INT22H-3  
 
ID Sexe Phenotype Length (Mb) and position hg19 
Structural variant detection 
technology 
Genes Inheritance 
Pathogenicity 
contribution 
Remarks References 
HEMO
A 
male Severe HA 0.18 (154,556,313 - 154,739,500) Affymetrix Cytoscan - HD Array 
6 (part of CLIC2, H2AFB2, F8A2,H2AFB3, 
F8A3, and part of TMLHE) 
unknown Likely benign 
 HA phenotype is caused 
by intrachromosomal 
rearrangement between 
int22h-1 and int22-h3 
copies  
this study 
HA54 male Severe HA 
0.14 (154,542,523 - 154,681,275) 
0.18 (154,543,828 - 154,724,508 ) 
Affymetrix Cytoscan - HD Array  
Agilent 8x15K array  
3 (CLIC2, H2AFB2, F8A2)                                                           
5 (part of CLIC2, H2AFB2, F8A2, H2AFB3, 
F8A3 ) 
Familial inheritance 
Mother is carrier 
Likely benign 
 HA phenotype is caused 
by intrachromosomal 
rearrangement between 
int22h-1 and int22-h2 
copies  
this study and 
Lannoy et al 
[7] 
HA183 male Severe HA 0.12 (154,556,313 - 154,680,732) Affymetrix Cytoscan - HD Array 3 (part of CLIC2, H2AFB2, F8A2) unknown Likely benign 
 HA phenotype is caused 
by intrachromosomal 
rearrangement between 
int22h-1 and int22-h2 
copies  
this study 
278479 male unknown 0.14 unknown 4 (CLIC2, H2AFB2, F8A2,H2AFB3) 
inherited from parent 
with unknown 
phenotype 
unknown NR Decipher 
288623 male 
Diffuse 
demyelinati
on of the 
cerebral 
white 
matter, 
Global 
developme
ntal delay, 
seizures 
0.13 unknown 5 (CLIC2, H2AFB2, F8A2,H2AFB3, F8A3) unknown Likely benign 
Presence of two others 
CNV. This localized in 3q29 
is possibly pathogenic 
Decipher 
nsv508
817 or 
GM189
94 
(Coriell 
Institut
e) 
male 
Japanese 
from the 
Tokyo 
metropolita
n area in 
Japan 
0.07 (154,127,686 - 154,197,147) Optical Mapping 
NM_001289 (CLIC2); NM_001017990 
(H2AFB1)*; NM_080720 (H2AFB3); 
NM_001017991 (H2AFB2); NM_012151 
(F8A1)*; NM_001007523 (F8A2); 
NM_001007524 (F8A3) 
unknown unknown 
Individual from normal 
human population 
Database of 
Genomic 
Variants and 
Teague et al 
[15] 
 
*: H2AFB1 and F8A1 genes (positioned in F8 intron 22) is mentioned due to their highly homologies with the H2AFB2/3 and F8A2/3 genes 
NR: non remarks 
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Abstract 
In approximately 90% of mild hemophilia A (HA) patients, a missense mutation can be identified 
using complete gene sequencing. In this study, multiplex ligation-dependent probe amplification 
(MLPA) analysis was performed as a second step in 10 French-speaking Belgian with mild HA 
presenting no detectable causal mutation by complete sequencing of the factor VIII (F8) gene’s 26 
exons and its 1.2kb of contiguous promoter sequence. This gene dosage technique enabled the 
detection of exon 1 duplications of F8 in three apparently unrelated subjects. Using array-
comparative genomic hybridization, breakpoint analysis delimited the duplication extent to 210kb in 
the F8 intron 1 and VBP1 gene intragenic position. We postulated that the rearrangement 
responsible for this duplication, never before reported, could be attributed to a symmetrical tandem 
inversion duplication resulting in a large 233kb rearrangement of F8 intron 1. This rearranged intron 
should lead to the production of a small number of normal mRNA transcripts in relation to the mild 
HA phenotype. Our analysis of the entire F8 mRNA from index case 1, particularly the segment 
containing exons 1 to 9, revealed normal amplification and sequencing. Reduced plasma FVIII antigen 
levels caused by cross-reacting material (CRM) is associated with a quantitative deficiency of plasma 
factor VIII. Male patients were unresponsive to desmopressin (1-deamino-8-D-arginine vasopressin 
[DDAVP]). All patients displayed identical F8 haplotypes, despite not being related, which suggests a 
possible founder effect caused by a 210kb duplication involving F8 exon 1.  
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Introduction 
Hemophilia A (HA), an X-linked coagulation disorder, is caused by mutations in the gene that encodes 
coagulation factor VIII (F8). With the exception of intron 22 and 1 inversions, point mutations, 
deletions, and insertions are distributed heterogeneously throughout the F8 26 exons in HA patients. 
These are responsible for the variable severity of the different phenotypes, which depends on the 
residual FVIII activity, ranging from complete to partial [http://www.eahad-db.org/].  
Other more recently reported genetic defects in HA patients have included deletions and 
duplications. Large deletions comprising over 50 base-pairs in F8, implicating one or more exons, 
account for approximately 5% of all severe HA cases [1-3]. With the aid of multiplex ligation-
dependent probe amplification (MLPA) technology, large duplications comprising one or more F8 
exons were identified, at an estimated occurrence rate of 1% [4-5]. These duplications were linked to 
different hemophilia severities depending on localization, length of exons involved, and whether the 
resulting proteins were in-frame or out-of-frame. An internal in-frame exon 13 duplication within the 
F8 gene was described in association with the mild HA phenotype [6], while duplications responsible 
for frameshift in the F8 mRNA and protein sequences have been identified in the severe HA form [4]. 
In this study comprising 96 apparently unrelated French-speaking Belgian mild HA families screened 
for F8 mutations, duplications involving only exon 1 of the gene were identified by means of MLPA in 
three unrelated patients, all with a mild HA phenotype. DNA sequencing did not identify any 
mutation. These three cases were further analyzed by high-resolution, custom array-comparative 
genomic hybridization (array-CGH) in order to identify the borders of these rearrangements, allowing 
for a comprehensive mechanistic model to be created in order to account for correlating genotypes 
and phenotypes. 
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Materials and Methods 
The following described cases were selected among referrals to the genetic center of the Cliniques 
Universitaires Saint-Luc in Brussels for identification of the causal hemophilia mutation. Out of the 10 
mild hemophilia index cases where no mutations were identified by direct sequencing of the coding 
regions, three unrelated patients were found to harbor duplications involving the F8 exon 1 when 
analyzed using MLPA. 
Case histories 
Index case 1 (II-1) from pedigree 1: This 45-year-old was diagnosed with HA at the age of 4. The 
FVIII:C activity, measured by both one-stage assay and chromogenic assays (data available in 2012) 
was  5% and 3.4%, respectively. During childhood, this patient experienced six episodes of 
spontaneous hemarthrosis on average each year, primarily affecting his knees and right ankle. Cross-
reactive material measured using polyclonal FVIII antibody revealed reduced plasma FVIII antigen 
levels, at 11.6%, in comparison with those of the wild-type at 100%. The patient was completely 
unresponsive to 1-deamino-8-D-arginine vasopressin (DDAVP) and on-demand replacement therapy 
was consequently initiated, with no inhibitor development observed. Genetic testing revealed his 
mother (I-1) to be a carrier, with an HA diagnosis also established in his grandson (IV-1) (Fig. 1). 
Index case 2 (IV-1) from pedigree 2: This 16-year-old was diagnosed with mild HA, exhibiting an 
FVIII:C activity estimated at 5% by means of one-stage assay. The patient experienced episodes of 
muscular hematomas and bruising, manifesting no response to DDAVP. HA was shown to have 
affected at least four generations of his family, dating back to his great-grandfather (I-1), with his 
maternal uncle (III-1) also being diagnosed with HA. His sister (IV-2) also tested positive as a carrier 
(Fig. 1). 
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FIGURE 1: PEDIGREES OF THREE APPARENTLY UNRELATED INDEX CASES WITH HEMOPHILIA A 
Males are indicated by squares, females by circles. Carriers are indicated by circles with inner dots, 
affected males by solid black squares. Index cases are shown by arrows. Patients analyzed with MLPA 
are indicated by *. 
Haplotype was obtained via analysis of two extragenic and two intronic (highlighted) markers (in the 
order of 3’→5’ with respect to the position of F8: DXS15, STR22, STR13, DXS1108) 
Index case 3 (III-2) from pedigree 3: This female patient was diagnosed as an obligate HA carrier, as 
her FVIII:C activity was evaluated at 37%. The disease was shown to have affected at least four 
generations of her family, dating back to her grandfather, with one maternal nephew (IV-1) also 
being diagnosed with HA presenting an FVIII:C activity estimated at 7%. DDAVP testing was not 
performed on this female patient (Fig. 1). 
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Methods 
FVIII activity and antigen assays  
FVIII activity was determined using both a one-stage clotting assay (FVIII:C), based on activated 
partial thromboplastin time (aPTT) and using an aPTT reagent (SynthasIL, Instrumentation 
Laboratory, Bedford, USA), and a chromogenic method (FVIII:CR), performed with the Biophen 
FVIII:C® kit (Hyphen Biomed, Paris, France). FVIII antigen (FVIII:Ag) levels were measured using a 
commercial ELISA assay (FVIII:C EIA kit, Stago BNL, Brussels, Belgium). The specific activity (UI.µg-1) of 
the FVIII was determined by the ratio FVIII:C/FVIII:Ag and expressed as a percentage of the wild type.  
Classical DNA and RNA analysis 
For each case, a 5-10ml blood sample was collected into an EDTA-coated tube, followed by genomic 
DNA extraction from peripheral leukocytes by means of the salting out procedure [7]. 
As per previous descriptions, we performed sequencing of the functional regions, including the 26 
exons with their immediate 5’ and 3’ flanking splice junctions and the approximate 1.2 kb contiguous 
promoter sequence corresponding to nucleotides -1214 to +441 of the F8 reference sequence 
NM_000132.3 [8].  
The method used for detecting intron 1 inversions was as previously described [9].  
MLPA was performed, as previously described, using the P178-B2 F8 probemix [3]. Amplification 
products were identified on an ABI3500xl capillary sequencer using Genescan-ROX-500 (Applied 
Biosystem, Foster City, CA, USA) as a size standard, then interpreted by means of GeneMarker 
software V2.2.0 (SoftGenetics LLC, State College, PA, USA) for MLPA analysis. 
Total cytoplasmic RNA was isolated from peripheral leukocytes using TRI-Reagent® (Invitrogen Life 
Science, California, USA), according to the manufacturer’s instructions and based on standard 
procedures. An analysis of full-length F8 mRNA transcript was performed by way of a nested 
approach, as previously reported [10, 11]. 
X chromosome inactivation analysis 
To distinguish the active from the inactive X chromosome, the highly polymorphic short-tandem 
repeat in the first exon of the androgen receptor gene was amplified by polymerase chain reaction 
(PCR) following digestion with the methylation sensitive enzyme, as previously described [3].  
Array CGH  
High-resolution custom CGH array (aCGH) was performed in case 1 (pedigree 1, II-1), as previously 
described [12]. In cases 2 and 3 (pedigree 2, IV-1; 3, III-2), whole-genome copy-number variation 
(CNV) analysis was performed using Affymetrix CytoScan High-Density (HD) Array, and Cytoscan 750K 
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Array (Affymetrix, Santa Clara, CA, USA), respectively, in accordance with the manufacturers’ 
instructions. The CNVs were analyzed using Chromosomal Analysis Suite V1.2.2 (ChAS) software 
(Affymetrix). Various arrays were used during the study according to the technical evolution in time 
adopted by the laboratory. 
Haplotype analysis 
The patients were tested for the following extragenic and intronic (highlighted) markers in the order 
of 3’→5’ with respect to the position of F8, as previously published: DXS15, STR22, STR13, DXS1108 
(Appendix section C Table C3.2). The PCR was performed in a 25µl solution containing 1 PCR FastStart 
buffer, 1 U of FastStart Taq polymerase (Hoffmann-La Roche, Basel, Switzerland), 0.2mM of each 
dNTP, and 10pmol of each primer. The cycling conditions were as follows: initial denaturation 
temperature at 94°C for 5 minutes (min); 30 cycles of amplification and 30 seconds (sec) of 
denaturation at 94°C; 1 min annealing at 55°C; 1 min elongation at 72°C; and finally 5 min extension 
at 72°C. A 1.5µl aliquot of the PCR product was added to 10µl of Hi-Di formamide (Applied 
Biosystems, Foster city, CA, USA). Amplification products were identified on an ABI3130xl capillary 
sequencer, using Genescan-ROX-500 (Applied Biosystems, Foster City, CA, USA) as a size standard, 
then interpreted by means of GeneMarker software V1.5 (SoftGenetics LLC, State College, PA, USA). 
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Results 
Molecular analysis 
 Of the 10 mild HA patients of our cohort (n=96) presenting negative results from coding 
region sequencing and the 1.2kb contiguous promoter sequence, three unrelated index cases were 
found to have large duplications ≥0.3kb involving F8 exon 1 by using MLPA (Fig. 2). This technique 
also identified the same exon 1 duplication in the three mothers (I-1, III-2, II-1, respectively) of our 
subjects (II-1, IV-1, III-2), as well as in other affected relatives (Fig. 1). Normal int1h-1 and inth-2 
amplification bands were detected by PCR, thus ruling out rearrangement involving the int1h 
repeats. 
FIGURE 2: MLPA ANALYSIS OF SYMPTOMATIC CARRIER INDEX CASE OF FAMILY 3 (III-2). 
 
The patient shows heterozygous duplication of exon 1 as detailed in the report obtained by the 
GeneMarker software. The report includes:  
A) electropherogram  
B) pick ratio  
C) report table.  
 
 Analysis of the entire F8 mRNA extracted from index case 1 (II-1), particularly the segment 
containing exons 1 to 9, revealed normal amplification and sequencing.  
 In order to delimitate the breakpoints of this duplication involving F8 exon 1, CGH arrays 
were conducted for all index cases. The results revealed large duplications of approximately 210kb 
between F8 intron 1 (position 154,246,965 bp, 154,244,746 bp, and 154,238,748 bp on genome hg19 
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build for index cases 1 [II-1], 2 [IV-1], and 3 [III-2], respectively) and VBP1 gene intragenic positions 
(at hg19: position 154,459,572 bp, 154,459,273 bp, and 154,449,116 bp, respectively for each case) 
(Fig. 3). The differences in start and end base positions among the index cases were due to the 
different coverage of the arrays used.  
FIGURE 3: DUPLICATION AT THE XQ28 LOCUS DETECTED BY AFFYMETRIX CYTOSCAN HD ASSAY 
 
Affymetrix CytoScan HD Array analysis of chromosome X showing the location and extent of the gain 
on Xq28 region (hg19: position ChrX: nt.154238748, nt.154449116). The copy number and log2 ratio 
were obtained using Chromosomal Analysis Suite V1.2.2 (ChAS) software. Large duplications of 
approximately 210 kb at Xq28 were detected in all cases. The above figure corresponds to index case 
3 (III-2). 
Symbol A corresponds to a graphical representation of the gain identified on Xq28 region; B shows 
the log2 ratio intensity for each probe; C is the copy number for each probe; D indicates the genes in 
this region; E shows the cytogenetic bands (hg19) and base-pair positions on or of the X chromosome 
 
FVIII antigen assays 
In order to determine if the mild HA phenotype was caused by a quantitative or qualitative FVIII 
deficiency, cross-reactive material was measured using polyclonal antibody in index case 1 (II-1 from 
pedigree 1). The results demonstrated reduced plasma FVIII:Ag levels (11.6%) in this case compared 
to the wild-type (100%). 
Haplotype analysis 
Analysis of extragenic and intronic markers indicated that the three index cases (II-1, IV-1, and III-2) 
had identical F8 haplotypes, 164bp – 80bp – 143bp – 171bp (Fig. 1), in all likelihood due to a common 
founder effect.  
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Discussion 
 In a large cohort of 96 unrelated Belgian mild HA patients referred for genetic testing, no 
causative mutations were identified in 10 using bidirectional sequencing of the F8 26 exons and 1.2 
kb contiguous promoter sequence. However, MLPA analysis, performed in a second step, revealed 
isolated duplications of exon 1 in three patients (referred to in this study as index cases 1 to 3), 
despite their being unrelated. To date, no study has reported this large duplication of the F8 exon 1 
in the international HA mutation database [http://www.eahad-db.org/], in the scientific literature, or 
in the CNV database [http://projects.tcag.ca/variation/], nor has it been described in studies of over 
300 patients from the general Belgian population. Nevertheless, three complex rearrangements 
involving severe HA patients have previously been reported describing duplications of F8 intron 1 
that, contrary to our cases, were associated with a classical inversion of intron 1 [13, 14, 15]. 
Recessive von Willebrand disease type 2 Normandy, transmitted as recessive disorder, could 
theoretically be ruled out given the clearly inherited X-linked recessive HA in the three families that 
has been present for at least four generations. The symptomatic carrier of family 3 (index case 3/III-
2) could be explained by her skewed chromosome X-inactivation (XCI) (ratio 90:10) at the androgen 
receptor [16, 17]. PCR amplification identified high digestion of the maternal allele by the 
methylation-sensitive restriction enzyme HpaII, which was, in contrast, fully inactive (or not digested) 
in her non-symptomatic carrier mother (II-1) who also presented a skewed XCI (ratio 96:4). With 
regard to the other seven patients, no causal mutations were identified, despite extensive analysis 
consisting of sequencing, MLPA, and mRNA analysis if a new fresh blood sample was available. 
Analysis of the F8 cDNA from index case 1 (II-1) using reverse transcription PCR revealed normal 
amplification and sequencing of the F8 mRNA segment containing exons 1 to 26. This result indicated 
that the open reading frame (ORF) of the cDNA was unaffected, thus ruling out deep intronic 
mutation that could be associated with mild HA [18]. 
 Breakpoint array CGH analyses in our index cases revealed that duplications involving F8 
exon 1 were delimited to F8 intron 1 and VBP1 gene intron 4, exhibiting the same size of 
approximately 210kb. CGH arrays were unable, however, to provide either genome position, i.e. in 
tandem or translocated to a different genomic position outside the target gene, or orientation 
information, for example direct or inverted duplication. Nevertheless, translocated recombination 
outside the target gene does not seem to be applicable to our families, given that the HA mild 
phenotype and duplication were found to have segregated over at least four generations. The 
duplicated segment could also be transposed in tandem duplication in F8 intron 1. Given this 
scenario, a complete copy of the F8 gene should have been preserved, with the duplicated segment 
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thus having no effect on the reading frame and not compromising transcription and the translation 
of an intact F8 mRNA transcript, hence producing normal FVIII levels. We propose that the 
rearrangement responsible for this duplication could have arisen due to a tandem inversed 
duplication (TID), less frequently seen in humans than direct duplication [19, 20, 21] and resulting in 
the large rearrangement of F8 intron 1 involving approximately 233kb [Fig. 4]. Recent studies have 
proposed that low-copy repeats, microhomology or sequence motifs could contribute to the 
formation of large duplications via different mechanisms, such as non-homologous end joining 
(NHEJ), non-allelic homologous recombination (NAHR), or microhomology-mediated break-induced 
replication (MMBIR) [22, 23, 24]. Despite using different primer combinations, the duplication 
breakpoints for index case 1 (II-1) and his relatives were impossible to characterize by means of long-
range PCR. Other PCR methods used for the precise identification of breakpoints, such as inverse 
PCR, should now be investigated in order to confirm this model of rearrangement.  
 This large ~ 210kb duplication involving F8 exon 1 associated with mild hemophilia is a 
challenging finding. When a large duplication localized inside of the gene does not interfere with the 
ORF of the F8, we have found that a mild phenotype was the likely result, while those causing a 
frameshift of the mRNA and protein sequence were found to be associated with a severe HA 
diagnosis [5, 6]. Yet in our study, the duplication was not completely intragenic due to one of the two 
junctions being located outside of F8. This kind of large duplication, affecting one or more exons 
comprising at least the exon 1 of a gene other than F8, has been only scarcely reported in the 
literature [5, 25, 26]. In addition, the borders and breakpoints of this kind of large rearrangements 
have been either ignored or impossible to define. As discussed above, to account for a mild 
hemophilia severity associated with a normal F8 mRNA segment containing exons 1 to 26, along with 
a quantitative deficiency of FVIII activity, we hypothesize that the duplication was obtained by a 
tandem inversed mechanism generating a new and bigger F8 intron 1. There are few reports of 
intronic rearrangements due to the insertion of duplicated DNA sequence in the literature. Recently, 
Waaijer’s study described the first case of a family of multiple osteochondroma (MO) patients who 
exhibited no alterations in EXT1 exons or intronic splice donor sites. However, the authors postulated 
that a complex genomic rearrangement involving a large deletion of EXT1 intron 1, into which a non-
coding duplicated DNA sequence was inserted, was associated with MO in one family [27]. In 
addition, Baskin et al. identified a complex genomic 90kb insertion of non-coding chromosome 4 into 
intron 43 of the dystrophin gene in a family with Duchenne muscular dystrophy [28]. To account for 
the normal mRNA segment containing the F8 in our first index case (II-1), we hypothesized that the 
new rearranged F8 intron 1 did not generate other strong enough donor or acceptor splicing 
sequences, thus producing normal intron 1 splicing and the presence of a normal F8 mRNA 
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transcript. Numerous human introns have been shown to be extremely long, such as the large intron 
described in the DMD gene encoding the dystrophin, with intron 44 containing over 248kb of 
nucleotides. Furthermore, over 3,000 human introns were reported to be longer than 50kb, 1,234 
longer than 100kb, and 299 longer than 200kb, with nine measuring over 500kb [29]. However, these 
‘‘large introns’’ must be spliced out of the pre-mRNA in a timely fashion, requiring distant 5’ and 3’ 
acceptor and donor splice sites to be united. It is possible that this new rearranged F8 intron 1 
cannot be spliced out efficiently enough by means of the process known as “recursive splicing”, 
described by Hatton et al. [30] and Burnette et al. [31]. These authors demonstrated that Drosophila 
large introns underwent this recursive splicing process, which consists of consecutively splicing out 
several pieces of the intron at the combined consensus donor-acceptor splice site, called the 
‘‘ratcheting point” (or RP-sites). This could account for the small number of normal mRNA transcripts 
produced in our index cases, in connection with their mild HA phenotype.  
FIGURE 4: PROPOSED MECHANISM FOR THE FORMATION OF COMPLEX DUPLICATION INVOLVING F8 GENE EXON 1  
(figure not to scale) 
 
A) Genomic organization at Xq28 extending from the beginning of F8 to VBP1 and the localization of 
the breakpoint of the 210-kb duplication obtained by the CGH array (F8 intron 1–hg19: position 
ChrX: nt.~154238748 to VBP1 inton 4-hg19: position ChrX: nt.~154449116) 
B) Proposition of new F8 rearranged intron 1 compatible with mild hemophilia A phenotype 
 The response to desmopressin in mild HA patients was reported to be strongly influenced by 
the mutation type, as well as the von Willebrand factor (vWF) protective effect against early F8 
degradation, as described by Castaman et al. [32]. F8 mutations and desmopressin responsiveness 
were recently reported on in 62 mild HA patients [33], with no clinically significant response 
observed in 15. Patients with mutations that affect the protein stability and thrombin activation 
cleavage site, or interfere with protein secretion, appeared to be less responsive to desmopressin 
administration. None of these patients exhibited an exon 1 duplication. Based on our study results, 
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we conclude that the large 210kb duplication involving F8 exon 1 was associated with a lack of 
response to desmopressin, though the underlying mechanisms are still unclear. 
 As shown by the pedigree analysis, the three index cases appeared to be unrelated. 
However, data from multi-allelic F8 intragenic and extragenic polymorphisms revealed that these 
patients displayed the same haplotype, suggesting that the ~210kb duplication involving F8 exon 1 
was likely a single, one-time event that was then disseminated throughout southern Belgium via a 
founder effect. 
 
Conclusions 
Our study suggests that, in the context of no mutations being detected by classical sequencing, MLPA 
should be performed in mild HA patients in order to identify large rearrangements in the F8 gene. 
This study describes a large ~ 210kb duplication involving F8 exon 1, which was associated with mild 
HA and no response to desmopressin. The haplotype segregation results demonstrated that our 
three patients were probably connected by a founder mechanism. Lastly, our study highlighted the 
complexity of the underlying molecular mechanisms in some mild HA patients. 
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Analysis of F8 mutations in patients with hemophilia A provides a mutual benefit for basic science 
and clinical application. It not only serves as a diagnostic confirmation of the disease but also aids in 
the prognosis of the severity and clinical course, in the prediction of the risk for development of FVIII-
inactivating antibodies [1] and in the choice of optimal treatment. Moreover, knowledge of the 
mutation is a prerequisite for prenatal diagnosis and for carrier testing in female relatives. 
As we have discussed throughout this thesis, new small or large variants were continually identified 
during F8 molecular screening reflecting the high mutation rate of this gene. We propose here to 
review and discuss genomic alterations described in this work without forgetting to examine the 
status of mutation-negative patients. 
1. Database statistics 
A total of 205 apparently unrelated HA families have been analyzed in this study. In this cohort, 104 
(51%) had severe, 10 (5%) moderate, and 75 (37%) mild phenotype. Two males (0.2%) were referred 
without factor FVIII value. Fourteen (6.8%) of the patients were female presenting with mild disease 
or normal factor VIII level, who were referred for analysis due to their father's haemophilia history or 
their presentation of de novo FVIII (first case) deficiency and bleeding symptoms (Appendix section 
B; Table b). The transmission of disease was clearly familial in 93 patients. In 3 affected HA patients, 
the mutation occurred de novo according to the carrier status analysis of the mother. Germinal 
mosaïcism mutation was identified in one family with moderate HA. 
As expected, our study confirms the predominance (n=49) of severe HA associated with intron 22 
inversion (47% of the severe class). Inversion of intron 1 has been found in three unrelated severe HA 
patients (3 % of the severe class). However, substitutions mutations (missense, nonsense, splicing) 
are the most prevalent mutation type responsible for all severities of HA (Table 1). 
TABLE 1: SPECIFIC UNIQUE VARIANTS TABLE EXTRACTED FROM 
 
 
A) EAHAD database (2015 unique F8 variants) 
missense (n=977)
nonsense (n=216)
splicing (n=149)
deletion (n=468)
duplication (n=97)
insertion (n=34)
indel (n=28)
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These unique F8 variants were extracted from EAHAD database [http:/ /www.eahad-db.org/version 
1.3/2015] comprising: 48.5% (missense), 11% (nonsense), 7.4% (splicing), 22.3% (deletion), 4.5% 
(duplication), 1.7% (insertion) 1.4% (indel) and 2.3% (polymorphism). 
 
These unique F8 variants were extracted from our study comprising: 65% (missense), 5% (nonsense), 
5% (splicing), 18.5% (deletion), 5.6% (duplication), 0.9% (insertion)  
2. Novel variants never reported: Polymorphism versus causal  
Genetic testing may detect variant that are clearly pathogenic, clearly neutral or variants of unclear 
clinical significance. Such variants present a considerable challenge to the diagnostic laboratory in 
terms of interpretation and clear presentation of the implications of the result to the patient. The 
potential for confusion among clinicians and patients is considerable and misinterpretation may lead 
to inappropriate clinical consequences. Thus, guidance for the interpretation of sequence variants 
was elaborated by the establishment of a classification of five classes of variants based on the degree 
of likelihood of pathogenicity (Table 2). Each class is associated with specific recommendations for 
clinical management of at-risk relatives that will depend on the syndrome [2].  
Class Description Probability of being Pathogenic 
5 Definitely Pathogenic >0.99 4 
4 Likely Pathogenic 0.95–0.99 
3 Uncertain 0.05–0.949 
2 Likely Not Pathogenic or of Little Clinical Significance 0.001–0.049 
1 Not Pathogenic or of No Clinical Significance <0.001 
TABLE 2: CLASSIFICATION SYSTEM FOR SEQUENCE VARIANTS IDENTIFIED BY GENETIC TESTING. 
Five classes of variants were established based on the degree of likehood of pathogenicity. 
 
A standard questionnaire is used to systematically evaluate and record the likely pathogenicity of the 
F8 unreported variant from the third class: 
B) Our study (103 unique F8 variants)  
missense (n=67)
nonsense (n=5)
splicing (n=5)
deletion (n=19)
duplication (n=6)
insertion (n=1)
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a) Is the variant cosegregated in other affected or carrier individuals from the same family?  
b) Is it detected in 200 X-chromosomes from the general Belgian population? 
c) Are there other nucleotide variations in the F8 coding region or in exon-intron boundaries? 
d) Is the mutated nucleotide reported in non-affected individuals in the available population 
SNP databases, NCBI (http://www.ncbi.nlm.nih.gov/projects/SNP/) and the International 
HapMap Project (http://www.hapmap.org/)? 
e) Is the mutated nucleotide located in highly conserved regions of F8 ? 
f) Is the changed amino acid conserved across species? 
g) the prediction of variations in RNA splicing should be analysed using the Splice Site Prediction 
programs (NNSPLICE from fruitfly.org [http://fruitly.org/seq_tools/splice.html], Human 
Splicing Finder [http://www.umd.be/HSF/], MaxEntScan 
[http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html] and GeneSplicer 
[https://www.cbcb.umd.edu/software/genesplicer]) 
h) Prediction software (PolyPhen-2, SIFT, Align GVGD) should be used to investigate the likely 
effect of each amino acid substitution 
Moreover, several of these new genetic alterations can be definitively considered as pathologic, as a 
substitution in the codon that they deteriorate was already reported in the hemophilia A database. 
New unreported substitutions from our 205 families were identified since our published work in 
2012. These are p.Tyr655His, p.Ala1954Val, p.Ser1868* and c.266-3C>G (Appendix section B; Table 
b). The p.Ser1868* nonsense mutation (class 4) may obviously be causative. The c.266-3C>G was 
considered as pathologic using 4 splice-site prediction tools detailed above. However, the pathogenic 
nature of this splicing mutation should be proven by the study of RNA sample, not yet obtained. The 
two other missense mutations (p.Tyr655His and p.Ala1954Val) meet the criteria of likely 
pathogenicity according the standard questionnaire developed above.  
Since the update of the hemophilia A database (EAHAD database [http://www.eahad-db.org]) in 
2014, three of the 15 missense changes never reported in our 2012 published study [3] were 
reported as causal (p.Gly1729Glu and p.Gly2147Ser) or polymorphism (p.Glu2023Lys) (Table 3). 
However, this p.Glu2023Lys missense was considered as probably causal by our 2012 published study 
described in chapter 1 [3]. Several of these seventeen missense variants (15 + 2 newly identified) 
could be considered as pathogenic, as another substitution in the codon that they deteriorate was 
already reported in EAHAD database. This was the case for the missense mutations described in [3]: 
p.Tyr25Gln, p.Trp157Cys, p.Ile277Ser, p.Ser700Leu, p.Gly2028Trp, p.Trp2266Cys and those newly 
updated in the database p.Arg259Gly, p.Ile277Ser, p.Tyr655His, p.Trp2065Cys, p.Trp2081Arg (Table 
3).  
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ID Family history Clinical severity 
Mutation Substitution in the same 
codon reported as 
deleterious 
ref  
Nucleotide Protein Exon 
HA90 Sporadic Moderate c.73T>C and c.75C>G p.Tyr25Gln 1 c.74A>G/p.Tyr25Cys 3 
HA41  Familial Severe c.471G>C p.Trp157Cys 4 c.471G>A/p.Trp157* 3 
HA109 Familial Mild c.733C>T p.Arg245Trp 6 
  
HA53 Sporadic Mild c.775A>G p.Arg259Gly 6 c.775A>T/p.Arg259Trp 4 
HA102 Familial Severe c.830T>G p.Ile277Ser 7 c.829A>G/p.Ile277Val 5 
HA88 Familial Mild c.1982T>A p.Ile661Asn 13 
  
HA204 Familial Mild c.1963T>C p.Tyr655His 13 c.1964A>G/p.Tyr655Cys 6 
HA1 Sporadic Mild c.2099C>T p.Ser700Leu 13 c.2099C>A/p.Ser700* 3 
HA9 Familial Mild c.5186G>A p.Gly1729Glu 14 published as causal 7 
HA205 Familial Unknown* c.5861C>T p.Ala1954Val 18   
HA103 Familial Mild c.6067G>A p.Glu2023Lys 19 published as polymorphism 8 
HA150  Familial Mild c.6082G>T  p.Gly2028Trp 19 c.6082G<A/p.Gly2028Arg 3 
HA117 Familial Unknown* c.6195G>C p.Trp2065Cys 21 c.6193T>C/p.Trp2065Arg 9 
HA35  Sporadic Severe c.6241T>C p.Trp2081Arg 21 c.6242G>C/p.Trp2081Ser 10 
HA113 Familial Mild c.6439G>A p.Gly2147Ser 23 published as causal 11 
HA70 Familial Severe c.6797G>T p.Gly2266Val 25 c.6797G>A/p.Gly2266Glu 3 
HA42 Familial Mild c.6823T>C p.Tyr2275His 25 
  
 
TABLE 3: UPDATE OF DESCRIPTION AND EVALUATION OF CAUSALITY OF 17 NOVEL MISSENSE MUTATIONS IN FACTOR 
VIII GENE IN SEVERE AND MODERATE/MILD HAEMOPHILIA A. 
*Only female carriers tested 
To decide whether a sequence abnormality identified in a patient is causal rather than a simple 
polymorphism, pathogenic mechanisms could be studied by in vitro or in vivo expression and 
functional analysis.  
In hemophilia A, expression studies have been mainly carried out to evaluate the pathogenicity and 
the severity of mutations identified in DNA of potentially carrier women (with low FVIII activity 
(FVIII:C) level without family history of HA or with normal FVIII:C but without index case available) 
and of missense mutations within the F8 B-domain (from codons 741 to 1648) dispensable for 
secretion and function of FVIII. Site directed mutagenesis were performed within mammalian 
expression vectors harboring either the full length human or B-domain deleted F8 cDNA. After 
transfection of mutant and control plasmids into COS-1 monkey kidney or Chinese hamster ovary 
cells, FVIII activity and FVIII antigen levels of wild type (WT) and mutant FVIII proteins were measured 
in the medium or in the cell lysate [12-14]. 
Results with this methodology confirmed the non-pathogenic nature of the p.Pro2311Ser and F8 B-
domain missense variants [12-13]. 
In the study by Roualdes et al, defect in FVIII synthesis, function, or combined defect in synthesis and 
secretion, were suspected after FVIII activity and antigen assay measurements of five new F8 variants 
in HA carrier females with a low FVIII clotting assay level [14]. In this work, two variants were 
considered to be potentially responsible for a severe HA, because they were associated with an 
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undetectable level of FVIII:C and FVIII:Ag levels and three others for a moderate or mild HA, because 
they were linked with significant decrease in FVIII:C and FVIII:Ag levels in the conditioned media 
compared to the WT.  
Variants in the exon/intron junction, and also exonic variants that would influence splicing, could be 
analyzed by functional splicing assays based on a minigene construct that assesses the impact of 
sequence variants on splicing [15].  
Quantitative RT-PCR can be applied for the quantification of mRNA expressed from genes. However, 
it is difficult to implement in HA because ectopic (expression of a gene in a tissue where it is not 
normally expressed) mRNA from circulating blood cells (mainly lymphocytes) may not reflect the 
correct expression level in the main factor VIII-producing cells, which are mainly in the liver and the 
lungs. 
3. Founder mutations 
When a mutation arises and is not eliminated by natural selection, and is transmitted by time to 
descendants, it is called a “founder mutation” and the long-gone ancestor is known as the “founder” 
of this population [16]. Thus, everyone with a founder mutation has a common ancestor—the 
founder—in whom the mutation first appeared. 
Geneticists have identified thousands of mutations responsible for diseases in humans, but patients 
with many genetic diseases die before reproducing, stopping the mutant genes from reaching future 
generations. However, in a few disorders, the same mutation is observed over and over again, and 
could be explained by two ways: as a hot-spot mutation or a founder mutation. For example, 
achondroplasia occurs usually as a result of a mutation at base pair 1138 in FGFR gene. In 98% the 
mutation results in substitution of a glycine by an arginine at codon 380 (c.1138G>A or p.Gly380Arg). 
It is also interesting to note that this mutation is located in a CpG dinucleotide considered as a “true 
hotspot” for the mutation in the human genome (Fig 1). Individuals who harbor hot-spot mutations 
are usually not related to one another, and thus the rest of their DNA will vary, as is typical of 
unrelated people. On the contrary, founder mutations, which get passed down intact over 
generations, are quite distinct from spontaneous hot-spot mutations. In several studies, the 
existence of a founder effect, revealed by haplotypic analysis, allowed the positional cloning 
approach of causative gene yet undetermined [17, 18]. In few rare diseases, founder mutations have 
survived centuries possibly by rendering some beneficial advantage. It is the case of the hereditary 
hemochromatosis, Sickle cell anemia, and cystic fibrosis. Indeed, carriers of the hereditary 
hemochromatosis mutation are thought to be protected from iron-deficiency anemia, those of the 
sickle cell anemia from malaria and cystic fibrosis from diarrhea. It is also interesting to note that the 
founder mutations p.Cys282Tyr and p.His63Asp for hemochromatosis (HFE), p.Glu6Val for sickle cell 
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anemia (HBB), and the ΔF508 for the cystic fibrosis (CFTR) are not positioned in a CpG sequence (Fig. 
1). 
 
FIGURE 1: RECURRENT SUBSTITUTIONS IN FGFR3, HFE AND HBB GENES. 
Mutations are described in relation to the coding DNA reference sequence.  
Numbers of reports have described F8 mutations that are present in specific populations at high 
frequencies: c.6104T>C (p.Val2035Ala), c.1538-18G>A and c.788-14T>G [1921]. These substitutions 
are not located in a 5’-CG-3’ dinucleotide and have, in all cases, been reported in subjects having a 
mild HA phenotype and a common ancestor. In chapter 2, we suggested that if a recurrent 
substitution shared by unrelated HA patients is located in F8, founder effect is more probable if this 
mutation does not affect a CpG sequence [22]. The age of a founder mutation can be estimated by 
determining the length of the haplotype common to all descendants. Indeed, a young founder 
mutation (few generations) should be found in the midst of a haplotype few altered by crossing-over 
in people who have it today. In contrary, an ancient founder mutation, perhaps tens of thousands of 
years old, rests in a high altered haplotype in current carriers due to the possibility of genomic 
rearrangement during meiosis. 
Given that most families sharing the p.Ser2030Asn mutation described in EAHAD db originated from 
England, it would be interesting to study their genetic identity in comparison with our data in the 
interests of identifying any similar haplotype, drawing up an estimate of when the mutation first 
appeared, and to enable mapping of human migration pathways. As reported in “Origin of Swedish 
hemophilia A mutations» article, the ESTIAGE program [23] could be used to estimate the time from 
the most recent common ancestor, based on the breakdown of haplotypes and assuming a common 
origin of identical mutations. 
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Further haplotype analysis needs to be examined to determine the pattern of F8 CpG site 
methylation. Indeed, of the 70 CpG sites distributed throughout the F8 gene coding sequence, only 
35 codons over 16 exons were mutated in proportions ranging from one (codons 362, 437, 446, 
1500, 1671, 2016, or 2109) to 137 for the codon 612 (EAHAD database). Sodium bisulfite conversion 
method to detect cytosine methylation in representative exons of F8 from different tissues could be 
used to evaluate the DNA methylation status. Data from different studies have suggested that 
methylation is an important contributor to, but not the only factor responsible for, substitution 
mutations in hereditary diseases [24-26]. 
4. Copy number variations:  
 int22h1/int22h2-mediated Xq28 0.5Mb duplication 
Because of the presence of directly oriented 9.5 kb long int22h LCRs flanking the 0.5Mb duplication 
(proximally int22h-1 and distally int22h-2), the recurrent copy number gain is likely due to a 
recombination of NAHR type. This mechanism of rearrangement was also proposed by El-Hattab and 
Vanmarsenille et al. [27, 28], but no direct molecular proof was provided. Despite the use of 
alternative primers, conditions and combinations, it was not possible to characterize the duplication 
breakpoints in our patients and relatives. 
We have postulated that these specific duplications are probably not responsible for hemophilia and 
intellectual disability (ID), but should be carefully considered in genetic counseling, while continuing 
to investigate the causal mutation of hemophilia. However, discrepancy about the causality in ID of 
the int22h-1/int22h-2-mediated Xq28 duplication persists in the scientific literature. The recent 
article published by El-Hattab et al [29] suggests that the int22h-1/int22h-2-mediated Xq28 
duplication is associated with mental retardation syndrome, confirming results obtained in the first 
study [27]. In their second paper, the authors described 11 additional individuals (males and females 
belonging to five families) and other cases reported in the scientific literature with similar or 
overlapping rearrangements. One of these reported cases was described by us (chapter 3) [30]. 
However, the second El-Hattab study never mentioned our two other families presenting hemophilia 
A without intellectual disability. No developmental delay or behavioral problem was noted in our 
two hemophiliac patients, mothers and relatives (obligate carrier grand-mother, affected uncle, and 
his two obligate carrier cousins for the first case), which are not the case of El-Hattab studies. A 
Vanmarsenille’s study reported the same recurrent 0.5 Mb duplication at Xq28 (ChrX:154,109,090-
154,615,708 (Hg19)) in four additional male patients with mild nonsyndromic intellectual disability 
and behavioral problems [28]. The authors demonstrated that overexpression of the Rab39b gene in 
mouse primary hippocampal neurons resulted in a significant decrease in neuronal branching as well 
as a decrease in the number of synapses compared to controls. These findings suggested that 
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increased dosage of the Rab39b gene may cause disturbed neuronal development leading to 
cognitive impairment in humans.  
Levy‘s study revealed one approximately same duplicated variant from one individual man’s DNA 
under the reference variation CNVR_77 [31]. The DNA donor, named J. Craig Venter, biochemist, 
geneticist, and entrepreneur, known for being one of the first to sequence the human genome, gave 
full consent to provide his DNA for study via sequencing methods. Several cases of this family were 
documented with chronic disease including hypertension, ovarian and skin cancer. The CNVR_77 
duplication (ChrX:154,009,347-154,929,412 (Hg19)) comprises the same protein coding genes, F8, 
FUNDC2, MTCP1, BRCC3, VBP1, RAB39B and CLIC2 and the genes H2AFB1, H2AFB2, H2AFB3, F8A1, 
F8A2, F8A3 as those described in the four studies [27-30]. Analysis of Decipher v8.9 (DatabasE of 
genomiC variation and Phenotype in Humans using Ensembl Resources) database 
[https://decipher.sanger.ac.uk/], which reports structural CNVs identified in patients associated with 
phenotype, interpretation of plausibly pathogenic, and inheritance, reports various cases with 
duplication at Xq28 locus comprising same genes as described above (Table 4). Phenotype, sexe and 
inheritance encountered in patients described in Table 4 vary greatly suggesting that further 
molecular analysis should be done to conclude definitively on the pathogenicity contributed by this 
int22h-1/int22h-2-mediated Xq28 duplication in ID. 
These discrepancies raise the question about the real consequence of this int22h-1/int22h-2-
mediated Xq28 duplication. Indeed, this rearrangement is shared in patients with apparently normal 
and no psychiatric symptoms, intellectual disability/learning disability, behavioral problems and 
other congenital malformations.  
Duplications can be heterogeneous in the case of intellectual disabilities. Affected individuals with 
duplication at 22q11 locus may have developmental delay, intellectual disability, slow growth leading 
to short stature, and weak muscle tone (hypotonia). Yet, many people with this 22q11 duplication 
have no apparent physical phenotype or ID [32]. Thus, authors should be careful before concluding 
that the int22h-1/int22h-2-mediated Xq28 duplication is probably associated with an intellectual 
deficiency. 
In conclusion, on the basis of the four reports [27-30] and data from DECIPHER resources, it is clear 
that the int22h-1/int22h-2-mediated Xq28 duplication is not associated with hemophilia A. However 
before resolving the intellectual disability discrepancy, this specific int22h-1/int22h-2-mediated Xq28 
duplication should be carefully considered in genetic counseling. 
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patient 
ID 
sex
e 
CNV 
type and size (in 
Mb) 
location 
number of 
genes* 
Phenotype Xq28 Inheritance 
Pathogenic 
contribution 
304825 M 2 
deletion (0.52)  1q21.1 19 
Global developmental 
delay and obesity   
paternal  ? 
duplication (0.46) Xq28 13 maternal ? 
288134 M 2 
deletion (0.12)  4q35.1 1 
Intellectual disability, 
mild 
unknown 
Possibly 
pathogenic 
duplication (0.45) Xq28 13 unknown 
Possibly 
pathogenic 
288462 U 2 
deletion (0.12 Mb)  4q35.1 1 
Abnormality of the 
plantar skin of foot, 
Intellectual disability, 
Obesity, Short stature 
paternal  
Possibly 
pathogenic 
duplication (0.52) Xq28 9 
paternal of unknown 
phenotype 
Possibly 
pathogenic 
288760 U 1 duplication (0.44) Xq28 9 
Hearing impairment and 
Trigonocephaly 
unknown 
Possibly 
pathogenic 
281277 F 1 duplication (0.48) Xq28 9 
Delayed speech and 
language development 
and Intellectual disability 
maternal of unknown 
phenotype but  
unaffected father with 
related or similar 
phenotype 
unknown 
299916 M 1 duplication (0.44) Xq28 9 
Cognitive impairment, 
seizures 
maternal of unknown 
phenotype 
? 
288196 F 1 duplication (0.44) Xq28 9 Situs inversus totalis unknown 
Possibly 
pathogenic 
272660 M 1 duplication (0.44) Xq28 9 No data available 
inherited from parent 
with unknown 
phenotype 
unknown 
304860 F 1 duplication (0.44) Xq28 9 
Cognitive impairment, 
delayed speech and 
language development 
unknown 
Probably 
pathogenic 
305177 M 1 duplication (0.44) Xq28 9 Cognitive impairment unknown 
Probably 
pathogenic 
305789 F 1 duplication (0.44) Xq28 9 No data available unknown 
Probably 
pathogenic 
253548 F 1 Duplication (0.43) Xq28 9 No data available 
inherited from normal 
parent  
unknown 
 
TABLE 4 : RELEVANT DATA OF RECURRENT INT22H1/INT22H2-MEDIATED XQ28 0.5MB DUPLICATION 
EXTRACTED FROM DECIPHER DATABASE. 
*Number of genes: The difference (9 or 13 genes) corresponds to the counting of genes F8, F8A1, 
F8A3, FUNDC2, MTCP1, BRCC3, VBP1, RAB39B and CLIC2 with or not four others H2AFB1, H2AFB2, 
H2AFB3, F8A2. 
M: male, F: female, U: unknown 
 int22h1/int22h2-mediated Xq28 0.6Mb duplication 
Several independent studies have reported unusual patterns in diagnostics by Southern blots, long-
range PCR or IS-PCR showing intron 22 inversion results accompanied by partial F8 deletion or 
duplication [33, 34]. Muehle et al [35] was the first to describe and perform molecular testing on one 
case with combination of an int22h-related inversion and a partial deletion of F8. The study suggests 
that this combination may actually be more frequent than expected. A more recent report [36] 
described severe patients carrying classical Inv22 and deletion of exons 1 or 2 to 22 of F8. They 
postulated that these rearrangements might not occur simultaneously because Inv22 should occur 
during spermatogenesis and the second event should happen on the maternal X chromosome with 
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Inv22. We propose that the 0.6Mb duplication mediated by int22h rearrangement described in 
chapter 3 is in accordance with this hypothesis: first occurrence concerning inversion of intron 22 
followed by a second rearrangement. Also, we have proposed that the second event should occur in 
maternal meiosis, as these rearrangements require the pairing of two homologous chromatids. 
Screening for additional mutations is rarely performed in routine testing after an inversion has been 
detected. This is unfortunate because the combination of int22h-related inversion and large deletion 
in F8 gene could increase significantly the risk for developing inhibitors [35, 36]. However, the patient 
described here, presenting an inversion of intron 22 together with a 0.6Mb int22h-mediated Xq28 
duplication, developed no inhibitor during replacement therapy. 
 Five int22h homologous repeats at the Xq28 locus 
Statistics and distribution of the sequence differences between the homologous copies strongly 
support theories that the copy in the F8 gene was introduced by a duplication more than 25 million 
years ago [37]. Hastings and co-workers suggested that the “microhomology-mediated break-
induced replication” (MMBIR) pathways could create LCRs that provides the homology required for 
NAHR, leading to genomic variants in future generations [38]. The authors also suggested that 
complex genomic regions generate secondary structures that increase the likelihood of MMBIR, so 
that complex architecture becomes more complex on an evolutionary timescale, as has been 
documented for primate evolution [39, 40].  
The int22h LCRs are present in three copies in human genome. However, the copy number of these 
repeats is probably higher mediated by 180kb duplication in some genotypes. The rate of these 
copies in the general population should be explored probably with qPCR for its low cost and speed. 
We have suggested that this genomic presentation is likely benign or polymorphic when it is 
identified by Southern blots, long-range PCR or IS-PCR analysis. 
 210kb duplication involving F8 exon 1 
In chapter 5, we hypothesized that this ~210kb duplication was obtained by a tandem inversed 
mechanism generating a new and bigger F8 intron 1. Identification of breakpoints should be 
investigated in order to confirm this model of rearrangement. Despite using different primer 
combinations, it was not possible to identify precisely the breakpoints by means of long-range PCR. 
Other PCR methods, such as inverse PCR detailed in Pezeshkpoor B et al, should now be tested [41]. 
Epigenetic default in F8 intron 1 should also be explored. Indeed, epigenetic mechanisms to regulate 
gene expression have been largely described in recent years associated with heritable diseases and 
tumor pathogenesis [42]. The major mechanism of epigenetic control of gene expression is 
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methylation of CpG dinucleotides in the promoter regions or other regulatory elements. Condensed 
chromatin obtained by methylation of cytosines and activation of enzymes that modify nucleosomal 
histone proteins interferes with transcription factors and thus reduces normal gene expression [43, 
44]. On the active X chromosome, CpG sites in regulatory sequences usually remain unmethylated 
which is not the case on the inactivated X chromosome [45]. Zimmermann and co-workers presented 
methylation analyses of CpG dinucleotides in the 5’UTR region and intron 1 of F8 in 80 mutation-
negative HA patients without distinguishing abnormalities compared to male controls [46], except for 
two patients with genomic rearrangements in F8 intron 1. 
5. Mutation-negative patients 
Most of the mutation in F8 (in the 26 exons and their flanking intron boundaries) can be identified 
using routine PCR-based methods with a mutation rate of 95 to 98% [1]. The mutation rate depends 
on several factors including the number of patients, the technologies used and the severity of the 
disease. 
The current mutation screening strategy performed for patients with reduced FVIII:C is described in 
Figure 2. However, despite applying sensitive methods for mutation detection by PCR analysis of 
genomic DNA, a causative mutation was not identified in the F8 in 3% of HA patients [47]. Thus, 
further research is needed to identify the underlying genetic variants in those cases. One possible 
mechanism is that other loci are involved. Such loci must interact with the F8 gene or the FVIII 
protein resulting in reduction of the FVIII activity observed in the patients called “mutation-negative 
patients”. Another possible mechanism is the presence of mutations in F8 regulatory sequences as 
promoter or 3’-untranslated region (3’UTR) and macrostructural rearrangements often difficult to 
identified using routine methods. Finally, an additional possibility is the lack of or faulty transcription 
occurring as a result of mutation in F8 introns (also called deep intronic mutation), which cannot be 
completely investigated using standard molecular diagnostic methods.  
  
FIGURE 2: MUTATION DETECTION STRATEGIES IN HA: ALGORITHM OF TESTS PROPOSED BY PEZESHKPOOR ET AL. [47] 
Six steps protocol is proposed to identify causal mutations in HA patients. 
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In our study, among 205 families screened until the end of 2014 detailed in Appendix section B, Table 
b, no mutation was described in eight families with the conventional mutation detection strategies. 
This corresponds to 3.9% of index patients, which represents normal rate if extensive routine 
analytical methods are used. Re-sequencing to avoid misanalysis related to technical and human 
errors was performed if a second independent DNA sample was obtained or if another affected 
family member was available. One patient developed a severe phenotype while the others have a 
mild severity. Sporadic/familial occurrence is detailed in Table 5. 
Mutation-
negative cases 
Bleeding 
phenotype* 
Familial/
sporadic 
Exclusion 
VWD 2N
§
 
FV/FVIII 
deficiency 
Regulatory 
sequences
$
 
Aberrant RNA 
for exon
≠
 
HA33
&
 Severe (<1%) F Yes NC No causal mutation NT 
HA69
&
 Mild (NT/16/NT) F Yes NT No causal mutation No 
HA110 Mild (NT/26/NT) NA Yes NT No causal mutation NT 
HA130 Mild (NT/NA/NT) NA Yes NA  No causal mutation NT 
HA132 Mild (NA/49/NA) S Yes NA No causal mutation exon 13 
HA144 Mild (NA/49/NA) NA Yes NA No causal mutation NT 
HA145 Mild (44/38/NT) S Yes NT No causal mutation NT 
HA146
&
 Mild (28/49/+) F Yes NT No causal mutation No 
 
TABLE 5: RESULTS OF TESTS PERFORMED IN “MUTATION-NEGATIVE PATIENTS”.  
& exclusion of misanalysis related to technical and human errors 
* Laboratory bleeding tests in order (chromogenic, chronometric, CRM);  
§ sequencing of VWF exon 17- 20 and 24-27 
$ 1.2-kb contiguous promoter and 3’UTR sequences; 
≠ RTPCR was performed for 8 overlapping regions corresponding to: exons 1-5, 4-8, 8-11, 11-14, 14-
17, 17-21, 20-22, 22-26. 
NA: not available; NC: not necessary; NT: not tested. 
 
 Further investigations to elucidate the molecular mechanism leading to FVIII deficiency in 
these mutation-negative patients were performed as shown in Table 4. To exclude mutations in 
genes that interact with the F8 protein and could thus produce an FVIII deficiency and mimic 
“hemophilia A like” (step 4), exons 17-20 and 24-27 of the VWF gene were analysed. Indeed, 
mutations in these exons have been associated with vWF/F8 binding defects (also called von 
Willebrand disease type 2N) affecting the half-life of the F8 protein [48-51]. Sequencing of these 
exons in these 8 patients revealed only reported polymorphisms, which are most probably not 
causative for VWF 2N disease. FV levels, which could reveal mutation in LMAN1(also known as 
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ERGIC-53) or MCFD2 genes by a combined FV and FVIII deficiency, were unfortunately not tested or 
not available for all patients with mild phenotype [52-54]. However, these eight patients are all 
males, indicating probably X-chromosomal inheritance. Therefore, we can conclude that the genomic 
mechanism of the HA disease are to be found in the F8 gene. 
 A wide spectrum of mutational mechanisms has been identified in patients classified as 
mutation-negative patients. Mutations in the F8 promoter can affect the transcription of the gene 
and were responsible for HA in few patients [55]. No causal mutation was identified in the promoter 
region 1200 bp upstream of the translation start and the 1976 bp downstream of the stop codon in 
the 3’UTR in the eight mutation-negative patients of this study. Other complex mechanisms have 
been reported in mutation-negative patients. Indeed, Xq28 locus is known to frequent recombination 
events due to its high frequency of micro/macro homologies and repetitive sequences that could 
induce deleterious genomic rearrangements [56, 57]. Thus the next step is to exclude such 
rearrangement caused by gross recombination or inversions. Such rearrangements could leave the 
exons intact but not in the right order. Two techniques could be used: Fluorescence in situ 
hybridization (FISH) and long-range amplification (LR-PCR). The first approach is a molecular 
cytogenetic technique to locate a specific genomic sequence on the chromosome. This could exclude 
translocation and large intra-chromosomal rearrangement in the diagnosis of hemophilia A using a 
F8 specific probe. However, a new blood sample is necessary to test this rearrangement. LR-PCR of 
28 overlapping fragments covering the whole genomic locus (approximatively 186 kb) constitutes the 
second approach. In patients where a breakpoint in F8 locus based on the absence of a given 
amplification is highlighted, the junctions of the breakpoint can be characterized using an inverse 
PCR method. With this strategy, a third inversion due to homologous recombination of inverted 
repeats within F8 intron 1 was described recently in a severe HA case [41]. But, such rearrangements 
could theoretically be associated with severe phenotype and be applied only in family HA33 of this 
study. 
 The last step (step 6) analyzes intronic mutations that affect splicing of the F8 mRNA. The 
most direct approach to find DNA variants that might disturb RNA splicing is qualitative reverse 
transcription-PCR (RT-PCR). Bagnall and co-workers were the first to report such an intronic mutation 
in F8 intron 1 (c.143+1567A>G) that activates a cryptic exon and generates a premature stop codon 
in F8 mRNA [58]. Other deep intronic mutations leading to aberrant mRNA splicing were reported 
[59, 560]. However, this is not easily practicable because it requires a sample of fresh blood to 
extract total RNA. This was possible for three families in this study (HA 69, 132 and 146). No aberrant 
mRNA was observed in the HA 69 and 146 patients. However, deep intronic mutation has been 
postulated in family HA132. Indeed, sequencing of F8 cDNA showed two mRNA sequences (one 
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normal sequence and one relatively low amount of abnormal spliced F8 mRNA) in electropherogram 
covering exons 11 to 14 (Figure 3). Such result could be explained by genomic mutation in intron 12 
or 13 leading of an aberrant mRNA transcript without exon 13 in small quantities in association with 
the mild phenotype of the patient (FVIII:C ~49%). Alternative approach using next generation 
sequencing (NGS) is possible for further investigations in patients where no abnormal mRNA splicing 
is observed. The advantage of this technique is that whole F8 (exons and introns) is screened in one 
single step. This approach might identify intronic variants that could affect F8 mRNA expression. 
Indeed, the study of Pezeshkpoor et al. [61] using combined NGS and mRNA analysis protocol, 
described deep intronic variants in a group of 7 mild/moderate HA patients. In two of these, intronic 
variations (c.5998+941C>T and c.5998+530C>T) in intron 18 was identified creating new cryptic sites 
that produced insertion of intronic sequences in F8 mRNA between exon 18 and 19. A recurrent 
variant in intron 16 (c.5586+194C>T) was identified in three others patients with no aberrant mRNA. 
However, quantitative mRNA analyses revealed a significant reduction in the amount of F8 mRNA at 
exon boundaries where the alternative splicing was suspected. This could indirectly indicate the 
presence of abnormal mRNA across this intron. In two other patients, a second recurrent intronic 
variant (absent in the healthy population) was identified in intron 13 (c.2113+11641insG) without 
associated qualitative or quantitative F8 mRNA defects. Thus, the causality of this new variant could 
not be proven.  
 
FIGURE 3: TWO mRNA FRAGMENTS WERE OBSERVED WHEN AMPLIFYING CDNA COVERING EXONS 11 TO 14. 
Sequencing identified normal and aberrant exon 13 splicing cDNA copies. 
The suspicion of deep intronic mutation in family HA132 could reduce the number of mutation-
negative patients by one unit (7/8). However, by way of haplotype analysis constructed with 10 
single nucleotide polymorphisms (SNPs) and 4 microsatellite repeats (Appendixes section C tables 
C3.1 and C3.2) distributed over the entire F8 gene, HA110, HA130 and HA146 families seem to be 
related (Table 6). Indeed, the presence of the extremely rare 169bp/DXS1108 allele, which is absent 
in 50 Belgian male controls (Chapter 2; Table 2c), and in the study of Reitter-Pfoertner et al. [62], is 
intriguing and suggests the presence of a common ancestor in these three families. The other 
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families, HA33, HA 69, HA145, and HA144, show 4 different SNPs and microsatellite haplotypes 
emphasizing the presence of at least 5 different causal mutations. 
SNP localization Haplotype results 
DXS15 extragenic 154 164 158 158 154 158 162 
rs6643620 extragenic A A G G G A G 
rs5945250 extragenic G G G G G G G 
rs1050705 3’-UTR A A A A A A A 
DXSint22 intron 22 82 82 80 80 82 80 82 
rs4898352 intron 18 A A A A A A A 
rs6643714 intron 14 T T C C C T C 
rs1800291 exon 14 C C C C C C C 
DXSint13 intron 13 145 143 145 145 145 143 145 
rs5987079 intron 2 G G G G G G G 
rs6649625 intron 2 T T C C C C C 
rs2313058 extragenic C C C C C C C 
rs5945279 extragenic C C C C C C C 
DXS1108 extragenic 173 171 169 169 169 175 163 
FAMILLE HA33 HA69 HA110 HA130 HA146 HA145 HA144 
Phenotype severe mild mild mild mild mild mild 
 
TABLE 6 : SNP AND STR HAPLOTYPE RESULTS FOR 7 NEGATIVE-MUTATION FAMILIES. 
Five different SNPs and microsatellite haplotypes were detected emphasizing the presence of at least 
five different causal mutations  
 
In conclusion, causal mutations in the F8 gene were identified in 197/205 families. In one of these 8 
mutation-negative patients, a deep intronic change within intron 12 or 13 is suspected. Genomic 
sequencing of the introns should be performed followed by, in case of unique variant identification, 
splice site prediction softwares like Berkeley Drosophila Genome Project 
(http://www.fruitfly.org/seq_tools/splice.html), NetGene2 server 
(http://www.cbs.dtu.dk/services/NetGene2/) and Human Splicing Finder server 
(http://www.umd.be/HSF/), screening in a cohort of healthy male controls and quantitative mRNA 
analysis.  
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Before proceeding to the expensive NGS technology in the 7 other families, we propose to look for  
1) third inversion due to homologous recombination of inverted repeats within F8 intron 1 
described by Pezeshkpoor et al [41] in the HA33 index case DNA 
2) deep intronic mutations causing HA already identified as reported in Table 7. 
Mutations in F8 Intron position Phenotype associated References 
c.143+1567A>G 1 severe 58 
c.1537+325A>G 10 mild 60 
c.2113+1152delA 13 mild 59 
c.5587-93C>T 16 mild 59, 61 
c.5586+194C>T 16 mild 61 
c.5998+530C>T 18 mild 61 
c.5998+941C>T 18 mild 61 
c.5999-227G>A 18 mild 59 
 
TABLE 7: DEEP INTRONIC MUTATIONS CAUSING HEMOPHILIA A.  
Deep intronic mutations causing HA already identified in the literature (see references in the 
table) 
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A) Details of METHODS 
DNA Extraction 
Genomic DNA was extracted from 3 to 10ml of patient blood using a modified protocol of the salting-
out method, as described by Miller et al [63]. Additionally, blood samples from extended family 
members and control groups were collected. All the DNA samples were stored at 4 or -80 °C. Briefly, 
red blood cell lysis was performed to remove the enucleated erythrocytes with their high 
hemoglobin content that might inhibit DNA polymerases. The blood was carefully mixed with 3 
volume of Red Blood Cell Lysis Solution (5 mM MgCl2, 10 mM NaCl in 10 mM Tris-HCl, pH 7.4) to 
selectively lyse erythrocytes that are more susceptible to hypotonic shock during 20 min at 4°C, 
followed by centrifugation for 10 min at 4°C and 1500 rpm and removal of the supernatant. White 
pellet of leukocytes (approximately 1 % of total blood volume) was washed with SE solution (75 mM 
NaCl, 24 mM EDTA) and was incubated with Proteinase K (100 mg/ml) and SDS (20%) in 5 ml of SE 
solution to achieve lysis. Incubation at room temperature (RT) was carried out overnight with gently 
agitation.  
Two milliliters of the 6% sodium chloride solution was added into the test tube. After shaking, 
centrifuge the mixture (at 4°C) 20 minutes at 3600 rpm. Repeat this step once. Precipitation of the 
DNA was operated with 9ml of isopropyl alcohol with kindly shaking for approximately 5 min. The 
DNA floats was recovered by a Pasteur pipette and transferred to a new tube. The DNA pellet was 
washed with 70% ETOH. Supernatant was carefully poured off and the DNA was dried off ETOH. 
Then, the DNA was suspended in 250ul to 500 µl of TE-4 (10mM Tris, 0,1mM EDTA) and leave 
overnight at RT. The DNA dissolved was centrifuged 10 min at 3000rpm. DNA was stored at -20C for 
long term storage. 
Yield and purity of the DNA were assessed by photometry, where 1 OD260 nm equals 50 μg 
dsDNA/ml. typical yields ranged from 3 to 10 μg DNA per 200 μl sample of blood with an OD ratio260 
nm/280 nm of 1.7 to 1.9. 
RNA Extraction 
RNA was extracted within 24 hours of sample collection from 7 ml of fresh patient blood collected in 
EDTA Vacutainers. Total cytoplasmic RNA was isolated from peripheral leucocytes using purified 
Ficoll® gradient centrifugation and Tri reagent (Invitrogen Life Science, California, USA) according to 
the manufacturer protocol based on a standard procedure. Briefly, transfer blood into a sterile 50 ml 
polypropylene conical centrifuge tube. Add 5 ml of sterile Hank’s Balanced Salt Solution (HBSS) 
without CaCl2 and MgCl2 (Gibco). 
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Mix was layered onto 20 ml Ficoll® (1.077 g/ml, Lymphoflot, Biotest, Germany) in a 50 ml conical 
tube and centrifuged in a swinging bucket rotor for 20 min at 400 g and room temperature 
stopping without break. The non-ionic synthetic sucrose polymer forms a gradient where 
platelets float diffusely at the top while lymphocytes and mononuclear cells collect in a tight 
band near the middle and granulocytes as well as erythrocytes settle at the bottom of the 
gradient. The whole interphase ring was aspirated and the cells were washed once in of sterile 
Hanks before centrifugation for 15 min at 400 g. Supernatant was removal and cells was 
suspended with 2 ml of Trizol® Reagent (Life Technologies): 
1. The sample was homogenized for 5 minutes at room temperature to permit complete 
dissociation of the nucleoprotein complex.  
2. 0.2 mL of chloroform per 1 mL of TRIzol® Reagent used for homogenization was added. The 
tube was capped securely.  
3. The tube was shacked vigorously by hand for 15 seconds.  
4. The mix was incubated for 2–3 minutes at room temperature.  
5. The sample was centrifuged at 12,000 × g for 15 minutes at 4°C.  
Note: The mixture separates into a lower red phenol-chloroform phase, an interphase, and a 
colorless upper aqueous phase. RNA remains exclusively in the aqueous phase. The upper 
aqueous phase is ~50% of the total volume. 
6. Remove the aqueous phase of the sample by angling 45° and pipetting the solution out. Avoid 
drawing any of the interphase or organic layer into the pipette when removing the aqueous 
phase. 
7. Place the aqueous phase into a new tube.  
8. Repeat twice steps 2 to 7 
For RNA precipitation, 0.5 mL of 100% isopropanol to the aqueous phase, per 1 mL of TRIzol® 
Reagent used for homogenization, was added to the aqueous phase. Then, the mix was incubated at 
RT for 10minutes and centrifuged at 12,000 × g for 15 minutes at 4°C. The supernatant was removed 
from the tube, leaving only the RNA pellet. The pellet was washed with 1 mL of 75% ethanol per 1 mL 
of TRIzol® Reagent used in the initial homogenization. (Note: The RNA can be stored in 75% ethanol 
at least 1 year at –20°C, or at least 1 week at 4°C). The sample was centrifuged, after briefly vortex, at 
7500 × g for 5 minutes at 4°C. Discard The wash was discarded. The RNA pellet was dried (vacuum or 
air dry) for 5-10 minutes (Note: Do not allow the RNA to dry completely, because the pellet can lose 
solubility. Partially dissolved RNA samples have an A260/280 ratio <1.6). The RNA pellet was 
suspended in RNase-free water by passing the solution up and down several times through a pipette 
tip and incubated in a water bath or heat block set at 55–60°C for 10–15 minutes.  
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Detection of the Intron 22 Inversion mutation 
Genomic DNA is digested with one or more restriction enzymes and the resulting fragments are 
separated, according to size, by agarose gel electrophoresis. The DNA is denatured in situ and 
transferred from the gel to a nylon membrane and the relative positions of the DNA fragments are 
preserved. The DNA, attached to the membrane, is hybridized to a labelled oligonucleotide probe 
and the bands complementary to the probe are located by the autoradiography.  
Digestion of Genomic DNA 
To detect the intron 22 inversion, approximately 7μg of genomic DNA was digested with 30U BclI 
restriction enzyme (Roche) in a reaction containing 1x reaction buffer M (Roche) and 0.05M 
spermidine, with a final volume made up to 40μl with dH2O. This reaction was incubated overnight 
at 50°C. The digested sample was mixed with 5μl Ficoll dye and loaded on a 0.8% agarose gel with 
ethidium bromide. The appropriate DNA Molecular Weight Marker II (Roche) was used as the size 
standards. The gel was run overnight. After sufficient separation of the products, the gel was 
prepared for Southern transfer. 
Southern Transfer 
The gel was soaked in depurating solution for 15 minutes, rinsed in dH2O and soaked in depurating 
solution for another 15 minutes. The gel was then soaked in denaturing solution for 30 minutes, 
followed by neutralizing solution for 30 minutes. The gel was finally soaked in 20x SSC for a minimum 
of 10 minutes, or until ready to blot. The DNA in the gel was transferred using upward capillary 
action onto a positively charged nylon membrane (Biorad) overnight. The membrane was rinsed in 
NaOh 0.4N for 1 hour to immobilize the DNA on the membrane. 
Southern/Hybridization 
The membrane was soaked at 65°C for at least 1 hour in 15-20ml of prehybridization buffer 
containing 0.5 M of Na2HPO42H2O at pH 7,2 adjusted by H3PO4 85%, 8,2% of SDS and 1mM of EDTA. 
During this time, the p482.6 probe was labelled with 32P-dCTP using the Megaprime DNA labelling 
kit (Amersham). The p482.6 probe, inserted in the pUC19 plasmid vector containing an Ampicillin 
resistance gene, is grown in E. coli bacterial cells. The probe is a 1kb fragment of a 9.6kb insert from 
intron 22 of the FVIII gene, and excised from the vector using an Eco RI and Sst I restriction enzyme 
(Roche) double digest]. The labelled probe was heat denatured, immediately added to the 
prehybridization buffer, then to the membrane. The membrane was incubated in this solution at 
65°C ON. After hybridization, excess and non-specifically bound probe was washed off the membrane 
by increasing the stringency of the washes. The washes performed were as follows: 2 washes in a 2x 
SSC, 0.1% SDS solution for 10 minutes each at RT; 2 washes of a 1x SSC, 0.1% SDS solution for 20 
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minutes each at 65°C; 1 wash of a 0.5x SSC, 0.1% SDS solution for 10 minutes at 65°C; 2 washes of a 
0.1x SSC, 0.1% SDS solution for 20 minutes each at 65°C; and finally 3 short rinses with a 0.1x SSC 
solution. 
The membrane was wrapped in plastic wrap, exposed to Hyperfilm MP (Amersham), stored in an X-
ray cassette and kept at -80°C for 3-21 days before the X-ray film was developed in an automated X-
ray film processor.  
Detection of the Intron 1 Inversion mutation 
The detection of the intron 1 inversion was performed using a PCR protocol as described by Bagnall, 
et al. [64] which involves the amplification of 100 ng genomic DNA, 1x PCR Faststart polymerase 
buffer (Hoffmann-La Roche, Basel, Switzerland), 1.25mM MgCl2, 0.125mM dNTP mix (Hoffmann-La 
Roche), 5% DMSO, 20pmol/µl of primers 9F, 9R and int1h-2F (IDT), 2.5U Faststart Taq polymerase 
(Hoffmann-La Roche) and made up to a final volume of 25µl with ddH2O [for conditions PCR, see 
table below]. Primer sequences can be found in Appendix C section [Table C2]. The reaction was 
placed in an Applied Biosystems 2720 PCR machine with the following conditions: 94°C for 6 minutes, 
followed by 30 cycles of 94°C for 1 minute, 55°C for 1 minute and 72°C for 1 minute. The reaction 
was completed with a final extension of 72°C for 4 minutes. Once the PCR was complete, 15μl of the 
PCR product was mixed with dye and detected on a 6% polyacrylamide gel. The expected PCR 
product size is 1.5kb in a normal individual and 1.0kb in a patient with an intron 1 inversion with pair 
of primers Int1h-1 and 1.0kb in a normal individual and 1.5kb in a patient with an intron 1 inversion 
with pair of primers Int1h-2.  
 
Mix int1H-1 
 
Composants Vol/Tube 
Eau 11,3 
Tp faststart + MgCl2 2,5 
dNTP (10mM) 0,5 
GC Rich 5 
BSA 0,5 
Spermine 1mM 1 
Primer INVint1-9F 1 
Primer INVint1-9CR 1 
Primer INT1H-2F 1 
Enz faststart 0,2 
ADN 1 
Total 25 
 
  
Mix int1H-2 
 
Composants Vol/Tube 
Eau 11,3 
Tp faststart + 
MgCl2 
2,5 
dNTP (10mM) 0,5 
GC Rich 5 
BSA 0,5 
Spermine 1mM 1 
Primer INT1H-2F 1 
Primer INT1H-2R 1 
Primer INVint1-9F 1 
Enz faststart 0,2 
ADN 1 
Total 25 
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PCR amplification of exons in the F8 gene 
Regions of F8 were amplified by exon-specific polymerase chain reaction (PCR) with new designed 
primer pairs created by Primer 3 software v.0.3.0 (SourceForge, Inc., Massachusets, USA) 
(NM_000132.3) as listed in Table C1 of the Appendix section C using 50-100 ng of genomic DNA as 
template in 25 μl reactions and primer concentrations of 200 nM, 200 μM dNTPs and 0.2 U Faststart 
Taq-Polymerase (ROCHE) in Faststart buffer (ROCHE). Wherever possible, primers were chosen to 
amplify two or more neighboring exons with the flanking intronic sequences to reduce the total 
number of primers and PCR reactions. Primer sequences were screened for the presence of 
underlying polymorphism(s). PCR conditions and annealing temperatures were separately optimized 
for each pair of primers. Generally, DNA was denatured at 95°C for 2 minutes followed by 30 cycles 
of 94 degrees C for 30 sec, 60 degrees C for 30 sec and 72 degrees C for 1 minute finishing with 7 min 
final extension at 72°C and holding at 10°C. Amplification of F8 exon 21 includes additives (100 ng/μl 
of BSA and 1 µl of 1mM spermine) and requires annealing at 50 degrees C for 30 sec. PCR products 
were separated on 0.8 to 1.5 % agarose gels and visualized by ethidium bromide fluorescence under 
UV light to verify the PCR product. 
Sequencing 
DNA sequencing can be used as a tool to identify variants and mutations in genes of particular 
interest. The technique used for DNA sequencing in this study is based on the dideoxy or chain 
termination method of Sanger [65]. The principle of the Sanger method requires an oligonucleotide 
to anneal to a single stranded DNA template and act as a primer for the reaction. All four dNTPs must 
be present in the reaction, together with a ddNTP. ddNTPs contain a 3’-H atom instead of the 3’-OH 
group of the dNTPs, which prevents the phosphodiester bond formation with the succeeding dNTP. 
There is a chance that a ddNTP will be incorporated into the growing DNA strand instead of a normal 
dNTP, and termination of chain elongation occurs at that site. The products are resolved on a 
polyacrylamide gel and as termination will occur at every position along the DNA strand, the order of 
the bands determines the sequence of the DNA. Using automated sequencing, four ddNTPs, each 
with a different colored fluorescent label, are added in a single reaction and the products are 
resolved using an automated DNA sequencing machine. The PCR products obtained from both the 
DNA exons and cDNA fragments were checked for amplification using polyacrylamide gel 
electrophoresis. The excess unincorporated primers and dNTPs were removed using single-step 
ExoSAP-IT reagent (Affymetrix, Santa Clara, California, United States). Cycle sequencing was 
performed on these cleaned PCR products using the ABI Prism® BigDye®Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems) and either the forward or reverse primer. All unincorporated 
ddNTPs and primers were removed from the cycle sequencing products using Sephadex® G-50 
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(Sigma-Aldrich). The cleaned cycle sequencing products were analyzed using the ABI3130xl genetic 
analyzer (Applied Bio systems). Samples were analyzed using the sequence analysis software v5.2 
(Applied Bio systems). These results were compared to a normal reference sequence to detect 
variations using the Mutation Surveyor® software (Soft Genetics L.L.C, State College, PA, United 
States). Any variations identified in the cDNA fragments were named using standard nomenclature 
based on the recommendations of den Dunne & Antonarakis [66]. To determine whether the 
variation was pathogenic or polymorphic, we accessed the HAMSTeRS mutation and polymorphism 
databases (http://www.factorviii-db.org/). Novel changes, possibly affecting splicing, were checked 
on one of two web-based splice site predictor programs, either NetGene2 server 
(www.cbs.dtu.dk/services/NetGene2) or Berkeley Drosophila Genome project Splice Site Predictor 
(www.fruitfly.org/seq_tools/splice.htlm). 
Reverse Transcription 
RNA was reverse transcribed into cDNA (NM_000132.3) in order to create a stable working stock of 
patient material. RT-PCR was generated by the access RT-PCR kit (Promega Corporation, Madison, 
USA) which coupled reverse transcription and first PCR amplification (PCR1) with 50pmol of each 
primers (Table C2 of this Appendix section C). Primers were described by Viel et al [67] and El-Maarri 
et al [68] or created by Primer 3 software v.0.3.0 (SourceForge, Inc., Massachusets, USA). The cycling 
conditions of the one-tube RT-PCR were 45 min at 48°C, 2 min at 48°C (to inactivate reverse 
transcriptase) followed directly by 35 cycles of amplification consisting of 94°C for 30 sec; 60°C for 1 
min; 72°C for 3 min and a final extension at 72°C for 5 min. One µl of PCR 1 was used as template in 
the nested PCR reaction (PCR 2). This PCR was performed in a 25 µl containing 1x PCR Faststart 
buffer, 1 U of Faststart Taq polymerase (Hoffmann-La Roche, Basel, Switzerland), 0,2 mM of each 
dNTP and 10pmol of each nested primer with sequences described by Viel et al [67] and El-Maarri et 
al [68] or generated by Primer 3 software. Fragments were directly sequenced in both directions 
using a Big Dye Terminator Cycle Sequencing Ready Reaction Kit on an ABI 3130xl automated 
sequencer (Applied Biosystems, Foster city, CA, USA).  
 
Q-PCR 
Amplification distal to repeat int22h-3 could not be easily assessed by microarray given the highly 
repetitive nature of the genomic interval between int22h-3 and TMLHE gene. Therefore to confirm 
array results a quantitative PCR system was performed using a Light Cycler 480 II real-time PCR 
system (Roche Applied Science, Penzberg, Germany).  
Briefly, 
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1. 100ng of DNA was mixed with a 20-μl PCR mix containing 100 ng of DNA, 10 µl of  SYBR Green 
master mix (Roche Applied Science, Penzberg, Germany), and 200 nM of the appropriate 
oligonucleotide primers. The selected primers (Forward: TGTGCCAAAGTCCAGAAATAGT; 
reverse: CCAACAGAGAAAGTAGCAGGAA) amplify two loci: chrX:154575182+154575278 
(proximal to repeat a2) and chrX:154724935-154725031 (distal to repeat int22h-3). 
2. The mix was preheated at 95°C (10 min) and then was amplified at 95°C (15 sec) and 60°C (60 
sec) for 40 cycles. 
3. After PCR amplification, the resolution curve was measured at 95°C for 5 sec, 65°C for 1 min 
and 95°C for 15 sec to check the specificity of the PCR reaction (absence of primer– dimers or 
other nonspecific amplification products). 
Two reference genes (GPR15 and P53) were used to normalize the data relative to a normal female 
DNA. An additional gene on chromosome X (MECP2) was also used as negative control. The threshold 
cycle (Ct) values were calculated from the threshold cycles with the instrument’s software (SDS 2.3) 
and were exported to Excel (Microsoft) for further analysis. Calculation of the two loci copy number 
was normalized to the three reference genes values. The data were analyzed using the comparative 
threshold cycle (2-ΔCT) method [69].  
Using this method, if duplication encompass a single site in a male, a genome equivalent (compare 
with a normal women) is 0.75 expected (3 copies versus 4 in the female) and if both site are 
duplicated a genome equivalent of 1 is expected still compared to a normal reference female DNA. In 
a female carrier of duplication at a single site or at both sites, a genome equivalent of 1.25 or 1.5 
respectively is expected.  
 
MLPA 
Gene dosage variations on F8 were analyzed by MLPA technology. The P178-B2 F8 probemix 
(http://www.mlpa.com; consulted in 08/10/2014) contains 45 MLPA probes which are hybridized to 
different target sequences within the F8 exons (amplification products between 136 and 476 nt). In 
addition, the kit contains 9 control fragments generating an amplification product smaller than 120 
nt. Each MLPA probe consists of two adjacent oligonucleotides, which are ligated to each other after 
hybridization to their target sequence. Only ligated probes can be amplified in a single-tube PCR 
reaction using a universal primer pair that anneals to adaptors attached to the probe 
oligonucleotides. 
Standard procedure is described in detail in the following: 
1. DNA (20-500 ng) samples are diluted with TE to 5 µl and are heated at 98°C for 5 min in 200 µl 
tubes in a thermocycler with a heated lid.  
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2. After addition of 1.5 µl salt solution (1.5 M KCl, 300 mM Tris–HCl pH 8.5, 1 mM EDTA) mixed 
with 1.5 µl probe mix (1–4 fmol of each synthetic probe oligonucleotide and each M13-derived 
oligonucleotide in TE), samples are heated for 1 min at 95°C and then incubated for 16 h at 
60°C. 
3. Ligation of annealed oligonucleotides is performed by diluting the samples to 40 µl with 
dilution buffer (2.6 mM MgCl2, 5 mM Tris–HCl pH 8.5, 0.013% non-ionic detergents, 0.2 mM 
NAD) containing 1 U Ligase-65 enzyme, and incubation for 15 min at 54°C. 
4. The ligase enzyme is inactivated by heating at 98°C for 5 min and ligation products are 
amplified by PCR. 
5. For most experiments, 10 µl of the ligation reaction is added to 30 µl PCR buffer. 
6. While at 60°C, 10 µl of a buffered solution containing the PCR primers (10 pmol), dNTPs (2.5 
nmol) and 2.5 U Taq polymerase (Promega) or SALSA polymerase (MRC-Holland) are added. 
Alternatively, the 10 µl solution containing PCR primers, dNTPs and polymerase is added to the 
complete MLPA reactions while at 60°C. 
7. The PCR reaction contains 35 cycles (30 s at 95°C, 30 s at 60°C and 1 min at 72°C). 
MLPA PCR products were separated on an ABI automatic sequencer. Then the raw data were 
interpreted by software as GeneMarker software (Softgenetics L.L.C, State College, PA, USA) or 
Coffalyser, which normalizes the data in relation to control peaks from other genes and converts the 
peak areas into electropherogram, ratio plot, validation box, report table or bar graphs. Samples 
were normalized by peak height comparing patients with 10 controls. These 10 control individuals 
had been confirmed to have no duplications or deletions in the studied genes, by a previous analysis 
using Affymetrix Genome-Wide Human SNP Arrays. 
With a normal gene dosage, the ratio of control and test bars lies at 1.0 (variance: 0.8–1.2). In case of 
male patient, the corresponding peak is null or doubled if the exon is deleted or duplicated. In case of 
carrier female, the probe ratios of the corresponding peak are below of 0.7 or above 1.3 in presence 
of heterozygous deletion or duplication respectively.  
CGH 
Array CGH is based on the use of differentially labeled test and reference genomic DNA samples that 
are simultaneously hybridized to DNA targets arrayed on a glass slide or other solid platform. The 
two genomes, a sample (or patient) and a reference (or control), are labelled with two different 
fluorochromes (red/green) and are cohybridized onto a solid support (usually a glass microscope 
slide) on which cloned or synthesized DNA fragments have been immobilized. The measurement of 
the fluorescence intensity ratio can detect DNA copy changes simultaneously at multiple loci in a 
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genome. These changes may include deletions, duplications, or amplifications at any locus as long as 
that region is represented on the array.  
Nine stages spread over 4 days are required for this technique according to the manufacturer’s 
instructions (Affymetrix CytoScan (Affymetrix, Santa Clara, CA, USA)). 
First stage: Restriction Enzyme Digestion 
250 ng of genomic DNA was digested with 5U NspI restriction enzyme in a reaction containing 1x 
reaction buffer and 100 ng/μl of BSA with a final volume made up to 20 μl with dH2O. This reaction 
was incubated at 37°C for two hours. The genomic DNA fragment must have NspI restriction sites 
intact so that ligation can occur on both ends of the fragment and PCR can be successful.  
Second stage: Ligation 
19,75 µl of the NSp1 digested samples were mixed with 2 µl of T4 DNA Ligase in a reaction containing 
T4 DNA Ligase 1x reaction buffer and 0.75µl of 50 μM Adaptor, NspI. Each mix was incubated at 16°C 
for three hours. Then, the enzyme was inactivated at 70°C for 20 min and each mix was maintained 
on ice before to proceed to the PCR setup. 
Third stage: PCR  
1. The ligated samples were diluted 4 times. 
2. Ten µl aliquots of each sample were mixed with a 100 μl PCR mix containing 1x reaction buffer 
of TITANIUM™ Taq PCR, 20 µl of GC-Melt Reagent, 200 μM dNTPs, 4,5 µl of primer 002 and 2 
µl of 50X TITANIUM™ Taq DNA Polymerase. Each sample was preheated at 94°C (3 min) and 
then was amplified at 94°C (30 sec), 60°C (45 sec) and 68°C (15 sec) for 30 cycles finishing with 
7 min final extension at 68°C and holding at 10°C. 
Note: To ensure enough quantity of product in final, the PCR of each sample were realized four 
times separately. 
3.  Gel electrophoresis was used to check to the PCR reaction. Three µl of PCR product was 
loaded onto a 2% agarose gel with ethidium bromide and migrated for 45 min (Fig. 1). The 
appropriate USB 50-2000 bp Ladder was loaded in the lanes before and after the samples. 
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FIGURE 1 : EXAMPLE OF PCR SEVEN PRODUCTS RUNS ON A 2% TBE GEL. Majority of product should be 
between 150 to 2000 bp. 
4. If the quality control results are good, proceed to Stage 4 – Purification. 
Fourth stage: PCR Product Purification 
1. All 4 PCR products for each sample were pooled by transferring all PCR reactions to the 
appropriately tube for purification with Beads.  
2. 720 ml of Purification Beads were added to each pooled sample and incubated at room 
temperature for 10 min. The tubes were centrifuged for 3 min at maximum speed (16,100 rcf). 
The supernatant without disturbing the bead pellet was pipeted off and discarded. 
3. 1 ml of Purification Wash Buffer was added to each tube. The tubes were centrifuged for 3 min 
at 16,100 rcf. The supernatant without disturbing the bead pellet was pipeted off and 
discarded. The tubes were taking off and left uncapped at RM for 10 min to allow any 
remaining Purification Wash Buffer to evaporate. 
4. 52 ml of Elution Buffer was added to each tube. The tubes were vortexed at maximum power 
for 10 min to resuspend the beads. Then, the tubes were centrifuged for 3 min at 16,100 rcf 
and 47 mL of eluted sample were transferred to new appropriate tube.  
Fifth stage: Quantitation 
The OD of each purified PCR sample was measured at 260, 280 and 320 nm (Spectrophotometer and 
Nanodrop). The OD 260/OD280 ratio should be between 1.8 and 2.0 and the OD 320 measurement 
should be very close to zero (< 0.1). Calculate the undiluted concentration of each sample was 
calculated in μg/μL. The average purification yield for 7 or more samples should be ≥3.0 μg/μL. 
Sixth stage: Fragmentation 
1. 45 µl of purified PCR Product were mixed with 10 µl of Fragmentation Master Mix containing 
the 1x fragmentation buffer and 7.2 µl of fragmentation reagent. Each mix was incubated at 
37°C for 35 min followed by 15 min at 95°C and maintained on ice. 
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2. Gel electrophoresis was used to check the fragmentation reaction. After dilution of 4 µl of each 
fragmented sample with 28 μL of Nuclease-Free water, 8 µl od this mix was loaded onto a 4% 
agarose gel with ethidium bromide and migrated for 45 min (Fig. 2). The appropriate USB 25 
bp Ladder was loaded in the lanes before and after the samples. 
 
FIGURE 2 : EXAMPLE OF FRAGMENTED SEVEN PRODUCTS RUNS ON A 4% TBE GEL. Majority of product should be 
between 25 to 125 bp. 
3. If the quality control results are good, proceed to Stage 8 – Labeling. 
Seventh stage: Labeling 
51 ml of the each fragmented product were mixed with 19.5 µl of Labelling Mix containing the 1x 
Todd buffer, 2 µl of the 30 mm DNA Labeling Reagent and 3.5 µl of Todd enzyme. Each mix was 
incubated at 37°C for 4 hours followed by 15 min at 95°C and maintained on ice. 
Eighth stage: Target Hybridization 
1. The Hybridization Master Mix was prepared in a 15 ml conical tube on ice containing: 
 165 µl of Hub Buffer Part 1 
 15 µl of Hub Buffer Part 2 
 7 µl of Hub Buffer Part 3 
 1 µl of Hub Buffer Part 4 
 2 µl of Oligo Control Reagent 0100 
2. Add 190 μL of Hybridization Master Mix to each sample. Each mix was incubated at 95°C for 10 
min and maintained at 49°C for at least 1 min before loading. 
3. 200 μL of sample was loaded onto each array 
4. The arrays were loaded into the hybridization oven and were hybridized 16 to 18 hrs. at 50 °C. 
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Ninth stage: Wash, Stain, and Scan 
Each array was washed with following reagents: 500 μl Stain Buffer 1, 500 μl Stain Buffer 2 and 800 μl 
Stain Buffer 3 successively according the type of CytoScanTM (CytoScanTM HD Array or CytoScanTM 
750K Array). 
Then, the arrays are scanned. 
Haplotype Analysis 
Flanking markers from 1.4Mb centromeric to 0.6Mb telomeric of the F8 locus were genotyped, 
including the four extragenic and intronic microsatellites (3’ DXS15–DXSint22–DXSint13–DXS1108-5’) 
and ten SNPs, as displayed in this Appendix section C; Table C3. The PCR was conducted in a 25µL 
containing 1x PCR Faststart buffer, 1U of Faststart Taq polymerase (Hoffmann-La Roche, Basel, 
Switzerland), 0.2mM of each dNTP, and 10pmol of each primer. Cycling conditions were set to initial 
denaturation at 94°C for 5 minutes, followed by 30 cycles of amplification. These comprised 30 
second denaturation at 94°C; 1 minute annealing at 55°C; 1 minute elongation at 72°C; and 5 minutes 
final extension at 72°C. A 1.5µL aliquot of STR PCR product was added to 10µL of Hi-Di Formamide 
(Applied Biosystems, Foster city, CA, USA). Amplification products were identified using an ABI3130xl 
capillary sequencer by employing the Genescan-ROX-500 (Applied Biosystem, Foster City, CA, USA) 
size standard, and the following parameters were selected: sample type was set to standard, the size 
standard was GS500(-250), the individual microsatellites panel was selected, analysis method was set 
to Microsatellite Default, and the instrument protocol 1 was microsatellites. The raw data results 
were analyzed using the Gene Marker software V1.5 (Soft Genetics LLC, State College, PA, USA). This 
software compares the peak sizes of the alleles of interest to the scored alleles of the ROX500 size 
standard to accurately size the peaks of interest. After analysis, each sample was analyzed to check 
that the ROX500 size standard peaks were scored correctly and that the required alleles were called 
and sized appropriately. 
Amplified SNP DNA fragments were purified and subjected to direct cycle sequence analysis using 
the Taq di-deoxy terminator method and an ABI PRISM 3130xl Genetic Analyzer sequencer, in 
accordance with the manufacturer’s instructions. 
MAQPCR 
Multiplex amplicon quantification (MAQ) is a robust, rapid, and easy-to-perform method for 
analyzing specific copy-number variations (CNVs). The method, performed according to the 
manufacturer’s protocol, consists of fluorescently labeled multiplex PCR with amplicons in the CNVs 
(target amplicons) and amplicons with a stable copy number. Two series of five primer pairs 
extending from position 154,147,798 to 154,344,960 on chromosome X for the first series, and from 
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154,441,804 to 154,664,293 on chromosome X for the second were designed to target F8 locus 
(Appendix section C; Table C4). The first amplicon was located in F8 gene intron 14, and the last 
between int22h-2 and int22h-3 repeats.  
MAQ analysis was performed according to the manufacturer’s protocol. 
Briefly: 
1. After receiving the primers from Multiplicom, adjust them to a final concentration of 100 µM 
2. The protocol requires a total of 20-50 ng of DNA 
3. Remove the PCR mix from the -20°C freezer and allow complete thawing on ice. 
4. Vortex and centrifuge tube at 12000 g for 10 sec before use. 
5. On ice, prepare a “master reaction mix” with the following reagents: 3 µl of the Flagged you-
MAQ PCR mix, 1 µl of Forward and 1 µl of Reverse primers pool and 0.075 µl of Taq DNA 
polymerase. 
6. Vortex briefly and centrifuge at 12000 g for 10 sec. 
7. Add 2-10 µl or DNA (20-50 ng) 
8. Complete the volume with ddH2O to obtain in final volume 15 µl. 
9. The mix was preheated at 98°C (10 min) and then was amplified at 95°C (45 sec), 60°C (45 sec) 
and 68°C (2 min) for 25 cycles. 
10. Prepare to fragment analysis with adding 10 µl of HiDi-Formamide and 0.3 µl of GS500 size 
standard to 2 µl of the MAQ PCR product. 
11. Denature the sample at 95°C for 3 min and put on ice immediately. 
12. Centrifuge for 10sec  
13. The PCR products were analyzed using the ABI3130xl genetic analyzer (Applied Biosystems). 
Raw data generated by fragment analysis on a capillary sequencer was analyzed using MAQ-S 
[Multiplicom [http://www.multiplicom.com]], a specially designed software program, to calculate and 
visualize the normalized peak area or dosage quotient, which reflected the copy number of each 
target amplicon. 
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B) Mutations in the FVIII gene identified in HA families 
a) MUTATIONS IN THE FVIII GENE IDENTIFIED IN MILD HA FAMILIES (supplementary material associated with the 
“Overrepresentation of missense mutations in mild hemophilia A patients from Belgium: founder effect or 
independent occurrence?” study [22]. Results are presented compared to exons (chronological exons). 
Mutations at the amino acid level are given using HGVS nomenclature [66]. Legacy numbering is maintained 
within parenthesis. 
Patient ID SEVERITY TYPE OF MUTATION GEMONIC PROTEINIC EX 
HA22, HA184, HA192 * mild duplication c.(?_-36)_(143+?)dup ? 1 
HA149 mild missense c.71A>G p.Tyr24Cys (5) 1 
HA133 mild missense c.683A>G p.His228Arg (209) 6 
HA109 * mild missense c.733C>T p.Arg245Trp (226) 6 
HA92 mild missense c.751C>G p.His251Asp (232) 6 
HA53 * mild missense c.775A>G p.Arg259Gly (240) 6 
HA158 
#
 mild missense c.797G>A p.Gly266Glu (247) 7 
HA172 *
,#
 mild missense c.893G>C p.Arg298Thr (279) 7 
HA206 
#
 mild missense c.896A>T p.Asn299Ile (280) 7 
HA28 mild missense c.1172G>A p.Arg391His (372) 8 
HA5, HA47, HA97, HA164 mild/moderate missense c.1293G>T p.Leu431Phe (412) 9 
HA173 
#
 mild missense c.1636C>T  p.Arg546Trp (527)  11 
HA2 mild missense c.1648C>T p.Arg550Cys (531) 11 
HA50, HA124 mild missense c.1649G>A p.Arg550His (531) 11 
HA48 mild missense c.1834C>T p.Arg612Cys (593) 12 
HA174 
#
 mild missense c.1930T>G  p.Leu644Val (625) 13 
HA88* mild missense c.1982T>A p.Ile661Asn (642) 13 
HA37 mild missense c.1988C>T p.Ala663Val (644) 13 
HA177 
#
 mild missense c.2059C>T p.Leu687Phe (668) 13 
HA1* mild missense c.2099C>T p.Ser700Leu (681) 13 
HA160 
#
 mild missense c.5122C>T p.Arg1708Cys (1689) 14 
HA9 mild missense c.5186G>A p.Gly1729Glu (1710) 14 
HA15, HA74, HA151 mild missense c.5305G>A p.Gly1769Arg (1750) 15 
HA40* mild missense c.5926C>G p.His1976Asp (1957) 18 
HA52, HA128 mild missense c.5954G>A p.Arg1985Gln (1966) 18 
HA83 mild missense c.5981T>C p.Leu1994Pro (1975) 18 
HA103 mild missense c.6067G>A p.Glu2023Lys (2004) 19 
HA150* mild missense c.6082G>T p.Gly2028Trp (2009) 19 
HA39, HA46, HA55, HA81, 
HA108, HA126, HA127, 
HA152, HA153, HA157 
mild missense c.6089G>A p.Ser2030Asn (2011) 19 
HA162 
#
 mild missense c.6113A>G p.Asn2038Ser (2019) 19 
HA117 * mild/moderate missense c.6195G>C p.Trp2065Cys (2046) 21 
HA19 mild missense c.6371A>G p.Tyr2124Cys (2105) 22 
HA113  mild missense c.6439G>A p.Gly2147Ser (2128) 23 
HA38 mild missense c.6443A>G p.Asn2148Ser (2129) 23 
HA114 mild missense c.6505C>T p.Arg2169Cys (2150) 23 
HA71 mild missense c.6506G>A p.Arg2169His (2150) 23 
HA10, HA18, HA104, HA105, 
HA141, HA154, HA17 
mild missense c.6532C>T p.Arg2178Cys (2159) 23 
HA84, HA115, HA137, HA11 mild missense c.6533G>A p.Arg2178His (2159) 23 
HA170 
#
 mild missense c.6533G>T p.Arg2178Leu (2159) 23 
HA134 moderate missense c.6544C>T p.Arg2182Cys (2163) 23 
HA42* mild missense c.6823T>C p.Tyr2275His (2256) 25 
HA136, HA13, HA142, HA56 mild/moderate missense c.6932C>A p.Pro2311His (2292) 26 
HA159 
#
 mild missense c.6995G>C p.Trp2332Ser (2313) 26 
* Mutations not reported by the EAHAD db; ≠ Mutations not reported in Lannoy et al. [3] 
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b) MUTATIONS IN THE FVIII GENE IDENTIFIED IN 205 HA FAMILIES.  
Results are presented in function of the nature of the causal variants and to chronological codon/exon 
ID Severity sexe 
Mutation 
type 
Observed cDNA change Predicted protein change* Predicted RNA change FVIII exon Reported
$
 References 
HA33 severe male ? ? ? ? ? ? 
 
HA69 mild male ? ? ? NORMAL RNA ? ? 
 
HA110 mild male ? ? ? ? ? ? 
 
HA130 mild male ? ? ? ? ? ? 
 
HA132 mild male ? ? ? ? ? ? 
 
HA144 mild male ? ? ? ? ? ? 
 
HA145 mild male ? ? ? ? ? ? 
 
HA146 mild male ? ? ? NORMAL RNA ? ? 
 
HA94 severe male deletion c.2006_2007delCT p.Ser669Cysfs*14 (650) 
 
13 N b 
HA138 severe male deletion c.2347_2348delAA p.Asn783fs* (764) 
 
14 N c 
HA25 severe male deletion c.3637delA p.Ile1213Phefs*5 (1194) 
 
14 Y a, b 
HA194 severe male deletion c.3637delA p.Ile1213Phefs*5 (1194) 
 
14 Y a, b 
HA62 severe male deletion c.3637delA p.Ile1213Phefs*5(1194) 
 
14 Y a, b 
HA82 severe male deletion c.3637delA p.Ile1213Phefs*5(1194) 
 
14 Y a, b 
HA24 severe male deletion c.3784delG p.Ala1262Hisfs*11 (1243)  14 Y a, b 
HA12 severe male deletion c.4379delA p.Asn1460Ilefs*4 (1441)  14 N b 
HA95 severe male deletion c.4981delG p.Val1661Serfs*1 (1642)  14 N b 
HA93 severe male deletion c.53705372delCAT p.Ile1790del (1771) 
 
15 N c 
HA112 severe male deletion c.5380_5381delTT p.Phe1794Glnfs*12(1775)  16 N b 
HA27 severe male deletion c.5956delA p.Lys1987LyxfsX42 (1968) 
 
18 N b 
HA139 ? male deletion c.5964_5966delGAG p.Glu1989del (1970)  18 N c 
HA44 severe male deletion c.5999-8_6006del16 p.Gly2000_Glu2038del39(1981) r.5999_6115del 19 N b 
HA107 severe male deletion c.6699delG p.Arg2234Glyfs*9 (2215) 
 
24 Y a, b 
HA26 severe male duplication c.2945dupA p.Asn982Lysfs*9 (963) 
 
14 y a, b 
HA80 severe male duplication c.3637dupA p.Ile1213Asnfs*28 (1194) 
 
14 y a, b 
HA129 severe male duplication c.4379dupA p.Asn1460Lysfs*5 (1441) 
 
14 y a, b 
HA140 severe male duplication c.4379dupA p.Asn1460Lysfs*5 (1441) 
 
14 y a, b 
HA171 severe male duplication c.4379dupA p.Asn1460Lysfs*5 (1441) 
 
14 y a, c 
HA201 severe male duplication c.4825dupA p.Thr1609Asnfs*3 (1590) 
 
14 Y a, c 
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HA116 severe male insertion c.6988_6989ins24 
p.Pro2329_Gln2330insAsnSerLeuPro
SerAsnSerPro  
26 N c 
HA100 severe male inversion 1 
    
y 
 
HA175 severe male inversion 1 
    
y 
 
HA185 severe male inversion 1 
    
y 
 
HA4 severe male 
inversion 22 
type 1     
y 
 
HA7 severe male 
inversion 22 
type 1     
y 
 
HA8 severe male 
inversion 22 
type 1     
y 
 
HA20 severe male 
inversion 22 
type 1     
y 
 
HA23 severe male 
inversion 22 
type 1     
y 
 
HA30 severe male 
inversion 22 
type 1     
y 
 
HA36 severe male 
inversion 22 
type 1     
y 
 
HA43 severe male 
inversion 22 
type 1     
y 
 
HA49 severe male 
inversion 22 
type 1     
y 
 
HA57 severe male 
inversion 22 
type 1     
y 
 
HA59 severe male 
inversion 22 
type 1     
y 
 
HA60 severe male 
inversion 22 
type 1     
y 
 
HA61 severe male 
inversion 22 
type 1     
y 
 
HA66 severe male 
inversion 22 
type 1     
y 
 
HA67 severe male 
inversion 22 
type 1     
y 
 
HA75 severe male 
inversion 22 
type 1     
y 
 
HA76 severe male 
inversion 22 
type 1     
y 
 
HA77 severe male 
inversion 22 
type 1     
y 
 
HA79 severe male 
inversion 22 
type 1     
y 
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HA85 severe male 
inversion 22 
type 1     
y 
 
HA87 severe male 
inversion 22 
type 1     
y 
 
HA89 severe male 
inversion 22 
type 1     
y 
 
HA96 severe male 
inversion 22 
type 1     
y 
 
HA99 severe male 
inversion 22 
type 1     
y 
 
HA101 severe male 
inversion 22 
type 1     
y 
 
HA106 severe male 
inversion 22 
type 1     
y 
 
HA118 severe male 
inversion 22 
type 1     
y 
 
HA119 severe male 
inversion 22 
type 1     
y 
 
HA120 severe male 
inversion 22 
type 1     
y 
 
HA121 severe male 
inversion 22 
type 1     
y 
 
HA122 severe male 
inversion 22 
type 1     
y 
 
HA125 severe male 
inversion 22 
type 1     
y 
 
HA131 severe male 
inversion 22 
type 1     
y 
 
HA148 severe male 
inversion 22 
type 1     
y 
 
HA166 Severe male 
inversion 22 
type 1     
y 
 
HA167 severe male 
inversion 22 
type 1     
y 
 
HA178 severe male 
inversion 22 
type 1     
y 
 
HA179 severe male 
inversion 22 
type 1     
y 
 
HA180 severe male 
inversion 22 
type 1     
y 
 
HA186 severe male 
inversion 22 
type 1     
y 
 
HA187 severe male 
inversion 22 
type 1     
y 
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HA188 severe male 
inversion 22 
type 1     
y 
 
HA190 severe male 
inversion 22 
type 1     
y 
 
HA191 severe female 
inversion 22 
type 1     
y 
 
HA193 severe male 
inversion 22 
type 1     
y 
 
HA199 severe male 
inversion 22 
type 1     
y 
 
HA147 severe male 
inversion 22 
type 2     
y 
 
HA54 severe male 
inversion 22 
type 3B     
y 
 
HA111 severe male 
inversion 22 
type 3B     
y 
 
HA73 mild female 
large 
deletion 
c.(?_-36)_1903+?del ? ? 1 to 12 N a, d 
HA182 severe male 
large 
délétion 
c.(?_-36)_2113+?del ? ? 1 to 13  c 
HA86 mild female 
large 
deletion 
c.144-?_266+?del 
p.Arg29_Gly70>ArgfsX9 + 
p.Gly22_Gly70del 
 2 N a, d 
HA78 severe male 
large 
deletion 
c.602-?_670+?del p.Gly201_Gly224del r.602_670del 5 N b, c 
HA65 severe male 
large 
deletion 
c.5220-?_5373+?del p.Ala1741_Ser1807del r.5220_5419del 15 N c 
HA181 severe male 
large 
délétion 
c.6431-?_-6900+?del ? ? 23 to 25 
 
c 
HA51 ? female 
large 
deletion 
c.6902-?_(*7056+?)del ? ? 26 N b 
HA22 mild male 
large 
duplication 
c.(?_-36)_(143+?)dup ? Normal 1 N e 
HA184 mild male 
large 
duplication 
c.(?_-36)_(143+?)dup ? Normal 1 N e 
HA192 mild male 
large 
duplication 
c.(?_-36)_(143+?)dup ? Normal 1 N e 
HA123 moderate male 
large 
duplication 
c.144-?_5219+?del ? ? 2 to 14 ? b 
HA149 mild male missense c.71A>G p.Tyr41Cys (5) 
 
1 Y a, f 
HA90 moderate male missense c.73T>C and c.75C>G p.Tyr25Gln (6)  1 N b 
HA3 severe male missense c.463T>A p.Tyr155Asn (136) 
 
4 N b 
HA202 ? male missense c.403G>T p.Asp135Tyr (116) 
 
4 Y a, c 
HA41 severe male missense c.471G>C p.Trp157Cys (138)  4 N b 
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HA197 mild male missense c.645A>G p.Ile215Met (196) 
 
5 Y a, c 
HA133 mild male missense c.683A>G p.His228Arg (209) 
 
6 Y a, f 
HA109 mild male missense c.733C>T p.Arg245Trp (226)  6 N b 
HA92 mild male missense c.751C>G p.His251Asp (232) 
 
6 Y a, b 
HA98 severe male missense c.757G>T p.Val253Phe (234) 
 
6 Y a, b 
HA53 mild male missense c.775A>G p.Arg259Gly (240)  6 N b 
HA158 mild male missense c.797G>A p.Gly266Glu (247) 
 
7 Y a, f 
HA102 severe male missense c.830T>G p.Ile277Ser (258) 
 
7 N b 
HA172 mild male missense c.893G>C p.Arg298Thr (279) 
 
7 N f 
HA206 mild male missense c.896A>T p.Asn299Ile (280) 
 
7 Y a, c 
HA189 severe male missense c.902G>A p.Arg301His (282) 
 
7 Y a, c 
HA91 moderate male missense c.992T>G p.Ile331Ser (312) 
 
7 Y a, b 
HA143 severe male missense c.1171C>T p.Arg391Cys (372) 
 
8 Y a, b 
HA28 mild male missense c.1172G>A p.Arg391His (372) 
 
8 Y a, b 
HA5 mild male missense c.1293G>T p.Leu431Phe (412) 
 
9 Y a, b 
HA47 mild male missense c.1293G>T p.Leu431Phe (412) 
 
9 Y a, b 
HA97 moderate male missense c.1293G>T p.Leu431Phe (412) 
 
9 Y a, b 
HA161 mild male missense c.1293G>T p.Leu431Phe (412) 
 
9 Y a, b 
HA164 ? female missense c.1293G>T p.Leu431Phe (412) 
 
9 Y a, b 
HA155 severe male missense c.1420G>A p.Gly474Arg (455) 
 
9 Y a, c 
HA173 mild female missense c.1636C>T p.Arg546Trp (527) 
 
11 Y a, f 
HA2 mild male missense c.1648C>T p.Arg550Cys (531) 
 
11 Y a, b 
HA50 mild male missense c.1649G>A p.Arg550His (531) 
 
11 Y a, b 
HA124 mild female missense c.1649G>A p.Arg550His (531) 
 
11 Y a, b 
HA16 severe male missense c.1814A>G p.Tyr605Cys (586) 
 
12 Y a, b 
HA48 mild male missense c.1834C>T p.Arg612Cys (593) 
 
12 Y a, b 
HA1 mild male missense c.2099C>T p.Ser700Leu (681) 
 
13 N b 
HA174 mild male missense c.1930T>G p.Leu644Val (625) 
 
13 Y a, f 
HA 204 mild male missense c.1963T>C p.Tyr655His (636) 
 
13 N c 
HA88 mild male missense c.1982T>A p.Ile661Asn (642) 
 
13 N b 
HA37 mild male missense c.1988C>T p.Ala663Val (644) 
 
13 Y a, b 
HA68 moderate male missense c.2059C>T p.Leu687Phe (668) 
 
13 Y a, b 
HA177 mild male missense c.2059C>T p.Leu687Phe (668) 
 
13 Y a, f 
HA32 severe male missense c.2179G>T p.Val727Phe (708) 
 
14 Y a, b 
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HA135 severe male missense c.5122C>T p.Arg1708Cys (1689) 
 
14 Y a, b 
HA160 ? female missense c.5122C>T p.Arg1708Cys (1689) 
 
14 Y a, f 
HA9 mild male missense c.5186G>A p.Gly1729Glu (1710) r.5186G>A 14 Y a, b 
HA15 mild male missense c.5305G>A p.Gly1769Arg (1750) 
 
15 Y a, b 
HA74 mild male missense c.5305G>A p.Gly1769Arg (1750) 
 
15 Y a, b 
HA151 mild male missense c.5305G>A p.Gly1769Arg (1750) 
 
15 Y a, f 
HA14 mild male missense c.5398C>T p.Arg1800Cys (1781) 
 
16 Y a, c 
HA72 moderate male missense c.5398C>T p.Arg1800Cys (1781) 
 
16 Y a, b 
HA163 moderate male missense c.5399G>A p.Arg1800His (1781) 
 
16 Y a, c 
HA 205 mild female missense c.5861C>T p.Ala1954Val (1935) 
 
18 N c 
HA40 mild male missense c.5926C>G p.His1976Asp (1957) 
 
18 N b 
HA203 mild male missense c.5936G>T p.Gly1979Val (1960) 
 
18 Y a, c 
HA52 ? female missense c.5954G>A p.Arg1985Gln (1966) 
 
18 Y a, b 
HA128 mild male missense c.5954G>A p.Arg1985Gln (1966) 
 
18 Y a, b 
HA83 mild male missense c.5981T>C p.Leu1994Pro (1975) 
 
18 Y a, b 
HA29 severe male missense c.6046C>T p.Arg2016Trp (1997) 
 
19 Y a, b 
HA103 mild male missense c.6067G>A p.Glu2023Lys (2004) 
 
19 Y a, b POLYM ? 
HA150 mild male missense c.6082G>T p.Gly2028Trp (2009) 
 
19 N b 
HA39 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, b 
HA46 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, b 
HA55 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, b 
HA81 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, b 
HA108 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, b 
HA126 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, b 
HA127 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, b 
HA152 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 
 
a, b 
HA153 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, b 
HA157 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, b 
HA183 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, c 
HA196 mild male missense c.6089G>A p.Ser2030Asn (2011) 
 
19 Y a, c 
HA162 mild male missense c.6113A>G p.Asn2038Ser (2019) 
 
19 Y a, f 
HA117 ? female missense c.6195G>C p.Trp2065Cys (2046) 
 
21 N b 
HA35 severe male missense c.6241T>C p.Trp2081Arg (2062) 
 
21 N b 
HA198 ? female missense c.6314C>T p.Thr2105Ile (2086) 
 
22 Y a, c 
HA64 moderate male missense c.6350T>G p.Ile2117Ser (2098) 
 
22 Y a, b 
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HA19 mild male missense c.6371A>G p.Tyr2124Cys (2105) 
 
22 Y a, b 
HA113 mild male missense c.6439G>A p.Gly2147Ser (2128) 
 
23 Y a, b 
HA38 mild male missense c.6443A>G p.Asn2148Ser (2129) 
 
23 Y a, b 
HA114 mild male missense c.6505C>T p.Arg2169Cys (2150) 
 
23 Y a, b 
HA71 mild male missense c.6506G>A p.Arg2169His (2150) 
 
23 Y a, b 
HA10 mild male missense c.6532C>T p.Arg2178Cys (2159) 
 
23 Y a, b 
HA17 moderate female missense c.6532C>T p.Arg2178Cys (2159) 
 
23 Y a, b 
HA18 mild male missense c.6532C>T p.Arg2178Cys (2159) 
 
23 Y a, b 
HA104 mild male missense c.6532C>T p.Arg2178Cys (2159) 
 
23 Y a, b 
HA105 mild male missense c.6532C>T p.Arg2178Cys (2159) 
 
23 Y a, b 
HA141 mild male missense c.6532C>T p.Arg2178Cys (2159) 
 
23 Y a, b 
HA154 mild male missense c.6532C>T p.Arg2178Cys (2159) 
 
23 Y a, b 
HA11 mild male missense c.6533G>A p.Arg2178His (2159) 
 
23 Y a, b 
HA84 mild male missense c.6533G>A p.Arg2178His (2159) 
 
23 Y a, b 
HA115 mild male missense c.6533G>A p.Arg2178His (2159) 
 
23 Y a, b 
HA137 mild male missense c.6533G>A p.Arg2178His (2159) 
 
23 Y a, b 
HA170 mild male missense c.6533G>T p.Arg2178Leu (2159) 
 
23 Y a, f 
HA134 moderate male missense c.6544C>T p.Arg2182Cys (2163) 
 
23 Y a, b 
HA156 severe male missense c.6545G>A p.Arg2182His (2163) 
 
23 Y a, c 
HA31 severe male missense c.6683G>A p.Arg2228Gln (2209) 
 
24 Y a, b 
HA70 severe male missense c.6797G>T p.Gly2226Val (2247) 
 
25 N b 
HA42 mild male missense c.6823T>C p.Tyr2275His (2256) 
 
25 N b 
HA13 mild male missense c.6932C>A p.Pro2311His (2292) 
 
26 Y a, b 
HA56 moderate male missense c.6932C>A p.Pro2311His (2292) 
 
26 Y a, b 
HA136 mild male missense c.6932C>A p.Pro2311His (2292) 
 
26 Y a, b 
HA142 mild male missense c.6932C>A p.Pro2311His (2292) 
 
26 Y a, b 
HA195 mild male missense c.6932C>A p.Pro2311His (2292) 
 
26 Y a, c 
HA159 mild male missense c.6995G>C p.Trp2332Ser (2313) 
 
26 Y a, f 
HA169 severe male nonsense c.1063C>T p.Arg355* (336) 
 
8 Y a, c 
HA168 severe male nonsense c.1812G>A p.Trp604* (585) 
 
12 Y a, c 
HA6 severe male nonsense c.3155T>A p.Leu1052* (1033)  14 N b 
HA165 ? female nonsense c.5603C>G p.Ser1868* (1849) 
 
17 N c 
HA63 severe male nonsense c.6496C>T p.Arg2166* (2147) 
 
23 Y a, b 
HA200 ? female splicing c.143+1G>A ? ? 1 Y a, c 
HA176 severe male splicing c.266-3C>G ? ? 3 N c 
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HA58 severe male splicing c.1271+1G>T p.Asp318GlyfsX40 r.1134_1271del 8 N b 
HA45 severe male splicing c.6187+1G>A p.Lys2062_Gly2044delinsArg r.6116_6187del 20 N b 
HA21 severe male splicing c.6274-8A>G p.Val2073_Met2124del r.6274_6429del 22 N b 
 
a) EAHAD database (http://www.factorviii-db.org/) 
b) Lannoy N, Abinet I, A. Bosmans, Lambert C, Vermylen Ch and Hermans C. Computational and molecular approaches for predicting unreported causal 
missense mutations in Belgian patients with Haemophilia A. Haemophilia 2012; 18:e331-339 
c) This study 
d) Lannoy N, Abinet I, Dahan K et al: Identification of de novo deletion in the factor VIII gene by MLPA technique in two girls with isolated factor VIII 
deficiency. Haemophilia 2009; 15: 797-801 
e) N. Lannoy, C. Bandelier, B. Grisart , M. Reginster, E Ronge-Collard , M. Vikkula, and C. Hermans. Tandem Inversion Duplication within F8 Intron 1 
associated with mild hemophilia A. Haemophilia 2015; 21:516-522. doi: 10.1111/hae.12675. Epub 2015 May 11 
f) N. Lannoy, C. Lambert, M. Vikkula, C. Hermans. Overrepresentation of missense mutations in mild hemophilia A patients from Belgium: founder 
effect or independent occurrence? Thromb Res. 2015; 135:1057-1063. 
*: Mutations at the amino acid level are given using HGVS nomenclature. Legacy numbering is maintained within parenthesis 
$: Y (yes) N (No) corresponds to reporting or not in EAHAD database 
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C) Primer sequences 
TABLE C1: PRIMERS FOR AMPLIFICATION OF F8 EXONS 
The forward primers for each PCR have a common tail (M13F-TGTAAAACGACGGCCAGT) to allow the use of one complementary sequencing primer in all 
forward sequencing reactions. All reverse primers have a second common tail (M13R-CAGGAAACAGCTATGACC) for reverse strand sequencing.  
Name sequences 5'-3'   Name sequences 5'-3'   Name sequences 5'-3' 
exon 1-F CCCCTCCTGGGAGCTAAAG   exon 12-F TTCCTACCTGACAACATCAGTAGC   exon16-F GGGATGTAAACCCTAAGGACC 
exon 1-R CCAAGCAGACTTACATCCCC   exon 12-R CATTCATTATCTGGACATCACTTTG   exon16-R AAAGCTTCTTATTGCACGTAGG 
exon 2-F TTGAAGTGTCCACCAAAATGAACGACT   exon 13-F CAATCACAATCCAAAATACT   exon17-F TCCACTCTGGTTCATAGGTGAG 
exon 2-R GATACCCAATTTCATAAATAGCATTCA   exon 13-R ATACGAATGGCTAGTGAAG   exon17-R CCCTGGATCAAGTCTCATTTG 
exon 3-F TTTGGAATAACAGGTTTTCTGG   exon14a-F ATCTGTGTTATGAGTAACCA   exon18-F GTGGAATCCTCATAGATGTCA 
exon 3-R AAAGCACACACATCTCACTGTTC   exon14a-R TCATATTTGGCTTCTTGGAG   exon18-R GAGTAGGTAGAAGAAAGAGCAC 
exon 4-F CATGTTTCTTTGAGTGTACAGTGG   exon14b-F CTGATCTCCAAGAAGCCAAA   exon19-F GCATAAACCAATGTATCTCATGC 
exon 4-R TTCAGGTGAAGGAACACAAATG   exon14b-R TCAACAAAGCAGGTCCATGA   exon19-R GGAAGAAAGCTGTAAAGAAGTAGGC 
exon 5-F CCTCCTAGTGACAATTTCCTA   exon14c-F TCAAAGTTGTTAGAATCAGG   exon20-F CCATTTTCATTGACTTACATTTGAG 
exon 5-R AGCAGAGGATTTCTTTCAGGAATCCAA   exon14c-R ATTTTGTGCATCTGGTGGAA   exon20-R AGATATAATCAGCCCAGGTTC 
exon 6-F GGTCATTCATGAGACACA   exon14d-F GTCCAACAGAAAAAAGAGGG   exon21-F TTTATTCTCAAGTGTCTAGGACTAACC 
exon 6-R TGAAGTACAGAACTCTGGTG   exon14d-R CTACATTTTGCCTAGTGCTC   exon21-R CAAATCATTAAGGCATTCTGTTC 
exon 7-F CAGATTCTCTACTTCATAGCCATAG   exon14e-F CTGGCACTAAGAATTTCATG   exon22-F TGTAGCAATGTAGATTCTTCCTAAGC 
exon 7-R ATTAAAAGTAGGACTGGATA   exon14e-R CCTTCTCATTGTAGTCTATC   exon22-R TTTGGAATTAAGTTTGTGGAAGC 
exon 8-F CCCATATAGCCTGCAGAAAC   exon14f-F GAAACATTTGACCCCGAGCA   exon23-F TCTCTGTATTCACTTTCCATG 
exon 8-R TGCCATTTGATTCCATACCTG   exon14f-R TTTTGGGCAAGTCTGGTTTC   exon23-R ACAGTTAGTCACCCTACCCA 
exon 9-F TGTTTTAGAGTTGGATTTGA   exon14g-F CACATACAAGAAAGTTGAGA   exon24-F GCCCTAGAATATCAGTGGAAGC 
exon 9-R TAGAAACTCAAAACTCTCCA   exon14g-R CTCATTTATTGCTGCTATTG   exon24-R TTTTCCCCAACCACTGCTC 
exon 10-F GACCACAGTTTTCTTGTTGATCC   exon14h-F TGGGATAACCACTATGGTACTCAG   exon25-F TAGGGATTTGGGAATTTCTGG 
exon 10-R CAACAGCTGGAGAAAGGACC   exon14h-R CAAGACACCTTGATTTTTCATCC   exon25-R TGTTAAGCTCTAGGAGAGGTGG 
exon 11-F AGAACCCTTGCAACAACAAC   exon 15-F ATGCAAAATGCTTCTCAGGC   exon26-F AGTGACCATTGTCCTGT 
exon 11-R TTTTCTTCAGGTTATAAGGGGAC   exon15-R AAAATTTCCAAAAGTGGGAATAC   exon26-R AAAGGTAGAAGGCAAGC 
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TABLE C2: PRIMERS FOR INVERSION INTRON 1 AND F8 C-DNA AMPLIFICATION 
Name Primer sequences Forward Primer sequences Reverse Fragment PCR 
Inversion intron 1    
INVintron1-9 GTTGTTGGGAATGGTTACGG CTAGCTTGAGCTCCCTGTGG 1.5kb (normal) or 1.0kb (rearranged) 
INT1H-2 GGCAGGGATCTTGTTGGTAAA TGGGTGATATAAGCTGCTGAGCTA 1.0kb (normal) or 1.5kb (rearranged) 
F8 c-DNA (first PCR)    
F8 ex 1-8 CTTCTCCAGTTGAACATTTG TCAGCAGCAATGTAATGTAC 1254 bp 
F8 ex 8-14 AAGTAGACAGCTGTCCAGAG CTAGGGTGTCTTGAATTCTG 1257 bp 
F8 ex 14-19 GGGAAATAACTCGTACTACT AACTGAGAGATGTAGAGGCT 1350 bp 
F8 ex 19-26 
F8 5’UTR-ex4 
TGAGACAGTGGAAATGTTAC 
TTTCCCCTCCTGGGAGCTA 
TTGCCTAGTTATATTGGAAAG 
TCTCTACATACTAGTAGGGCTCCAA 
1285 bp 
680 bp 
F8 c-DNA (NESTED PCR) 
F8 ex 1-8/N1 
F8 ex 1-8/N2 
F8 ex 8-14/N1 
F8 ex 8-14/N2 
F8 ex 14-19/N1 
F8 ex 14-19/N2 
F8 ex 19-26/N1 
F8 ex 19-26/N1 
F8 5’UTR-ex4/N 
 
GCAAATAGAGCTCTCCACCT 
TTGAATTCAGGCCTCATTGG 
AGAAGCGGAAGACTATGATG 
TGCCTGACCCGCTATTACTC 
AGTCAGATCAAGAGGAAATTG 
CCTGCTCATGGGAGACAAGT 
AGCAATAAGTGTCAGACTCCC 
GCCATTGGGAATGGAGAGTA 
GCTCTCCACCTGCTTCTTTC 
 
TGGCCAGACTCCCTTCTCTA 
GAGCGAATTTGGATAAAGGA 
GAGAGGGCCAATGAGTCCTGA 
AGAAGCTTCTTGGTTCAATG 
CCAGCTTTTGGTCTCATCAA 
GATTGATCCGGAATAATGAAG 
TCGAGCTTTTGAAGGAGACC 
AGTTAATTCAGGAGGCTTCA 
GGCCTGAATTCAAGTCTTTTACC 
 
611 bp 
617 bp 
633 bp 
645 bp 
700 bp 
583 bp 
575bp 
605 bp 
560 bp 
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TABLE C3: INTRONIC AND EXTRAGENIC MARKERS 
1. SNPs markers 
 
SNP Physical position at Xq28 
RefSNP 
Alleles 
Minor 
allele 
MAF* Forward sequence Reverse sequence 
rs6643620 ~169kb 3’ of the F8 gene A/G G 0.452/747 5’-TTTCTGGTTGCTAGAATTATGGA3’ 5’-AAAGAGTGGGGCATTTGCTA-3’ 
rs5945250 ~162kb 3’ of the F8 gene G/T T 0.349/577 5’-TCTCACCATCACGAACATAAGG-3’ 5’-TGTTGCACAACAATGTGAATG-3’ 
rs1050705 3'-UTR variant A/G C 0.374/619 5’-CTGAAGAAACCAGCAGGAAAA-3’ 5’-GCAAATGGTTTATAGCCCTGT-3’ 
rs4898352 intron 18 of the F8 gene A/T T 0.3761/621 5’-TGTGACATTAATTATCCATTTATTCTG-3’ 5’-TGGCACTGTACAATCTCTATCCA-3’ 
rs6643714 intron 14 of the F8 gene C/T T 0.4907/811 5’-TGAGAAAATCTTTATCACCCCTTC-3’ 5’-TTCTCTGATGGCCAGTGATG-3’ 
rs1800291 exon 14 of the F8 gene C/G C 0.2461/406 5’-TCGTCAACAGAGAGTGGTAGG-3’ 5’-TTTCTCAGACAAGAAATTCTGACC-3’ 
rs5987079 intron 2 of the F8 gene A/G A 0.2866/474 5’-GAACCCACTAATGATCAAATTCC-3’ 5’-CATTTGCTGTTTTGGTTTTTGT-3’ 
rs6649625 intron 2 of the F8 gene C/T A 0.2424/201 5’-GCACTCATAAATGGAAATAGGAGAA-3’ 5’-ATCTGGTGGGTGAAAGCAAT-3’ 
rs2313058 ~13kb 3’ of the F8 gene C/T A 0.2956/489 5’- CAACAGTTCATTCCTTTTTATTGC-3’ 5’-GCACTTTAAAAACTGGCAGGTA-3’ 
rs5945279 ~22kb 3’ of the F8 gene C/T T 0.2183/361 5’-TAGAGCAGGGGTCAGCAAAG-3’ 5’-TCTGCTGGGTCTATACCATGA-3’ 
 
MAF*: Minor allele frequency (MAF) is the ratio of chromosomes in the population carrying the less common variant to those with the more common variant. This means that for 
rs6643620, the minor allele is “G” and has a frequency of 45.2% in the 1000 Genomes Phase 1 population, and that “G” is observed 747 times in the sample population of 629 
people (or 1.258 chromosomes) [http://www.ncbi.nlm.nih.gov/snp/ and http://www.ncbi.nlm.nih.gov/projects/SNP/docs/rs_attributes.html#gmaf] 
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2. Variable number tandem repeat (VNTR) markers 
 
Locus name Forward sequence Reverse sequence Physical position 
Allele size product (minimum 
to maximum) 
DXS15
a
 5'-AGCACATGGTATAATGAACCTCCACG-3' 5'-CAGTGTGAGTAGCATGCTAGCATTTG-3' ~1.452 Kb 3’ of the F8 gene 152 pb to 166 pb 
STR22
b
 5'-TTCTAAGAATGTAGTGTGTG-3' 5'-TAATGCCCACATTATAGA-3' Within the F8 gene 78 pb to 86 pb 
STR13
c
 5'-TGCATCACTGTACATATGTATCTT-3' 5'-CCAAATTACATATGAATAAGCC-3' Within the F8 gene 133 pb to 149 pb 
DXS1108
d
 5'-GTGAATTCATCATATGTGATTTCC-3' 5'-ACTAGGCGACTAATACAGTGGTGC-3' ~610 kb 5’ of the F8 gene 163 pb to 177 pb 
 
a) Wehnert M, Reiner O, Caskey CT. Four STR polymorphisms map to a 500 kb region between DXS15 and DXS134. Hum. Mol. Genet. 1993; 2:1503. 
b) Sánchez-García JF, Gallardo D, Ramírez L, Vidal F. Multiplex fluorescent analysis of four short tandem repeats for rapid haemophilia A molecular diagnosis. 
Thromb Haemost. 2005; 94:1099-1103. 
c) Lalloz MR, McVey JH, Pattinson JK, Tuddenham EG. Haemophilia A diagnosis by analysis of a hypervariable dinucleotide repeat within the factor VIII gene. 
Lancet 1991; 338: 207-211. 
d) Freije D, Helms C, Watson MS, Donis-Keller H. Identification of a second pseudoautosomal region near the Xq and Yq telomeres. Science 1992; 258:1784-
1787.  
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TABLE C4: LOCALIZATION, PRIMER SEQUENCES, AND SIZES OF PCR PRODUCTS FOR STUDYING COPY NUMBER CHANGES AT THE F8 LOCUS 
MAQ01 assay      
Amplicon Size in bpa Start* Stop* Primer Forwardb Primer Reversec 
amp1_1 91+30 154147798 154147888 AGGAAACTTGGGCAGCAGA AACAATGCCACCAAGCAGA 
amp1_2 180+30 154213190 154213369 CAGCAAAGTAGGCACACAGC CCTGATGCCTCAAGCTAACC 
amp1_3 143+30 154282491 154282633 GAAACAGAATTGCCTCTGTAACC CCTGATGGGAAGGAGGATG 
amp1_4 70+30 154318777 154318846 AATAAGTTTGTCAGCTTTCAGGATG CAAACACAAGAACCAGGAACC 
amp1_5 295+30 154344666 154344960 ATCTTTCAAGGGCAAGGATG GTGGCAAAGCAGCACTGA 
MAQ02 assay      
Amplicon Size in pba Start* Stop* Primer Forward Primer Reverse 
amp2_1 136+30 154441669 154441804 GTGGAGATTGGGACAGAACC GATATCCTTAGCAACTTCCAGAACC 
amp2_2 188+30 154470742 154470929 GATTTGAAACACCTCACTCATAACC TCACCTAACCCAGACAGAAATG 
amp2_3 86+30 154563105 154563190 CTCCTCACATAACAAGCACACAG CTTCTACAATGGACAAACATCACAG 
amp2_4 165+30 154630587 154630751 GAGTGCTTGAGGAAAGAGGCTA TGGCAAACACATCCATGC 
amp2_5 107+30 154664187 154664293 TTTAAGCTAGAGCAGCCGTGT AGGGAAGAGGAGAGGCAGA 
*The positions of primers on chromosome X are based on the hg19 assembly 
a The size of amplicons corresponds to the sum of the distance between primer pairs and the length of the tail added to the locus-specific primer pairs for 
PCR amplification (30bp in total) 
b A tail used for PCR amplification was added at the 5’ end of these locus specific primers (AGCGGATAACAATTTCACACAGG) 
c A tail used for PCR amplification was added at the 5’ end of these locus specific primers (GTTTCTT) 
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